Michael A Hogarth

UNIVERSITY OF CALIFORNIA, SAN DIEGO, LA JOLLA, CA

High-opportunity lead · 88/100

Likely hiring

Large award

Very recent

Active award

$10,295,345

FY 2026

Project Title

CTSA UM1 Program at University of California San Diego Altman Clinical and Translational Research Institute

Grant Number:

5UM1TR005449-02

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

8/1/2025

End Date:

4/30/2032

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The Altman Clinical and Translational Research Institute (ACTRI) at the University of California San Diego (UCSD) dynamically and rapidly translates scientific discoveries into innovative health solutions. Given the significant growth of our biomedical research portfolio during the last funding cycl...

Research Terms

<0-11 years old><2 year college><AI system><Academy><Acceleration><Access to Care><Address><Adolescent><Adolescent Youth><Area><Artificial Intelligence><Basic Research><Basic Science><Bioinformatics><Biomedical Research><Biometrics><Biometry><Biostatistics><Businesses><California><Career Choice><Career Path><Child><Child Youth><Children (0-21)><Children's Hospital><Clinical><Clinical Research><Clinical Sciences><Clinical Skills><Clinical Study><Clinical and Translational Science Awards><Collaborations><Communication Methods><Competence><Computer Reasoning><Decentralization><Development><Devices><Discipline><Economics><Education><Educational aspects><Effectiveness><Elements><Engineering><Ensure><Environment><Evaluation><Evolution><Fostering><Funding><Generalized Growth><Goals><Grant><Growth><Health><Health Care Systems><Health Informatics><Health Priorities><Health Services Accessibility><Home><Immune><Immunes><Immunology><Improve Access><Industry><Infrastructure><Institution><Investigators><K12><K12 Award><K12 Mechanism><K12 Program><Knowledge><Leadership><Learning><Machine Intelligence><Measurable><Measures><Medical><Medical center><Medicine><Mentored Clinical Scientist Development Program><Methods><Modeling><NCATS><Naloxone><Narcan><Narcanti><National Center for Advancing Translational Sciences><Outcome><Patients><Pediatric Hospitals><Pilot Projects><Policies><Position><Positioning Attribute><Preparation><Preparedness><Process><Public Health><Public Health Informatics><QOC><Quality of Care><Readiness><Research><Research Infrastructure><Research Institute><Research Personnel><Research Resources><Researchers><Resources><Rural><Sampling><Science><Services><Strategic Planning><Structure><Students><System><Testing><Thinking><Tissue Growth><Training><Translating><Translational Research><Translational Science><Translations><Trust><United States Department of Veterans Affairs><United States Veterans Administration><Universities><Upper respiratory tract><Veterans Administration><Veterans Affairs><Workforce Development><access to health services><access to services><access to treatment><accessibility to health services><assess effectiveness><availability of services><biobank><biorepository><care access><career><career aspiration><career interest><career pathway><career track><clinical translation><clinically translatable><college><collegiate><community college><consumer informatics><continuous monitoring><design><designing><determine effectiveness><developmental><dissemination strategy><distribute naloxone><economic><effectiveness assessment><effectiveness evaluation><evaluate effectiveness><examine effectiveness><flexibility><flexible><health service access><health services availability><higher education><homes><implementation strategy><improved><innovate><innovation><innovative><invention><junior college><juvenile><juvenile human><kids><method development><military veteran><multidisciplinary><naloxone availability><naloxone dispensary><naloxone dispensation><naloxone dispensing><naloxone distribution><naloxone provision><next generation><novel><ontogeny><outreach><overdose death><overdose fatalities><pilot study><preparations><programs><provide naloxone><rural area><rural location><rural region><service availability><service organization><skills><strategies for implementation><success><thoughts><tool><translation><translation research><translational investigation><treatment access><two year college><upper airway tract><veteran population><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

David Mitchell Smith

UNIVERSITY OF CALIFORNIA, SAN DIEGO, LA JOLLA, CA

High-opportunity lead · 88/100

Likely hiring

Large award

Very recent

Active award

$10,295,345

FY 2026

Project Title

CTSA UM1 Program at University of California San Diego Altman Clinical and Translational Research Institute

Grant Number:

5UM1TR005449-02

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

8/1/2025

End Date:

4/30/2032

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The Altman Clinical and Translational Research Institute (ACTRI) at the University of California San Diego (UCSD) dynamically and rapidly translates scientific discoveries into innovative health solutions. Given the significant growth of our biomedical research portfolio during the last funding cycl...

Research Terms

<0-11 years old><2 year college><AI system><Academy><Acceleration><Access to Care><Address><Adolescent><Adolescent Youth><Area><Artificial Intelligence><Basic Research><Basic Science><Bioinformatics><Biomedical Research><Biometrics><Biometry><Biostatistics><Businesses><California><Career Choice><Career Path><Child><Child Youth><Children (0-21)><Children's Hospital><Clinical><Clinical Research><Clinical Sciences><Clinical Skills><Clinical Study><Clinical and Translational Science Awards><Collaborations><Communication Methods><Competence><Computer Reasoning><Decentralization><Development><Devices><Discipline><Economics><Education><Educational aspects><Effectiveness><Elements><Engineering><Ensure><Environment><Evaluation><Evolution><Fostering><Funding><Generalized Growth><Goals><Grant><Growth><Health><Health Care Systems><Health Informatics><Health Priorities><Health Services Accessibility><Home><Immune><Immunes><Immunology><Improve Access><Industry><Infrastructure><Institution><Investigators><K12><K12 Award><K12 Mechanism><K12 Program><Knowledge><Leadership><Learning><Machine Intelligence><Measurable><Measures><Medical><Medical center><Medicine><Mentored Clinical Scientist Development Program><Methods><Modeling><NCATS><Naloxone><Narcan><Narcanti><National Center for Advancing Translational Sciences><Outcome><Patients><Pediatric Hospitals><Pilot Projects><Policies><Position><Positioning Attribute><Preparation><Preparedness><Process><Public Health><Public Health Informatics><QOC><Quality of Care><Readiness><Research><Research Infrastructure><Research Institute><Research Personnel><Research Resources><Researchers><Resources><Rural><Sampling><Science><Services><Strategic Planning><Structure><Students><System><Testing><Thinking><Tissue Growth><Training><Translating><Translational Research><Translational Science><Translations><Trust><United States Department of Veterans Affairs><United States Veterans Administration><Universities><Upper respiratory tract><Veterans Administration><Veterans Affairs><Workforce Development><access to health services><access to services><access to treatment><accessibility to health services><assess effectiveness><availability of services><biobank><biorepository><care access><career><career aspiration><career interest><career pathway><career track><clinical translation><clinically translatable><college><collegiate><community college><consumer informatics><continuous monitoring><design><designing><determine effectiveness><developmental><dissemination strategy><distribute naloxone><economic><effectiveness assessment><effectiveness evaluation><evaluate effectiveness><examine effectiveness><flexibility><flexible><health service access><health services availability><higher education><homes><implementation strategy><improved><innovate><innovation><innovative><invention><junior college><juvenile><juvenile human><kids><method development><military veteran><multidisciplinary><naloxone availability><naloxone dispensary><naloxone dispensation><naloxone dispensing><naloxone distribution><naloxone provision><next generation><novel><ontogeny><outreach><overdose death><overdose fatalities><pilot study><preparations><programs><provide naloxone><rural area><rural location><rural region><service availability><service organization><skills><strategies for implementation><success><thoughts><tool><translation><translation research><translational investigation><treatment access><two year college><upper airway tract><veteran population><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

PATRICE DELAFONTAINE

UNIVERSITY OF ALABAMA AT BIRMINGHAM, BIRMINGHAM, AL

High-opportunity lead · 88/100

Likely hiring

Large award

Very recent

Active award

$9,681,310

FY 2026

Project Title

CTSA UM1 at the University of Alabama at Birmingham

Grant Number:

5UM1TR004771-03

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/1/2024

End Date:

4/30/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The Center for Clinical and Translational Science (CCTS), the CTSA Hub at the University of Alabama at Birmingham (UAB), serves a region of the country with a heavy burden of chronic diseases. The high toll of these chronic diseases on health outcomes including mortality and morbidity has brought in...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Orlando M Gutierrez

UNIVERSITY OF ALABAMA AT BIRMINGHAM, BIRMINGHAM, AL

High-opportunity lead · 88/100

Likely hiring

Large award

Very recent

Active award

$9,681,310

FY 2026

Project Title

CTSA UM1 at the University of Alabama at Birmingham

Grant Number:

5UM1TR004771-03

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/1/2024

End Date:

4/30/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The Center for Clinical and Translational Science (CCTS), the CTSA Hub at the University of Alabama at Birmingham (UAB), serves a region of the country with a heavy burden of chronic diseases. The high toll of these chronic diseases on health outcomes including mortality and morbidity has brought in...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

RACHEL HESS

UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH, SALT LAKE CITY, UT

High-opportunity lead · 88/100

Likely hiring

Large award

Very recent

Active award

$5,598,722

FY 2026

Project Title

CTSA UM1 Program at University of Utah

Grant Number:

5UM1TR004409-04

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2023

End Date:

3/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The vision of the Utah Clinical & Translational Science Institute (CTSI) is to strategically and ethically develop and apply generalizable, reproducible clinical and translational science (CTS) innovations to expand the reach and impact of scientific knowledge. The Utah CTSI works with local, region...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jennifer Juhl Majersik

UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH, SALT LAKE CITY, UT

High-opportunity lead · 88/100

Likely hiring

Large award

Very recent

Active award

$5,598,722

FY 2026

Project Title

CTSA UM1 Program at University of Utah

Grant Number:

5UM1TR004409-04

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2023

End Date:

3/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The vision of the Utah Clinical & Translational Science Institute (CTSI) is to strategically and ethically develop and apply generalizable, reproducible clinical and translational science (CTS) innovations to expand the reach and impact of scientific knowledge. The Utah CTSI works with local, region...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Michael Z. Lin

MAX PLANCK FLORIDA CORPORATION, Jupiter, FL

High-opportunity lead · 88/100

Likely hiring

Large award

Very recent

Active award

$1,987,526

FY 2026

Project Title

Optimization of genetically encoded voltage and neurotransmitter indicators for multiwavelength in vivo analysis of brain circuits

Grant Number:

5UM1MH136462-03

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2024

End Date:

1/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The brain is remarkably dynamic, adaptive, and flexible in response to environmental changes. These capacities are enabled by diverse cell types which communicate with an array of chemical neurotransmitters (NTs) or neuromodulators (NMs) and receptors. Neurochemical inputs have a wide-ranging and dr...

Research Terms

<2-photon><4-Aminobutanoic Acid><4-Aminobutyric Acid><4-amino-butanoic acid><5-HT><5-Hydroxytryptamine><5HT><Acceleration><Acetylcholine><Address><Adoption><Algorithms><Aminalon><Aminalone><Anatomic Sites><Anatomic structures><Anatomy><Area><Behavior><Behavioral><Benchmarking><Best Practice Analysis><Brain><Brain Nervous System><Brain region><Calibration><Capsid><Catalogs><Cell Communication and Signaling><Cell Signaling><Chemicals><Collaborations><Color><Communication><Communities><Computer Models><Computerized Models><Data><Data Set><Diffusion><Directed Molecular Evolution><Disease><Disorder><Encephalon><Engineering><Ensure><Enteramine><Fiber><Foundations><Funding><GABA><Glutamates><Goals><Health><Hippophaine><Image><In Vitro><In vivo analysis><Individual><Institution><Interdisciplinary Research><Interdisciplinary Study><Intracellular Communication and Signaling><Investigators><Knowledge><L-Glutamate><Levarterenol><Levonorepinephrine><Link><Location><Logic><Machine Learning><Measurement><Measures><Membrane><Mice><Mice Mammals><Microscopy><Molecular><Multidisciplinary Collaboration><Multidisciplinary Research><Murine><Mus><NIH><National Institutes of Health><Nerve Cells><Nerve Impulse Transmission><Nerve Transmission><Nerve Transmitter Substances><Nerve Unit><Neural Cell><Neurocyte><Neuromodulator><Neuronal Transmission><Neurons><Neurosciences><Neurotransmitters><Noradrenaline><Norepinephrine><Optics><Output><Pattern><Performance><Photometry><Process><Protocol><Protocols documentation><Reagent><Receptor Protein><Regulatory Element><Reporter Genes><Reproducibility><Research><Research Personnel><Researchers><Resolution><Serotonin><Shapes><Signal Transduction><Signal Transduction Systems><Signaling><Specificity><Speed><Structure><Synapses><Synaptic><System><Technology><Testing><Transgenic Organisms><United States National Institutes of Health><Validation><Variant><Variation><Viral><axon signaling><axon-glial signaling><axonal signaling><benchmark><biological signal transduction><brain control><catalog><cell type><computational modeling><computational models><computer based models><computerized modeling><data science resource><data sharing><design><designing><diffused><diffuses><diffusing><diffusions><directed evolution><environmental change><experiment><experimental research><experimental study><experiments><flexibility><flexible><gamma-Aminobutyric Acid><glia signaling><glial signaling><glutamatergic><imaging><in vivo><in vivo evaluation><in vivo testing><information processing><internet portal><machine based learning><membrane structure><multidisciplinary><nerve signaling><neural><neural circuit><neural circuitry><neural control><neural regulation><neural signaling><neurochemical><neurochemistry><neurocircuitry><neuromodulation><neuromodulatory><neuronal><neuronal signaling><neuroregulation><neurotransmission><on-line portal><online portal><optical><optogenetics><postsynaptic><programs><promoter><promotor><rational design><receptor><resolutions><response><sensor><spatial and temporal><spatial temporal><spatiotemporal><success><synapse><synaptic circuit><synaptic circuitry><temporal measurement><temporal resolution><theories><time measurement><tool><transgenic><two-photon><validations><voltage><web portal><web-based portal><γ-Aminobutyric Acid>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Kaspar Podgorski

MAX PLANCK FLORIDA CORPORATION, Jupiter, FL

High-opportunity lead · 88/100

Likely hiring

Large award

Very recent

Active award

$1,987,526

FY 2026

Project Title

Optimization of genetically encoded voltage and neurotransmitter indicators for multiwavelength in vivo analysis of brain circuits

Grant Number:

5UM1MH136462-03

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2024

End Date:

1/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The brain is remarkably dynamic, adaptive, and flexible in response to environmental changes. These capacities are enabled by diverse cell types which communicate with an array of chemical neurotransmitters (NTs) or neuromodulators (NMs) and receptors. Neurochemical inputs have a wide-ranging and dr...

Research Terms

<2-photon><4-Aminobutanoic Acid><4-Aminobutyric Acid><4-amino-butanoic acid><5-HT><5-Hydroxytryptamine><5HT><Acceleration><Acetylcholine><Address><Adoption><Algorithms><Aminalon><Aminalone><Anatomic Sites><Anatomic structures><Anatomy><Area><Behavior><Behavioral><Benchmarking><Best Practice Analysis><Brain><Brain Nervous System><Brain region><Calibration><Capsid><Catalogs><Cell Communication and Signaling><Cell Signaling><Chemicals><Collaborations><Color><Communication><Communities><Computer Models><Computerized Models><Data><Data Set><Diffusion><Directed Molecular Evolution><Disease><Disorder><Encephalon><Engineering><Ensure><Enteramine><Fiber><Foundations><Funding><GABA><Glutamates><Goals><Health><Hippophaine><Image><In Vitro><In vivo analysis><Individual><Institution><Interdisciplinary Research><Interdisciplinary Study><Intracellular Communication and Signaling><Investigators><Knowledge><L-Glutamate><Levarterenol><Levonorepinephrine><Link><Location><Logic><Machine Learning><Measurement><Measures><Membrane><Mice><Mice Mammals><Microscopy><Molecular><Multidisciplinary Collaboration><Multidisciplinary Research><Murine><Mus><NIH><National Institutes of Health><Nerve Cells><Nerve Impulse Transmission><Nerve Transmission><Nerve Transmitter Substances><Nerve Unit><Neural Cell><Neurocyte><Neuromodulator><Neuronal Transmission><Neurons><Neurosciences><Neurotransmitters><Noradrenaline><Norepinephrine><Optics><Output><Pattern><Performance><Photometry><Process><Protocol><Protocols documentation><Reagent><Receptor Protein><Regulatory Element><Reporter Genes><Reproducibility><Research><Research Personnel><Researchers><Resolution><Serotonin><Shapes><Signal Transduction><Signal Transduction Systems><Signaling><Specificity><Speed><Structure><Synapses><Synaptic><System><Technology><Testing><Transgenic Organisms><United States National Institutes of Health><Validation><Variant><Variation><Viral><axon signaling><axon-glial signaling><axonal signaling><benchmark><biological signal transduction><brain control><catalog><cell type><computational modeling><computational models><computer based models><computerized modeling><data science resource><data sharing><design><designing><diffused><diffuses><diffusing><diffusions><directed evolution><environmental change><experiment><experimental research><experimental study><experiments><flexibility><flexible><gamma-Aminobutyric Acid><glia signaling><glial signaling><glutamatergic><imaging><in vivo><in vivo evaluation><in vivo testing><information processing><internet portal><machine based learning><membrane structure><multidisciplinary><nerve signaling><neural><neural circuit><neural circuitry><neural control><neural regulation><neural signaling><neurochemical><neurochemistry><neurocircuitry><neuromodulation><neuromodulatory><neuronal><neuronal signaling><neuroregulation><neurotransmission><on-line portal><online portal><optical><optogenetics><postsynaptic><programs><promoter><promotor><rational design><receptor><resolutions><response><sensor><spatial and temporal><spatial temporal><spatiotemporal><success><synapse><synaptic circuit><synaptic circuitry><temporal measurement><temporal resolution><theories><time measurement><tool><transgenic><two-photon><validations><voltage><web portal><web-based portal><γ-Aminobutyric Acid>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Karel Svoboda

MAX PLANCK FLORIDA CORPORATION, Jupiter, FL

High-opportunity lead · 88/100

Likely hiring

Large award

Very recent

Active award

$1,987,526

FY 2026

Project Title

Optimization of genetically encoded voltage and neurotransmitter indicators for multiwavelength in vivo analysis of brain circuits

Grant Number:

5UM1MH136462-03

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2024

End Date:

1/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The brain is remarkably dynamic, adaptive, and flexible in response to environmental changes. These capacities are enabled by diverse cell types which communicate with an array of chemical neurotransmitters (NTs) or neuromodulators (NMs) and receptors. Neurochemical inputs have a wide-ranging and dr...

Research Terms

<2-photon><4-Aminobutanoic Acid><4-Aminobutyric Acid><4-amino-butanoic acid><5-HT><5-Hydroxytryptamine><5HT><Acceleration><Acetylcholine><Address><Adoption><Algorithms><Aminalon><Aminalone><Anatomic Sites><Anatomic structures><Anatomy><Area><Behavior><Behavioral><Benchmarking><Best Practice Analysis><Brain><Brain Nervous System><Brain region><Calibration><Capsid><Catalogs><Cell Communication and Signaling><Cell Signaling><Chemicals><Collaborations><Color><Communication><Communities><Computer Models><Computerized Models><Data><Data Set><Diffusion><Directed Molecular Evolution><Disease><Disorder><Encephalon><Engineering><Ensure><Enteramine><Fiber><Foundations><Funding><GABA><Glutamates><Goals><Health><Hippophaine><Image><In Vitro><In vivo analysis><Individual><Institution><Interdisciplinary Research><Interdisciplinary Study><Intracellular Communication and Signaling><Investigators><Knowledge><L-Glutamate><Levarterenol><Levonorepinephrine><Link><Location><Logic><Machine Learning><Measurement><Measures><Membrane><Mice><Mice Mammals><Microscopy><Molecular><Multidisciplinary Collaboration><Multidisciplinary Research><Murine><Mus><NIH><National Institutes of Health><Nerve Cells><Nerve Impulse Transmission><Nerve Transmission><Nerve Transmitter Substances><Nerve Unit><Neural Cell><Neurocyte><Neuromodulator><Neuronal Transmission><Neurons><Neurosciences><Neurotransmitters><Noradrenaline><Norepinephrine><Optics><Output><Pattern><Performance><Photometry><Process><Protocol><Protocols documentation><Reagent><Receptor Protein><Regulatory Element><Reporter Genes><Reproducibility><Research><Research Personnel><Researchers><Resolution><Serotonin><Shapes><Signal Transduction><Signal Transduction Systems><Signaling><Specificity><Speed><Structure><Synapses><Synaptic><System><Technology><Testing><Transgenic Organisms><United States National Institutes of Health><Validation><Variant><Variation><Viral><axon signaling><axon-glial signaling><axonal signaling><benchmark><biological signal transduction><brain control><catalog><cell type><computational modeling><computational models><computer based models><computerized modeling><data science resource><data sharing><design><designing><diffused><diffuses><diffusing><diffusions><directed evolution><environmental change><experiment><experimental research><experimental study><experiments><flexibility><flexible><gamma-Aminobutyric Acid><glia signaling><glial signaling><glutamatergic><imaging><in vivo><in vivo evaluation><in vivo testing><information processing><internet portal><machine based learning><membrane structure><multidisciplinary><nerve signaling><neural><neural circuit><neural circuitry><neural control><neural regulation><neural signaling><neurochemical><neurochemistry><neurocircuitry><neuromodulation><neuromodulatory><neuronal><neuronal signaling><neuroregulation><neurotransmission><on-line portal><online portal><optical><optogenetics><postsynaptic><programs><promoter><promotor><rational design><receptor><resolutions><response><sensor><spatial and temporal><spatial temporal><spatiotemporal><success><synapse><synaptic circuit><synaptic circuitry><temporal measurement><temporal resolution><theories><time measurement><tool><transgenic><two-photon><validations><voltage><web portal><web-based portal><γ-Aminobutyric Acid>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Lin Tian

MAX PLANCK FLORIDA CORPORATION, Jupiter, FL

High-opportunity lead · 88/100

Likely hiring

Large award

Very recent

Active award

$1,987,526

FY 2026

Project Title

Optimization of genetically encoded voltage and neurotransmitter indicators for multiwavelength in vivo analysis of brain circuits

Grant Number:

5UM1MH136462-03

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2024

End Date:

1/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The brain is remarkably dynamic, adaptive, and flexible in response to environmental changes. These capacities are enabled by diverse cell types which communicate with an array of chemical neurotransmitters (NTs) or neuromodulators (NMs) and receptors. Neurochemical inputs have a wide-ranging and dr...

Research Terms

<2-photon><4-Aminobutanoic Acid><4-Aminobutyric Acid><4-amino-butanoic acid><5-HT><5-Hydroxytryptamine><5HT><Acceleration><Acetylcholine><Address><Adoption><Algorithms><Aminalon><Aminalone><Anatomic Sites><Anatomic structures><Anatomy><Area><Behavior><Behavioral><Benchmarking><Best Practice Analysis><Brain><Brain Nervous System><Brain region><Calibration><Capsid><Catalogs><Cell Communication and Signaling><Cell Signaling><Chemicals><Collaborations><Color><Communication><Communities><Computer Models><Computerized Models><Data><Data Set><Diffusion><Directed Molecular Evolution><Disease><Disorder><Encephalon><Engineering><Ensure><Enteramine><Fiber><Foundations><Funding><GABA><Glutamates><Goals><Health><Hippophaine><Image><In Vitro><In vivo analysis><Individual><Institution><Interdisciplinary Research><Interdisciplinary Study><Intracellular Communication and Signaling><Investigators><Knowledge><L-Glutamate><Levarterenol><Levonorepinephrine><Link><Location><Logic><Machine Learning><Measurement><Measures><Membrane><Mice><Mice Mammals><Microscopy><Molecular><Multidisciplinary Collaboration><Multidisciplinary Research><Murine><Mus><NIH><National Institutes of Health><Nerve Cells><Nerve Impulse Transmission><Nerve Transmission><Nerve Transmitter Substances><Nerve Unit><Neural Cell><Neurocyte><Neuromodulator><Neuronal Transmission><Neurons><Neurosciences><Neurotransmitters><Noradrenaline><Norepinephrine><Optics><Output><Pattern><Performance><Photometry><Process><Protocol><Protocols documentation><Reagent><Receptor Protein><Regulatory Element><Reporter Genes><Reproducibility><Research><Research Personnel><Researchers><Resolution><Serotonin><Shapes><Signal Transduction><Signal Transduction Systems><Signaling><Specificity><Speed><Structure><Synapses><Synaptic><System><Technology><Testing><Transgenic Organisms><United States National Institutes of Health><Validation><Variant><Variation><Viral><axon signaling><axon-glial signaling><axonal signaling><benchmark><biological signal transduction><brain control><catalog><cell type><computational modeling><computational models><computer based models><computerized modeling><data science resource><data sharing><design><designing><diffused><diffuses><diffusing><diffusions><directed evolution><environmental change><experiment><experimental research><experimental study><experiments><flexibility><flexible><gamma-Aminobutyric Acid><glia signaling><glial signaling><glutamatergic><imaging><in vivo><in vivo evaluation><in vivo testing><information processing><internet portal><machine based learning><membrane structure><multidisciplinary><nerve signaling><neural><neural circuit><neural circuitry><neural control><neural regulation><neural signaling><neurochemical><neurochemistry><neurocircuitry><neuromodulation><neuromodulatory><neuronal><neuronal signaling><neuroregulation><neurotransmission><on-line portal><online portal><optical><optogenetics><postsynaptic><programs><promoter><promotor><rational design><receptor><resolutions><response><sensor><spatial and temporal><spatial temporal><spatiotemporal><success><synapse><synaptic circuit><synaptic circuitry><temporal measurement><temporal resolution><theories><time measurement><tool><transgenic><two-photon><validations><voltage><web portal><web-based portal><γ-Aminobutyric Acid>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Sanjay Sethi

STATE UNIVERSITY OF NEW YORK AT BUFFALO, AMHERST, NY

High-opportunity lead · 74/100

Likely hiring

Large award

Active award

Team-scale grant

$4,121,403

FY 2026

Project Title

CTSA UM1 State University of New York at Buffalo

Grant Number:

5UM1TR005296-02

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/6/2025

End Date:

12/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

The University at Buffalo Clinical and Translational Science Institute (CTSI) and Buffalo Translational Consortium (BTC), the region’s leading academic, clinical and research institutions, with influential community partners has established genuine, enduring partnerships to implement translational s...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Robert Wilson Frenck

CINCINNATI CHILDRENS HOSP MED CTR, CINCINNATI, OH

High-opportunity lead · 74/100

Likely hiring

Large award

Active award

Team-scale grant

$1,354,801

FY 2026

Project Title

Cincinnati Children's Hospital Medical Center Vaccine and Treatment Evaluation Units (UM1 Clinical Trial Required)

Grant Number:

5UM1AI148372-07

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/11/2019

End Date:

11/30/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

PROJECT SUMMARY Throughout history, infectious diseases have been, and continue to be, a leading cause of morbidity and mortality throughout the world. While all ages are affected by infectious diseases, the ends of the spectrum of life (young children and elderly) are particularly vulnerable. Thus,...

Research Terms

<0-11 years old><21+ years old><Address><Adolescent><Adolescent Youth><Adult><Adult Human><Affect><Age><Airway infections><Applied Research><Applied Science><Area><Assay><Award><Bioassay><Biological Agent><Biological Assay><Biological Products><Budgets><Child><Child Youth><Children (0-21)><Children's Hospital><Clinical><Clinical Research><Clinical Study><Clinical Trials><Collaborations><Communicable Diseases><Compensation><Consent Documents><Consent Forms><Cooperative Agreements><Data Analyses><Data Analysis><Development><Devices><Diagnostic><Disease><Disease Outbreaks><Disorder><Elderly><Emerging Communicable Diseases><Emerging Infectious Diseases><Enrollment><Ensure><Enteral><Enteric><Epidemiology><Evaluation><Faculty><Future><Goals><Grippe><Group Structure><H1N1><H1N1 Virus><H5N1><H5N1 virus><History><Human><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunosuppressed Host><Infant><Infection><Infectious Diseases><Infectious Disorder><Influenza><Influenza A H5N1><Influenza A Virus, H1N1 Subtype><Influenza A Virus, H5N1 Subtype><Influenza Vaccines><Informed Consent Documents><Informed Consent Forms><Intervention Trial><Interventional trial><Investigators><Laboratories><Leadership><Letters><Life><Manuals><Medical center><Mentors><Methods><Microbiology><Mission><Modeling><Modern Man><Modification><Morbidity><Multi-center studies><Multicenter Studies><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><Norovirus><Norwalk-like Viruses><Ohio><Organization Charts><Out-patients><Outbreaks><Outpatients><Participant><Pediatric Hospitals><Performance><Persons><Phase><Population><Pregnant Women><Preparation><Prevention><Preventive><Prognostic Marker><Protocol><Protocols documentation><Public Health><Publications><Quality Control><Recording of previous events><Research Design><Research Personnel><Researchers><Respiratory Infections><Respiratory Tract Infections><Respiratory infectious agent><Respiratory tract pathogen><S sonnei><S. sonnei><Scientific Publication><Sexually Transmitted Diseases><Sexually Transmitted Disorder><Sexually Transmitted Infection><Shigella sonnei><Site><Specialty><Study Type><Systems Biology><Technology><Testing><Therapeutic><Training><U-Series Cooperative Agreements><United States National Institutes of Health><Vaccination acquired immunity><Vaccination induced immunity><Vaccines><Venereal Diseases><Venereal Disorders><Venereal Infections><adulthood><advanced age><ages><avian influenza H5N1><avian influenza H5N1 virus><biodefense><biologics><biopharmaceutical><biotherapeutic agent><clinical research site><clinical site><clinical trial implementation><data dissemination><data interpretation><design><designing><develop a vaccine><develop vaccines><development of a vaccine><developmental><emerging pathogen><enroll><enteral pathogen><enteric pathogen><enteropathogen><epidemiologic><epidemiological><evaluate vaccines><expectant mother><expectant women><expecting mother><expecting women><flu vaccine><flu virus vaccine><geriatric><histories><immunosuppressed patient><implementation of clinical trials><individuals who are pregnant><infectious disease treatment><influenza virus vaccine><innovate><innovation><innovative><intestinal pathogen><intestine pathogen><investigator-initiated trial><juvenile><juvenile human><kids><medical specialties><mortality><neglected tropical diseases><new pathogen><novel><novel pathogen><operation><operations><organizational structure><people who are pregnant><predictive biological marker><predictive biomarkers><predictive marker><predictive molecular biomarker><pregnant females><pregnant mothers><pregnant people><pregnant populations><preparations><prevent><preventing><prognostic biomarker><prognostic indicator><recruit><respiratory pathogen><response><senior citizen><sexually acquired infection><study design><those who are pregnant><tool><trial design><vaccination study><vaccination trial><vaccine acquired immunity><vaccine against flu><vaccine against influenza><vaccine associated immunity><vaccine candidate><vaccine development><vaccine effectiveness><vaccine evaluation><vaccine screening><vaccine study><vaccine testing><vaccine trial><vaccine-induced immunity><vaccine-induced protection><women who are pregnant><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ting Wang

SALK INSTITUTE FOR BIOLOGICAL STUDIES, La Jolla, CA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$25,320,000

FY 2022

Project Title

Center for Multiomic Human Brain Cell Atlas

Grant Number:

1UM1MH130994-01

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/1/2022

End Date:

6/30/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

Abstract Understanding cell identities and their spatial distributions throughout different regions of the human brain is a fundamental step when trying to integrate physiological, behavioral, neurochemical and molecular data. At present, although major categories of the cell-types present in the hu...

Research Terms

<21+ years old><3-D><3-Dimensional><3D><Address><Adeno-Associated Viruses><Adult><Adult Human><Anatomic><Anatomic Sites><Anatomic structures><Anatomical Sciences><Anatomy><Assay><Atlases><Autopsy><BRAIN initiative><Behavioral><Bioassay><Biologic Assays><Biological Assay><Body Tissues><Brain><Brain Mapping><Brain Nervous System><Brain Pathology><Brain Research through Advancing Innovative Neurotechnologies initiative><Brain region><Categories><Cell Body><Cell Function><Cell Process><Cell physiology><Cells><Cellular Function><Cellular Physiology><Cellular Process><Censuses><Chromatin><Communities><Complex><Cytosine><DNA><DNA Methylation><DNA analysis><Data><Data Analyses><Data Analysis><Data Set><Dataset><Deoxyribonucleic Acid><Dependoparvovirus><Dependovirus><Encephalon><Enhancers><Expression Signature><Functional RNA><Gene Expression><Gene Expression Profile><Gene Transcription><Gene variant><Generations><Genes><Genetic><Genetic Transcription><Genetic analyses><Genome><Genomics><Glia><Glial Cells><Goals><Heterochromatin><Histones><Human><Individual><Joints><Kolliker's reticulum><Location><Low Molecular Weight Nuclear RNA><Maps><Mediating><Methods><Mice><Mice Mammals><Mitotic><Modern Man><Molecular><Morphology><Murine><Mus><Nerve Cells><Nerve Unit><Nervous System Diseases><Neural Cell><Neuranatomies><Neuranatomy><Neuroanatomies><Neuroanatomy><Neurocyte><Neuroglia><Neuroglial Cells><Neurologic Disorders><Neurological Disorders><Neurons><Non-Coding><Non-Coding RNA><Non-Polyadenylated RNA><Non-neuronal cell><Non-translated RNA><Noncoding RNA><Nonneuronal cell><Nontranslated RNA><Nucleic Acid Regulator Regions><Nucleic Acid Regulatory Sequences><Physiologic><Physiological><Population Heterogeneity><Production><Property><RNA><RNA Expression><RNA Gene Products><Records><Regulation><Regulator Genes><Regulatory Element><Regulatory Regions><Research Specimen><Resolution><Ribonucleic Acid><Sampling><Series><Spatial Distribution><Specimen><Structure><Subcellular Process><Survey Instrument><Surveys><Technology><Testing><Tissue Sample><Tissues><Transcript><Transcription><Transcriptional Regulatory Elements><Untranslated RNA><Validation><Visualization><adeno associated virus group><adulthood><allele variant><allelic variant><base><brain cell><brain tissue><cell type><cohesion><cost effective><data integration><data interpretation><data management><data portal><data sharing portal><diverse populations><epigenome><epigenomics><experiment><experimental research><experimental study><gene expression pattern><gene expression signature><genetic analysis><genetic regulatory element><genetic variant><genomic variant><global gene expression><global transcription profile><heterogeneous population><histone modification><imaging approach><imaging based approach><improved><large scale data><large scale data sets><large scale datasets><molecular imaging><molecule imaging><multi-modality><multidisciplinary><multimodality><multiomics><multiple omics><necropsy><nerve cement><nervous system disorder><neural circuit><neural circuitry><neurochemical><neurochemistry><neurocircuitry><neurological disease><neuronal><neuropsychiatric disease><neuropsychiatric disorder><noncoding><population diversity><postmortem><programs><promoter><promotor><regulatory gene><single cell analysis><snRNA><success><synaptic circuit><synaptic circuitry><three dimensional><tool><trans acting element><transcriptional profile><transcriptional signature><transcriptome><transcriptomics><uRNA>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

MARIA MARGARITA BEHRENS

SALK INSTITUTE FOR BIOLOGICAL STUDIES, La Jolla, CA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$17,644,498

FY 2025

Project Title

Center for Multiomic Human Brain Cell Atlas

Grant Number:

5UM1MH130994-04

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/1/2022

End Date:

6/30/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

Abstract Understanding cell identities and their spatial distributions throughout different regions of the human brain is a fundamental step when trying to integrate physiological, behavioral, neurochemical and molecular data. At present, although major categories of the cell-types present in the hu...

Research Terms

<21+ years old><3-D><3-Dimensional><3D><Acceleration><Address><Adeno-Associated Viruses><Adult><Adult Human><Anatomic Sites><Anatomic structures><Anatomy><Assay><Atlases><Autopsy><BRAIN initiative><Behavioral><Bioassay><Biological Assay><Body Tissues><Brain><Brain Mapping><Brain Nervous System><Brain Pathology><Brain Research through Advancing Innovative Neurotechnologies initiative><Brain region><Categories><Cell Body><Cells><Censuses><Chromatin><Communities><Complex><Cytosine><DNA><DNA Methylation><DNA analysis><Data><Data Analyses><Data Analysis><Data Set><Deoxyribonucleic Acid><Dependoparvovirus><Dependovirus><Encephalon><Enhancers><Expression Signature><Functional RNA><Gene Expression><Gene Expression Profile><Gene Transcription><Gene variant><Generations><Genes><Genetic><Genetic Markers><Genetic Transcription><Genome><Genomics><Glia><Glial Cells><Goals><Heterochromatin><Histones><Human><Image><Individual><Joints><Kolliker's reticulum><Location><Low Molecular Weight Nuclear RNA><Maps><Mediating><Methods><Mice><Mice Mammals><Modern Man><Molecular><Morphology><Murine><Mus><Nerve Cells><Nerve Unit><Nervous System Diseases><Nervous System Disorder><Neural Cell><Neuranatomies><Neuranatomy><Neuroanatomies><Neuroanatomy><Neurocyte><Neuroglia><Neuroglial Cells><Neurologic Disorders><Neurological Disorders><Neurons><Non-Polyadenylated RNA><Non-neuronal cell><Noncoding RNA><Nonneuronal cell><Nontranslated RNA><Nucleic Acid Regulator Regions><Nucleic Acid Regulatory Sequences><Physiologic><Physiological><Population Heterogeneity><Production><Property><RNA><RNA Expression><RNA Gene Products><Records><Regulation><Regulatory Element><Regulatory Regions><Research Specimen><Resolution><Ribonucleic Acid><Sampling><Series><Single-Nucleus Sequencing><Spatial Distribution><Specimen><Structure><Survey Instrument><Surveys><Technology><Testing><Tissue Sample><Tissues><Transcript><Transcription><Untranslated RNA><Validation><Visualization><adeno associated virus group><adulthood><allelic variant><analyze DNA><brain cell><brain tissue><cell type><cost effective><data integration><data interpretation><data management><data portal><data sharing portal><diverse populations><epigenome><epigenomics><experiment><experimental research><experimental study><experiments><gene biomarker><gene expression biomarker><gene expression pattern><gene expression signature><gene marker><gene signature biomarker><genetic analysis><genetic biomarker><genetic regulatory element><genetic variant><genomic variant><global gene expression><global transcription profile><heterogeneous population><histone modification><imaging><imaging approach><imaging based approach><improved><invention><large scale data><large scale data sets><large scale datasets><multi-modality><multidisciplinary><multimodality><multiomics><multiple omics><necropsy><nerve cement><neural circuit><neural circuitry><neurochemical><neurochemistry><neurocircuitry><neurological disease><neuronal><neuropsychiatric disease><neuropsychiatric disorder><noncoding><panomics><population diversity><postmitotic><postmortem><programs><promoter><promotor><resolutions><sNuc-Seq><single cell analysis><single nucleus RNA-sequencing><single nucleus seq><single-nucleus RNA-seq><snRNA><snRNA sequencing><snRNA-seq><success><synaptic circuit><synaptic circuitry><three dimensional><tool><transcriptional profile><transcriptional signature><transcriptome><transcriptomics><uRNA><validations>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Joseph R Ecker

SALK INSTITUTE FOR BIOLOGICAL STUDIES, La Jolla, CA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$17,644,498

FY 2025

Project Title

Center for Multiomic Human Brain Cell Atlas

Grant Number:

5UM1MH130994-04

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/1/2022

End Date:

6/30/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

Abstract Understanding cell identities and their spatial distributions throughout different regions of the human brain is a fundamental step when trying to integrate physiological, behavioral, neurochemical and molecular data. At present, although major categories of the cell-types present in the hu...

Research Terms

<21+ years old><3-D><3-Dimensional><3D><Acceleration><Address><Adeno-Associated Viruses><Adult><Adult Human><Anatomic Sites><Anatomic structures><Anatomy><Assay><Atlases><Autopsy><BRAIN initiative><Behavioral><Bioassay><Biological Assay><Body Tissues><Brain><Brain Mapping><Brain Nervous System><Brain Pathology><Brain Research through Advancing Innovative Neurotechnologies initiative><Brain region><Categories><Cell Body><Cells><Censuses><Chromatin><Communities><Complex><Cytosine><DNA><DNA Methylation><DNA analysis><Data><Data Analyses><Data Analysis><Data Set><Deoxyribonucleic Acid><Dependoparvovirus><Dependovirus><Encephalon><Enhancers><Expression Signature><Functional RNA><Gene Expression><Gene Expression Profile><Gene Transcription><Gene variant><Generations><Genes><Genetic><Genetic Markers><Genetic Transcription><Genome><Genomics><Glia><Glial Cells><Goals><Heterochromatin><Histones><Human><Image><Individual><Joints><Kolliker's reticulum><Location><Low Molecular Weight Nuclear RNA><Maps><Mediating><Methods><Mice><Mice Mammals><Modern Man><Molecular><Morphology><Murine><Mus><Nerve Cells><Nerve Unit><Nervous System Diseases><Nervous System Disorder><Neural Cell><Neuranatomies><Neuranatomy><Neuroanatomies><Neuroanatomy><Neurocyte><Neuroglia><Neuroglial Cells><Neurologic Disorders><Neurological Disorders><Neurons><Non-Polyadenylated RNA><Non-neuronal cell><Noncoding RNA><Nonneuronal cell><Nontranslated RNA><Nucleic Acid Regulator Regions><Nucleic Acid Regulatory Sequences><Physiologic><Physiological><Population Heterogeneity><Production><Property><RNA><RNA Expression><RNA Gene Products><Records><Regulation><Regulatory Element><Regulatory Regions><Research Specimen><Resolution><Ribonucleic Acid><Sampling><Series><Single-Nucleus Sequencing><Spatial Distribution><Specimen><Structure><Survey Instrument><Surveys><Technology><Testing><Tissue Sample><Tissues><Transcript><Transcription><Untranslated RNA><Validation><Visualization><adeno associated virus group><adulthood><allelic variant><analyze DNA><brain cell><brain tissue><cell type><cost effective><data integration><data interpretation><data management><data portal><data sharing portal><diverse populations><epigenome><epigenomics><experiment><experimental research><experimental study><experiments><gene biomarker><gene expression biomarker><gene expression pattern><gene expression signature><gene marker><gene signature biomarker><genetic analysis><genetic biomarker><genetic regulatory element><genetic variant><genomic variant><global gene expression><global transcription profile><heterogeneous population><histone modification><imaging><imaging approach><imaging based approach><improved><invention><large scale data><large scale data sets><large scale datasets><multi-modality><multidisciplinary><multimodality><multiomics><multiple omics><necropsy><nerve cement><neural circuit><neural circuitry><neurochemical><neurochemistry><neurocircuitry><neurological disease><neuronal><neuropsychiatric disease><neuropsychiatric disorder><noncoding><panomics><population diversity><postmitotic><postmortem><programs><promoter><promotor><resolutions><sNuc-Seq><single cell analysis><single nucleus RNA-sequencing><single nucleus seq><single-nucleus RNA-seq><snRNA><snRNA sequencing><snRNA-seq><success><synaptic circuit><synaptic circuitry><three dimensional><tool><transcriptional profile><transcriptional signature><transcriptome><transcriptomics><uRNA><validations>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Daofeng Li

SALK INSTITUTE FOR BIOLOGICAL STUDIES, La Jolla, CA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$17,644,498

FY 2025

Project Title

Center for Multiomic Human Brain Cell Atlas

Grant Number:

5UM1MH130994-04

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/1/2022

End Date:

6/30/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

Abstract Understanding cell identities and their spatial distributions throughout different regions of the human brain is a fundamental step when trying to integrate physiological, behavioral, neurochemical and molecular data. At present, although major categories of the cell-types present in the hu...

Research Terms

<21+ years old><3-D><3-Dimensional><3D><Acceleration><Address><Adeno-Associated Viruses><Adult><Adult Human><Anatomic Sites><Anatomic structures><Anatomy><Assay><Atlases><Autopsy><BRAIN initiative><Behavioral><Bioassay><Biological Assay><Body Tissues><Brain><Brain Mapping><Brain Nervous System><Brain Pathology><Brain Research through Advancing Innovative Neurotechnologies initiative><Brain region><Categories><Cell Body><Cells><Censuses><Chromatin><Communities><Complex><Cytosine><DNA><DNA Methylation><DNA analysis><Data><Data Analyses><Data Analysis><Data Set><Deoxyribonucleic Acid><Dependoparvovirus><Dependovirus><Encephalon><Enhancers><Expression Signature><Functional RNA><Gene Expression><Gene Expression Profile><Gene Transcription><Gene variant><Generations><Genes><Genetic><Genetic Markers><Genetic Transcription><Genome><Genomics><Glia><Glial Cells><Goals><Heterochromatin><Histones><Human><Image><Individual><Joints><Kolliker's reticulum><Location><Low Molecular Weight Nuclear RNA><Maps><Mediating><Methods><Mice><Mice Mammals><Modern Man><Molecular><Morphology><Murine><Mus><Nerve Cells><Nerve Unit><Nervous System Diseases><Nervous System Disorder><Neural Cell><Neuranatomies><Neuranatomy><Neuroanatomies><Neuroanatomy><Neurocyte><Neuroglia><Neuroglial Cells><Neurologic Disorders><Neurological Disorders><Neurons><Non-Polyadenylated RNA><Non-neuronal cell><Noncoding RNA><Nonneuronal cell><Nontranslated RNA><Nucleic Acid Regulator Regions><Nucleic Acid Regulatory Sequences><Physiologic><Physiological><Population Heterogeneity><Production><Property><RNA><RNA Expression><RNA Gene Products><Records><Regulation><Regulatory Element><Regulatory Regions><Research Specimen><Resolution><Ribonucleic Acid><Sampling><Series><Single-Nucleus Sequencing><Spatial Distribution><Specimen><Structure><Survey Instrument><Surveys><Technology><Testing><Tissue Sample><Tissues><Transcript><Transcription><Untranslated RNA><Validation><Visualization><adeno associated virus group><adulthood><allelic variant><analyze DNA><brain cell><brain tissue><cell type><cost effective><data integration><data interpretation><data management><data portal><data sharing portal><diverse populations><epigenome><epigenomics><experiment><experimental research><experimental study><experiments><gene biomarker><gene expression biomarker><gene expression pattern><gene expression signature><gene marker><gene signature biomarker><genetic analysis><genetic biomarker><genetic regulatory element><genetic variant><genomic variant><global gene expression><global transcription profile><heterogeneous population><histone modification><imaging><imaging approach><imaging based approach><improved><invention><large scale data><large scale data sets><large scale datasets><multi-modality><multidisciplinary><multimodality><multiomics><multiple omics><necropsy><nerve cement><neural circuit><neural circuitry><neurochemical><neurochemistry><neurocircuitry><neurological disease><neuronal><neuropsychiatric disease><neuropsychiatric disorder><noncoding><panomics><population diversity><postmitotic><postmortem><programs><promoter><promotor><resolutions><sNuc-Seq><single cell analysis><single nucleus RNA-sequencing><single nucleus seq><single-nucleus RNA-seq><snRNA><snRNA sequencing><snRNA-seq><success><synaptic circuit><synaptic circuitry><three dimensional><tool><transcriptional profile><transcriptional signature><transcriptome><transcriptomics><uRNA><validations>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Bing Ren

SALK INSTITUTE FOR BIOLOGICAL STUDIES, La Jolla, CA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$17,644,498

FY 2025

Project Title

Center for Multiomic Human Brain Cell Atlas

Grant Number:

5UM1MH130994-04

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/1/2022

End Date:

6/30/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

Abstract Understanding cell identities and their spatial distributions throughout different regions of the human brain is a fundamental step when trying to integrate physiological, behavioral, neurochemical and molecular data. At present, although major categories of the cell-types present in the hu...

Research Terms

<21+ years old><3-D><3-Dimensional><3D><Acceleration><Address><Adeno-Associated Viruses><Adult><Adult Human><Anatomic Sites><Anatomic structures><Anatomy><Assay><Atlases><Autopsy><BRAIN initiative><Behavioral><Bioassay><Biological Assay><Body Tissues><Brain><Brain Mapping><Brain Nervous System><Brain Pathology><Brain Research through Advancing Innovative Neurotechnologies initiative><Brain region><Categories><Cell Body><Cells><Censuses><Chromatin><Communities><Complex><Cytosine><DNA><DNA Methylation><DNA analysis><Data><Data Analyses><Data Analysis><Data Set><Deoxyribonucleic Acid><Dependoparvovirus><Dependovirus><Encephalon><Enhancers><Expression Signature><Functional RNA><Gene Expression><Gene Expression Profile><Gene Transcription><Gene variant><Generations><Genes><Genetic><Genetic Markers><Genetic Transcription><Genome><Genomics><Glia><Glial Cells><Goals><Heterochromatin><Histones><Human><Image><Individual><Joints><Kolliker's reticulum><Location><Low Molecular Weight Nuclear RNA><Maps><Mediating><Methods><Mice><Mice Mammals><Modern Man><Molecular><Morphology><Murine><Mus><Nerve Cells><Nerve Unit><Nervous System Diseases><Nervous System Disorder><Neural Cell><Neuranatomies><Neuranatomy><Neuroanatomies><Neuroanatomy><Neurocyte><Neuroglia><Neuroglial Cells><Neurologic Disorders><Neurological Disorders><Neurons><Non-Polyadenylated RNA><Non-neuronal cell><Noncoding RNA><Nonneuronal cell><Nontranslated RNA><Nucleic Acid Regulator Regions><Nucleic Acid Regulatory Sequences><Physiologic><Physiological><Population Heterogeneity><Production><Property><RNA><RNA Expression><RNA Gene Products><Records><Regulation><Regulatory Element><Regulatory Regions><Research Specimen><Resolution><Ribonucleic Acid><Sampling><Series><Single-Nucleus Sequencing><Spatial Distribution><Specimen><Structure><Survey Instrument><Surveys><Technology><Testing><Tissue Sample><Tissues><Transcript><Transcription><Untranslated RNA><Validation><Visualization><adeno associated virus group><adulthood><allelic variant><analyze DNA><brain cell><brain tissue><cell type><cost effective><data integration><data interpretation><data management><data portal><data sharing portal><diverse populations><epigenome><epigenomics><experiment><experimental research><experimental study><experiments><gene biomarker><gene expression biomarker><gene expression pattern><gene expression signature><gene marker><gene signature biomarker><genetic analysis><genetic biomarker><genetic regulatory element><genetic variant><genomic variant><global gene expression><global transcription profile><heterogeneous population><histone modification><imaging><imaging approach><imaging based approach><improved><invention><large scale data><large scale data sets><large scale datasets><multi-modality><multidisciplinary><multimodality><multiomics><multiple omics><necropsy><nerve cement><neural circuit><neural circuitry><neurochemical><neurochemistry><neurocircuitry><neurological disease><neuronal><neuropsychiatric disease><neuropsychiatric disorder><noncoding><panomics><population diversity><postmitotic><postmortem><programs><promoter><promotor><resolutions><sNuc-Seq><single cell analysis><single nucleus RNA-sequencing><single nucleus seq><single-nucleus RNA-seq><snRNA><snRNA sequencing><snRNA-seq><success><synaptic circuit><synaptic circuitry><three dimensional><tool><transcriptional profile><transcriptional signature><transcriptome><transcriptomics><uRNA><validations>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

XIANGMIN XU

SALK INSTITUTE FOR BIOLOGICAL STUDIES, La Jolla, CA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$17,644,498

FY 2025

Project Title

Center for Multiomic Human Brain Cell Atlas

Grant Number:

5UM1MH130994-04

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/1/2022

End Date:

6/30/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

Abstract Understanding cell identities and their spatial distributions throughout different regions of the human brain is a fundamental step when trying to integrate physiological, behavioral, neurochemical and molecular data. At present, although major categories of the cell-types present in the hu...

Research Terms

<21+ years old><3-D><3-Dimensional><3D><Acceleration><Address><Adeno-Associated Viruses><Adult><Adult Human><Anatomic Sites><Anatomic structures><Anatomy><Assay><Atlases><Autopsy><BRAIN initiative><Behavioral><Bioassay><Biological Assay><Body Tissues><Brain><Brain Mapping><Brain Nervous System><Brain Pathology><Brain Research through Advancing Innovative Neurotechnologies initiative><Brain region><Categories><Cell Body><Cells><Censuses><Chromatin><Communities><Complex><Cytosine><DNA><DNA Methylation><DNA analysis><Data><Data Analyses><Data Analysis><Data Set><Deoxyribonucleic Acid><Dependoparvovirus><Dependovirus><Encephalon><Enhancers><Expression Signature><Functional RNA><Gene Expression><Gene Expression Profile><Gene Transcription><Gene variant><Generations><Genes><Genetic><Genetic Markers><Genetic Transcription><Genome><Genomics><Glia><Glial Cells><Goals><Heterochromatin><Histones><Human><Image><Individual><Joints><Kolliker's reticulum><Location><Low Molecular Weight Nuclear RNA><Maps><Mediating><Methods><Mice><Mice Mammals><Modern Man><Molecular><Morphology><Murine><Mus><Nerve Cells><Nerve Unit><Nervous System Diseases><Nervous System Disorder><Neural Cell><Neuranatomies><Neuranatomy><Neuroanatomies><Neuroanatomy><Neurocyte><Neuroglia><Neuroglial Cells><Neurologic Disorders><Neurological Disorders><Neurons><Non-Polyadenylated RNA><Non-neuronal cell><Noncoding RNA><Nonneuronal cell><Nontranslated RNA><Nucleic Acid Regulator Regions><Nucleic Acid Regulatory Sequences><Physiologic><Physiological><Population Heterogeneity><Production><Property><RNA><RNA Expression><RNA Gene Products><Records><Regulation><Regulatory Element><Regulatory Regions><Research Specimen><Resolution><Ribonucleic Acid><Sampling><Series><Single-Nucleus Sequencing><Spatial Distribution><Specimen><Structure><Survey Instrument><Surveys><Technology><Testing><Tissue Sample><Tissues><Transcript><Transcription><Untranslated RNA><Validation><Visualization><adeno associated virus group><adulthood><allelic variant><analyze DNA><brain cell><brain tissue><cell type><cost effective><data integration><data interpretation><data management><data portal><data sharing portal><diverse populations><epigenome><epigenomics><experiment><experimental research><experimental study><experiments><gene biomarker><gene expression biomarker><gene expression pattern><gene expression signature><gene marker><gene signature biomarker><genetic analysis><genetic biomarker><genetic regulatory element><genetic variant><genomic variant><global gene expression><global transcription profile><heterogeneous population><histone modification><imaging><imaging approach><imaging based approach><improved><invention><large scale data><large scale data sets><large scale datasets><multi-modality><multidisciplinary><multimodality><multiomics><multiple omics><necropsy><nerve cement><neural circuit><neural circuitry><neurochemical><neurochemistry><neurocircuitry><neurological disease><neuronal><neuropsychiatric disease><neuropsychiatric disorder><noncoding><panomics><population diversity><postmitotic><postmortem><programs><promoter><promotor><resolutions><sNuc-Seq><single cell analysis><single nucleus RNA-sequencing><single nucleus seq><single-nucleus RNA-seq><snRNA><snRNA sequencing><snRNA-seq><success><synaptic circuit><synaptic circuitry><three dimensional><tool><transcriptional profile><transcriptional signature><transcriptome><transcriptomics><uRNA><validations>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

KIMBERLY S. JOHNSON

DUKE UNIVERSITY, DURHAM, NC

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$9,890,205

FY 2025

Project Title

CTSA UM1 at Duke University

Grant Number:

1UM1TR005436-01

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

8/15/2025

End Date:

7/31/2032

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

The mission of the Duke Clinical and Translational Science Institute (CTSI), home to the Clinical and Translational Science Award (CTSA) since 2006, is to catalyze translational science in ways that effectively and efficiently bring medical discoveries to society. In the next phase of our CTSA, we a...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Christopher J. Lindsell

DUKE UNIVERSITY, DURHAM, NC

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$9,890,205

FY 2025

Project Title

CTSA UM1 at Duke University

Grant Number:

1UM1TR005436-01

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

8/15/2025

End Date:

7/31/2032

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

The mission of the Duke Clinical and Translational Science Institute (CTSI), home to the Clinical and Translational Science Award (CTSA) since 2006, is to catalyze translational science in ways that effectively and efficiently bring medical discoveries to society. In the next phase of our CTSA, we a...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Susanna Naggie

DUKE UNIVERSITY, DURHAM, NC

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$9,890,205

FY 2025

Project Title

CTSA UM1 at Duke University

Grant Number:

1UM1TR005436-01

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

8/15/2025

End Date:

7/31/2032

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

The mission of the Duke Clinical and Translational Science Institute (CTSI), home to the Clinical and Translational Science Award (CTSA) since 2006, is to catalyze translational science in ways that effectively and efficiently bring medical discoveries to society. In the next phase of our CTSA, we a...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

JANINE A HIGGINS

UNIVERSITY OF COLORADO DENVER, Aurora, CO

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$7,667,611

FY 2025

Project Title

Colorado Clinical and Translational Sciences Institute (CCTSI)

Grant Number:

5UM1TR004399-03

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/15/2023

End Date:

7/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

Instruction: Funded by NIH since 2008, the Colorado Clinical and Translational Sciences Institute (CCTSI) at the University of Colorado Denver (CU Denver) has transformed the clinical and translational research and training enterprise in the Colorado region with the vision of accelerating the transl...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

RONALD J. SOKOL

UNIVERSITY OF COLORADO DENVER, Aurora, CO

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$7,667,611

FY 2025

Project Title

Colorado Clinical and Translational Sciences Institute (CCTSI)

Grant Number:

5UM1TR004399-03

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/15/2023

End Date:

7/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

Instruction: Funded by NIH since 2008, the Colorado Clinical and Translational Sciences Institute (CCTSI) at the University of Colorado Denver (CU Denver) has transformed the clinical and translational research and training enterprise in the Colorado region with the vision of accelerating the transl...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Sara Becker

NORTHWESTERN UNIVERSITY AT CHICAGO, CHICAGO, IL

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$7,541,744

FY 2025

Project Title

NUCATS CTSA UM1 at Northwestern University

Grant Number:

5UM1TR005121-02

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/1/2024

End Date:

7/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

Over prior funding cycles, the Northwestern University Clinical and Translational Sciences (NUCATS) Institute has developed and delivered a robust institutional infrastructure to support clinical and translational research. Our mature CTSA hub has made exceptional contributions to the consortium, at...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Richard D'Aquila

NORTHWESTERN UNIVERSITY AT CHICAGO, CHICAGO, IL

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$7,541,744

FY 2025

Project Title

NUCATS CTSA UM1 at Northwestern University

Grant Number:

5UM1TR005121-02

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/1/2024

End Date:

7/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

Over prior funding cycles, the Northwestern University Clinical and Translational Sciences (NUCATS) Institute has developed and delivered a robust institutional infrastructure to support clinical and translational research. Our mature CTSA hub has made exceptional contributions to the consortium, at...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Clyde W. Yancy

NORTHWESTERN UNIVERSITY AT CHICAGO, CHICAGO, IL

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$7,541,744

FY 2025

Project Title

NUCATS CTSA UM1 at Northwestern University

Grant Number:

5UM1TR005121-02

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/1/2024

End Date:

7/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

Over prior funding cycles, the Northwestern University Clinical and Translational Sciences (NUCATS) Institute has developed and delivered a robust institutional infrastructure to support clinical and translational research. Our mature CTSA hub has made exceptional contributions to the consortium, at...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mark S Anderson

BENAROYA RESEARCH INST AT VIRGINIA MASON, SEATTLE, WA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$7,500,000

FY 2024

Project Title

Immune Tolerance Network UM1 2023 Supplement

Grant Number:

3UM1AI109565-10S2

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2014

End Date:

1/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

Project Summary / Abstract The mission of the ITN is to advance the clinical application of immune tolerance by performing high quality clinical trials of emerging therapeutics based upon testable mechanistic hypotheses. The ITN is structured in order to interrogate different diseases across the imm...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jane Hoyt Buckner

BENAROYA RESEARCH INST AT VIRGINIA MASON, SEATTLE, WA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$7,500,000

FY 2024

Project Title

Immune Tolerance Network UM1 2023 Supplement

Grant Number:

3UM1AI109565-10S2

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2014

End Date:

1/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

Project Summary / Abstract The mission of the ITN is to advance the clinical application of immune tolerance by performing high quality clinical trials of emerging therapeutics based upon testable mechanistic hypotheses. The ITN is structured in order to interrogate different diseases across the imm...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ignacio E. Sanz

EMORY UNIVERSITY, ATLANTA, GA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$4,394,852

FY 2025

Project Title

Regulation of B cell Responses in SLE and Other Autoimmune Diseases

Grant Number:

5U19AI110483-12

Activity Code:

U19

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/1/2014

End Date:

4/30/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

The overarching objective of the Emory Autoimmunity Center of Excellence (ACE) U19 is to decipher the molecular programs responsible for the aberrant B cell responses underpinning autoimmune diseases. A central tenet of the Emory ACE is that unraveling the heterogeneity of human autoimmune diseases ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

GARY E ROSENTHAL

WAKE FOREST UNIVERSITY HEALTH SCIENCES, WINSTON-SALEM, NC

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$4,030,000

FY 2024

Project Title

CTSA UM1 Program at Wake Forest

Grant Number:

1UM1TR004929-01

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2024

End Date:

6/30/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

PROJECT SUMMARY/ABSTRACT The emergence of large integrated health systems linked by common informatics platforms offers an unprecedented opportunity to study the impact of new therapies, healthcare delivery models, and strategies to mitigate health disparities in real world settings. Such integrated...

Research Terms

<0-11 years old><Acceleration><Accident and Emergency department><Accountability><Achievement><Achievement Attainment><Address><Adoption><Advocate><Ambulatory Surgery><Ambulatory Surgical Procedures><Biologic Models><Biological Models><Caring><Child><Child Youth><Children (0-21)><Clinic><Clinical Sciences><Clinical effectiveness><Collaborations><Communities><Data><Decrease disparity><Decrease health disparities><Development><Disease><Disorder><Dissemination and Implementation><EXTMR><Education><Educational aspects><Educational process of instructing><Electronic Health Record><Elements><Emergencies><Emergency Department><Emergency Situation><Emergency room><Environment><Evidence based practice><Extramural><Extramural Activities><Funding><Generalized Growth><Goals><Growth><Health><Health Facilities><Health care facility><Health disparity mitigation><Health disparity reduction><Health system><Healthcare Facility><Hospitals><Human><Incentives><Informatics><Integrated Health Care Systems><Knowledge><Learning><Link><Lower disparity><Lower health disparities><Medical Rehabilitation><Medical center><Methods><Midwest><Midwest U.S.><Midwest US><Midwestern United States><Mission><Mitigate health disparities><Model System><Modeling><Modern Man><North Carolina><Outpatient Surgery><Patient Recruitments><Patients><Pilot Projects><Prevention><Primary Care><Process><Reaction Time><Reduce health disparities><Rehabilitation><Rehabilitation therapy><Research><Research Design><Research Resources><Resources><Respondent><Response RT><Response Time><Sampling><Scholarship><Science><Service delivery model><Service model><Sight><Site><Source><Specialty><Structure><Study Type><System><Teaching><Techniques><Testing><Tissue Growth><Training><Translational Research><Translational Science><Translations><United States><Vision><Work><behavioral health><care delivery><care delivery model><care facilities><clinical translation><clinically translatable><community setting><developmental><disparity in care><disparity in healthcare><disparity reduction><diversity, equity, and inclusiveness><electronic health care record><electronic health data><electronic health medical record><electronic health plan record><electronic health registry><electronic medical health record><equity, diversity, and inclusion><experience><health care delivery model><health care disparity><health care inequality><health care inequity><health care settings><health equity><healthcare delivery model><healthcare disparity><healthcare inequality><healthcare inequity><healthcare settings><improved><innovate><innovation><innovative><integrated health system><integrated healthcare systems><integrated system of care><kids><medical specialties><mitigate disparity><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><ontogeny><participant recruitment><pilot study><population survey><practice setting><pragmatic study><programs><psychomotor reaction time><recruit><reduce disparity><reduction in disparity><rehab therapy><rehabilitative><rehabilitative therapy><safety net><social health determinants><study design><systems research><translation><translation research><translational investigation><visual function><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jamy D Ard

WAKE FOREST UNIVERSITY HEALTH SCIENCES, WINSTON-SALEM, NC

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$3,951,899

FY 2025

Project Title

CTSA UM1 Program at Wake Forest

Grant Number:

5UM1TR004929-02

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2024

End Date:

6/30/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

The emergence of large integrated health systems linked by common informatics platforms offers an unprecedented opportunity to study the impact of new therapies and healthcare delivery models in real world settings. Such integrated systems also offer opportunities to test approaches to implement and...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

KRISTIE L FOLEY

WAKE FOREST UNIVERSITY HEALTH SCIENCES, WINSTON-SALEM, NC

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$3,951,899

FY 2025

Project Title

CTSA UM1 Program at Wake Forest

Grant Number:

5UM1TR004929-02

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2024

End Date:

6/30/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

The emergence of large integrated health systems linked by common informatics platforms offers an unprecedented opportunity to study the impact of new therapies and healthcare delivery models in real world settings. Such integrated systems also offer opportunities to test approaches to implement and...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Thomas K Houston

WAKE FOREST UNIVERSITY HEALTH SCIENCES, WINSTON-SALEM, NC

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$3,951,899

FY 2025

Project Title

CTSA UM1 Program at Wake Forest

Grant Number:

5UM1TR004929-02

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2024

End Date:

6/30/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

The emergence of large integrated health systems linked by common informatics platforms offers an unprecedented opportunity to study the impact of new therapies and healthcare delivery models in real world settings. Such integrated systems also offer opportunities to test approaches to implement and...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

MICHAEL L BOEHNKE

BROAD INSTITUTE, INC., CAMBRIDGE, MA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$3,197,364

FY 2025

Project Title

The next iteration of the AMP-T2D Knowledge Portal

Grant Number:

5UM1DK105554-10

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/1/2015

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

Abstract Despite much progress in mapping genetic associations for T2D, its complications, and related traits, the underlying causal variants, effector genes, and gene networks are not well understood. The AMP-T2D consortium aims to accelerate the pace by which these disease mechanisms are elucidat...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Noel P Burtt

BROAD INSTITUTE, INC., CAMBRIDGE, MA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$3,197,364

FY 2025

Project Title

The next iteration of the AMP-T2D Knowledge Portal

Grant Number:

5UM1DK105554-10

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/1/2015

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

Abstract Despite much progress in mapping genetic associations for T2D, its complications, and related traits, the underlying causal variants, effector genes, and gene networks are not well understood. The AMP-T2D consortium aims to accelerate the pace by which these disease mechanisms are elucidat...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jason Flannick

BROAD INSTITUTE, INC., CAMBRIDGE, MA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$3,197,364

FY 2025

Project Title

The next iteration of the AMP-T2D Knowledge Portal

Grant Number:

5UM1DK105554-10

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/1/2015

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

Abstract Despite much progress in mapping genetic associations for T2D, its complications, and related traits, the underlying causal variants, effector genes, and gene networks are not well understood. The AMP-T2D consortium aims to accelerate the pace by which these disease mechanisms are elucidat...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Frank Alber

CARNEGIE-MELLON UNIVERSITY, PITTSBURGH, PA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$2,075,409

FY 2024

Project Title

Multiscale Analyses of 4D Nucleome Structure and Function by Comprehensive Multimodal Data Integration

Grant Number:

5UM1HG011593-05

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/22/2020

End Date:

6/30/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

PROJECT SUMMARY The cell nucleus is a heterogeneous organelle that consists of nuclear bodies such as nuclear lamina, speckles, nucleoli and PML bodies. These structures continuously tether and tug chromatin at the small and large scales to synergistically orchestrate dynamic functions in distinct s...

Research Terms

<3-D Imaging><3D imaging><Address><Architecture><Basal Transcription Factor><Basal transcription factor genes><Binding><Biochemical><CUT&RUN><Cell Body><Cell Cycle><Cell Division Cycle><Cell Function><Cell Nucleus><Cell Physiology><Cell Process><Cells><Cellular Function><Cellular Physiology><Cellular Process><Chromatin><Chromatin Loop><Chromatin Loop Domains><Chromatin Structure><Chromosomal Organization><Chromosomal Structure><Chromosome Mapping><Chromosome Organization><Chromosome Structures><Chromosomes><Cleavage Targets and Release Using Nuclease><Cleavage Under Targets and Release Using Nuclease><Collaborations><Communities><Computational toolkit><Computing Methodologies><Cytology><DNA Loop><DNA Replication Timing><Data><Data Set><Development><Disease><Disorder><Engineering / Architecture><Formulation><Gene Expression><Gene Localization><Gene Mapping><Gene Mapping Genetics><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Genetic><Genetic Transcription><Genome><Genomics><Goals><Health><Human><Image><Interphase Chromosome><Intuition><Investigators><Knowledge><Link><Linkage Mapping><Maps><Measurement><Measures><Methods><Microscopy><Mission><Modality><Modeling><Modern Man><Molecular><Molecular Interaction><Multimodal Imaging><NIH><National Institutes of Health><Nuclear><Nuclear Lamina><Nuclear Structure><Nucleus><Organelles><Outcome><Output><PRO-seq><Phase><Population><Precision Run-On Sequencing><Precision nuclear run-on sequencing><Production><Public Health><RNA Expression><RNA Seq><RNA sequencing><RNAseq><Research><Research Personnel><Researchers><Resolution><Role><Structure><Subcellular Process><Technology><Temporal DNA Replication Order><Temporal DNA Replication Pattern><Three-Dimensional Imaging><Total Human and Non-Human Gene Mapping><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><United States National Institutes of Health><Validation><Variant><Variation><Visualization><Work><cell fixing><cell type><computational framework><computational methodology><computational methods><computational toolbox><computational tools><computational toolset><computer based method><computer based prediction><computer framework><computer methods><computerized tools><computing method><data exploration><data integration><data tools><developmental><empowerment><entire genome><experiment><experimental research><experimental study><experiments><full genome><genetic mapping><genome scale><genome-wide><genomewide><genomic data><genomic data-set><genomic dataset><histone modification><image-based method><imaging><imaging method><imaging modality><improved><insight><interactive data visualization><interactive visualization><intuitive><machine learned algorithm><machine learning algorithm><machine learning based algorithm><multi-modal data><multi-modal datasets><multi-modal imaging><multi-modality><multi-modality imaging><multi-scale atlas><multi-scale data><multimodal data><multimodal datasets><multimodality><multimodality imaging><multiple data types><multiscale atlas><multiscale data><predictive modeling><resolutions><response><social role><spatiotemporal><superresolution microscopy><tool><transcription factor><transcriptome sequencing><transcriptomic sequencing><user-friendly><validations><whole genome>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Andrew Steven Belmont

CARNEGIE-MELLON UNIVERSITY, PITTSBURGH, PA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$2,075,409

FY 2024

Project Title

Multiscale Analyses of 4D Nucleome Structure and Function by Comprehensive Multimodal Data Integration

Grant Number:

5UM1HG011593-05

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/22/2020

End Date:

6/30/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

PROJECT SUMMARY The cell nucleus is a heterogeneous organelle that consists of nuclear bodies such as nuclear lamina, speckles, nucleoli and PML bodies. These structures continuously tether and tug chromatin at the small and large scales to synergistically orchestrate dynamic functions in distinct s...

Research Terms

<3-D Imaging><3D imaging><Address><Architecture><Basal Transcription Factor><Basal transcription factor genes><Binding><Biochemical><CUT&RUN><Cell Body><Cell Cycle><Cell Division Cycle><Cell Function><Cell Nucleus><Cell Physiology><Cell Process><Cells><Cellular Function><Cellular Physiology><Cellular Process><Chromatin><Chromatin Loop><Chromatin Loop Domains><Chromatin Structure><Chromosomal Organization><Chromosomal Structure><Chromosome Mapping><Chromosome Organization><Chromosome Structures><Chromosomes><Cleavage Targets and Release Using Nuclease><Cleavage Under Targets and Release Using Nuclease><Collaborations><Communities><Computational toolkit><Computing Methodologies><Cytology><DNA Loop><DNA Replication Timing><Data><Data Set><Development><Disease><Disorder><Engineering / Architecture><Formulation><Gene Expression><Gene Localization><Gene Mapping><Gene Mapping Genetics><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Genetic><Genetic Transcription><Genome><Genomics><Goals><Health><Human><Image><Interphase Chromosome><Intuition><Investigators><Knowledge><Link><Linkage Mapping><Maps><Measurement><Measures><Methods><Microscopy><Mission><Modality><Modeling><Modern Man><Molecular><Molecular Interaction><Multimodal Imaging><NIH><National Institutes of Health><Nuclear><Nuclear Lamina><Nuclear Structure><Nucleus><Organelles><Outcome><Output><PRO-seq><Phase><Population><Precision Run-On Sequencing><Precision nuclear run-on sequencing><Production><Public Health><RNA Expression><RNA Seq><RNA sequencing><RNAseq><Research><Research Personnel><Researchers><Resolution><Role><Structure><Subcellular Process><Technology><Temporal DNA Replication Order><Temporal DNA Replication Pattern><Three-Dimensional Imaging><Total Human and Non-Human Gene Mapping><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><United States National Institutes of Health><Validation><Variant><Variation><Visualization><Work><cell fixing><cell type><computational framework><computational methodology><computational methods><computational toolbox><computational tools><computational toolset><computer based method><computer based prediction><computer framework><computer methods><computerized tools><computing method><data exploration><data integration><data tools><developmental><empowerment><entire genome><experiment><experimental research><experimental study><experiments><full genome><genetic mapping><genome scale><genome-wide><genomewide><genomic data><genomic data-set><genomic dataset><histone modification><image-based method><imaging><imaging method><imaging modality><improved><insight><interactive data visualization><interactive visualization><intuitive><machine learned algorithm><machine learning algorithm><machine learning based algorithm><multi-modal data><multi-modal datasets><multi-modal imaging><multi-modality><multi-modality imaging><multi-scale atlas><multi-scale data><multimodal data><multimodal datasets><multimodality><multimodality imaging><multiple data types><multiscale atlas><multiscale data><predictive modeling><resolutions><response><social role><spatiotemporal><superresolution microscopy><tool><transcription factor><transcriptome sequencing><transcriptomic sequencing><user-friendly><validations><whole genome>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

JIAN MA

CARNEGIE-MELLON UNIVERSITY, PITTSBURGH, PA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$2,075,409

FY 2024

Project Title

Multiscale Analyses of 4D Nucleome Structure and Function by Comprehensive Multimodal Data Integration

Grant Number:

5UM1HG011593-05

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/22/2020

End Date:

6/30/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

PROJECT SUMMARY The cell nucleus is a heterogeneous organelle that consists of nuclear bodies such as nuclear lamina, speckles, nucleoli and PML bodies. These structures continuously tether and tug chromatin at the small and large scales to synergistically orchestrate dynamic functions in distinct s...

Research Terms

<3-D Imaging><3D imaging><Address><Architecture><Basal Transcription Factor><Basal transcription factor genes><Binding><Biochemical><CUT&RUN><Cell Body><Cell Cycle><Cell Division Cycle><Cell Function><Cell Nucleus><Cell Physiology><Cell Process><Cells><Cellular Function><Cellular Physiology><Cellular Process><Chromatin><Chromatin Loop><Chromatin Loop Domains><Chromatin Structure><Chromosomal Organization><Chromosomal Structure><Chromosome Mapping><Chromosome Organization><Chromosome Structures><Chromosomes><Cleavage Targets and Release Using Nuclease><Cleavage Under Targets and Release Using Nuclease><Collaborations><Communities><Computational toolkit><Computing Methodologies><Cytology><DNA Loop><DNA Replication Timing><Data><Data Set><Development><Disease><Disorder><Engineering / Architecture><Formulation><Gene Expression><Gene Localization><Gene Mapping><Gene Mapping Genetics><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Genetic><Genetic Transcription><Genome><Genomics><Goals><Health><Human><Image><Interphase Chromosome><Intuition><Investigators><Knowledge><Link><Linkage Mapping><Maps><Measurement><Measures><Methods><Microscopy><Mission><Modality><Modeling><Modern Man><Molecular><Molecular Interaction><Multimodal Imaging><NIH><National Institutes of Health><Nuclear><Nuclear Lamina><Nuclear Structure><Nucleus><Organelles><Outcome><Output><PRO-seq><Phase><Population><Precision Run-On Sequencing><Precision nuclear run-on sequencing><Production><Public Health><RNA Expression><RNA Seq><RNA sequencing><RNAseq><Research><Research Personnel><Researchers><Resolution><Role><Structure><Subcellular Process><Technology><Temporal DNA Replication Order><Temporal DNA Replication Pattern><Three-Dimensional Imaging><Total Human and Non-Human Gene Mapping><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><United States National Institutes of Health><Validation><Variant><Variation><Visualization><Work><cell fixing><cell type><computational framework><computational methodology><computational methods><computational toolbox><computational tools><computational toolset><computer based method><computer based prediction><computer framework><computer methods><computerized tools><computing method><data exploration><data integration><data tools><developmental><empowerment><entire genome><experiment><experimental research><experimental study><experiments><full genome><genetic mapping><genome scale><genome-wide><genomewide><genomic data><genomic data-set><genomic dataset><histone modification><image-based method><imaging><imaging method><imaging modality><improved><insight><interactive data visualization><interactive visualization><intuitive><machine learned algorithm><machine learning algorithm><machine learning based algorithm><multi-modal data><multi-modal datasets><multi-modal imaging><multi-modality><multi-modality imaging><multi-scale atlas><multi-scale data><multimodal data><multimodal datasets><multimodality><multimodality imaging><multiple data types><multiscale atlas><multiscale data><predictive modeling><resolutions><response><social role><spatiotemporal><superresolution microscopy><tool><transcription factor><transcriptome sequencing><transcriptomic sequencing><user-friendly><validations><whole genome>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

CHAO-TING WU

CARNEGIE-MELLON UNIVERSITY, PITTSBURGH, PA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$2,075,409

FY 2024

Project Title

Multiscale Analyses of 4D Nucleome Structure and Function by Comprehensive Multimodal Data Integration

Grant Number:

5UM1HG011593-05

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/22/2020

End Date:

6/30/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

PROJECT SUMMARY The cell nucleus is a heterogeneous organelle that consists of nuclear bodies such as nuclear lamina, speckles, nucleoli and PML bodies. These structures continuously tether and tug chromatin at the small and large scales to synergistically orchestrate dynamic functions in distinct s...

Research Terms

<3-D Imaging><3D imaging><Address><Architecture><Basal Transcription Factor><Basal transcription factor genes><Binding><Biochemical><CUT&RUN><Cell Body><Cell Cycle><Cell Division Cycle><Cell Function><Cell Nucleus><Cell Physiology><Cell Process><Cells><Cellular Function><Cellular Physiology><Cellular Process><Chromatin><Chromatin Loop><Chromatin Loop Domains><Chromatin Structure><Chromosomal Organization><Chromosomal Structure><Chromosome Mapping><Chromosome Organization><Chromosome Structures><Chromosomes><Cleavage Targets and Release Using Nuclease><Cleavage Under Targets and Release Using Nuclease><Collaborations><Communities><Computational toolkit><Computing Methodologies><Cytology><DNA Loop><DNA Replication Timing><Data><Data Set><Development><Disease><Disorder><Engineering / Architecture><Formulation><Gene Expression><Gene Localization><Gene Mapping><Gene Mapping Genetics><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Genetic><Genetic Transcription><Genome><Genomics><Goals><Health><Human><Image><Interphase Chromosome><Intuition><Investigators><Knowledge><Link><Linkage Mapping><Maps><Measurement><Measures><Methods><Microscopy><Mission><Modality><Modeling><Modern Man><Molecular><Molecular Interaction><Multimodal Imaging><NIH><National Institutes of Health><Nuclear><Nuclear Lamina><Nuclear Structure><Nucleus><Organelles><Outcome><Output><PRO-seq><Phase><Population><Precision Run-On Sequencing><Precision nuclear run-on sequencing><Production><Public Health><RNA Expression><RNA Seq><RNA sequencing><RNAseq><Research><Research Personnel><Researchers><Resolution><Role><Structure><Subcellular Process><Technology><Temporal DNA Replication Order><Temporal DNA Replication Pattern><Three-Dimensional Imaging><Total Human and Non-Human Gene Mapping><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><United States National Institutes of Health><Validation><Variant><Variation><Visualization><Work><cell fixing><cell type><computational framework><computational methodology><computational methods><computational toolbox><computational tools><computational toolset><computer based method><computer based prediction><computer framework><computer methods><computerized tools><computing method><data exploration><data integration><data tools><developmental><empowerment><entire genome><experiment><experimental research><experimental study><experiments><full genome><genetic mapping><genome scale><genome-wide><genomewide><genomic data><genomic data-set><genomic dataset><histone modification><image-based method><imaging><imaging method><imaging modality><improved><insight><interactive data visualization><interactive visualization><intuitive><machine learned algorithm><machine learning algorithm><machine learning based algorithm><multi-modal data><multi-modal datasets><multi-modal imaging><multi-modality><multi-modality imaging><multi-scale atlas><multi-scale data><multimodal data><multimodal datasets><multimodality><multimodality imaging><multiple data types><multiscale atlas><multiscale data><predictive modeling><resolutions><response><social role><spatiotemporal><superresolution microscopy><tool><transcription factor><transcriptome sequencing><transcriptomic sequencing><user-friendly><validations><whole genome>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

KEITH T FLAHERTY

DANA-FARBER CANCER INST, BOSTON, MA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$2,074,014

FY 2025

Project Title

Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)

Grant Number:

5UM1CA186709-09

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/13/2014

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

The NCI-designated Dana-Farber/Harvard Cancer Center (DF/HCC) includes the Dana-Farber Cancer Institute (DFCI)/Brigham and Women's Hospital (BWH), Massachusetts General Hospital (MGH) and the Beth Israel Deaconess Medical Center (BIDMC), which together comprise a Lead Academic Organization (LAO) in ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

DONALD W. KUFE

DANA-FARBER CANCER INST, BOSTON, MA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$2,074,014

FY 2025

Project Title

Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)

Grant Number:

5UM1CA186709-09

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/13/2014

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

The NCI-designated Dana-Farber/Harvard Cancer Center (DF/HCC) includes the Dana-Farber Cancer Institute (DFCI)/Brigham and Women's Hospital (BWH), Massachusetts General Hospital (MGH) and the Beth Israel Deaconess Medical Center (BIDMC), which together comprise a Lead Academic Organization (LAO) in ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Geoffrey I. Shapiro

DANA-FARBER CANCER INST, BOSTON, MA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$2,074,014

FY 2025

Project Title

Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)

Grant Number:

5UM1CA186709-09

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/13/2014

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

The NCI-designated Dana-Farber/Harvard Cancer Center (DF/HCC) includes the Dana-Farber Cancer Institute (DFCI)/Brigham and Women's Hospital (BWH), Massachusetts General Hospital (MGH) and the Beth Israel Deaconess Medical Center (BIDMC), which together comprise a Lead Academic Organization (LAO) in ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

A. Dimitrios Colevas

BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, DUARTE, CA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$1,903,401

FY 2025

Project Title

Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN

Grant Number:

5UM1CA186717-09

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/28/2014

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

PROJECT SUMMARY As the California Cancer Consortium (CCC), four National Cancer Institute (NCI)-Designated Cancer Centers propose to participate in the NCI Experimental Therapeutics Clinical Trials Network (ETCTN) to conduct early phase clinical trials of experimental therapeutics. The CCC compris...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Alexey V. Danilov

BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, DUARTE, CA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$1,903,401

FY 2025

Project Title

Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN

Grant Number:

5UM1CA186717-09

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/28/2014

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

PROJECT SUMMARY As the California Cancer Consortium (CCC), four National Cancer Institute (NCI)-Designated Cancer Centers propose to participate in the NCI Experimental Therapeutics Clinical Trials Network (ETCTN) to conduct early phase clinical trials of experimental therapeutics. The CCC compris...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

PRIMO N. LARA

BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, DUARTE, CA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$1,903,401

FY 2025

Project Title

Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN

Grant Number:

5UM1CA186717-09

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/28/2014

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

PROJECT SUMMARY As the California Cancer Consortium (CCC), four National Cancer Institute (NCI)-Designated Cancer Centers propose to participate in the NCI Experimental Therapeutics Clinical Trials Network (ETCTN) to conduct early phase clinical trials of experimental therapeutics. The CCC compris...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

HEINZ JOSEF LENZ

BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, DUARTE, CA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$1,903,401

FY 2025

Project Title

Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN

Grant Number:

5UM1CA186717-09

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/28/2014

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

PROJECT SUMMARY As the California Cancer Consortium (CCC), four National Cancer Institute (NCI)-Designated Cancer Centers propose to participate in the NCI Experimental Therapeutics Clinical Trials Network (ETCTN) to conduct early phase clinical trials of experimental therapeutics. The CCC compris...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

SUSANNE M ARNOLD

OHIO STATE UNIVERSITY, Columbus, OH

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$1,731,705

FY 2025

Project Title

The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network

Grant Number:

5UM1CA186712-09

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/28/2014

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

PROJECT SUMMARY This project encompasses a multi-disciplinary team of basic scientists and clinical investigators dedicated to finding effective new therapies for patients with cancer. The Ohio State University Comprehensive Cancer Center (OSUCCC) is a comprehensive biomedical research campus with...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

WILLIAM E. CARSON

OHIO STATE UNIVERSITY, Columbus, OH

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$1,731,705

FY 2025

Project Title

The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network

Grant Number:

5UM1CA186712-09

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/28/2014

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

PROJECT SUMMARY This project encompasses a multi-disciplinary team of basic scientists and clinical investigators dedicated to finding effective new therapies for patients with cancer. The Ohio State University Comprehensive Cancer Center (OSUCCC) is a comprehensive biomedical research campus with...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Narendranath Epperla

OHIO STATE UNIVERSITY, Columbus, OH

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$1,731,705

FY 2025

Project Title

The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network

Grant Number:

5UM1CA186712-09

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/28/2014

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

PROJECT SUMMARY This project encompasses a multi-disciplinary team of basic scientists and clinical investigators dedicated to finding effective new therapies for patients with cancer. The Ohio State University Comprehensive Cancer Center (OSUCCC) is a comprehensive biomedical research campus with...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Philippe Bedard

UNIVERSITY HEALTH NETWORK, TORONTO, ON, CANADA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$1,720,919

FY 2025

Project Title

North American Star Consortium

Grant Number:

5UM1CA186644-09

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/7/2014

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

This UM1 renewal application is designated the North American Star Consortium (NASC), which includes Moffitt Cancer Center (MCC) as the Lead Academic Organization (LAO) with Daniel Sullivan, MD as the contact PI. MCC is joined by four highly productive Academic Organizations (AO) including Princes...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Kevin D Courtney

UNIVERSITY HEALTH NETWORK, TORONTO, ON, CANADA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$1,720,919

FY 2025

Project Title

North American Star Consortium

Grant Number:

5UM1CA186644-09

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/7/2014

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

This UM1 renewal application is designated the North American Star Consortium (NASC), which includes Moffitt Cancer Center (MCC) as the Lead Academic Organization (LAO) with Daniel Sullivan, MD as the contact PI. MCC is joined by four highly productive Academic Organizations (AO) including Princes...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Steven Grant

UNIVERSITY HEALTH NETWORK, TORONTO, ON, CANADA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$1,720,919

FY 2025

Project Title

North American Star Consortium

Grant Number:

5UM1CA186644-09

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/7/2014

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

This UM1 renewal application is designated the North American Star Consortium (NASC), which includes Moffitt Cancer Center (MCC) as the Lead Academic Organization (LAO) with Daniel Sullivan, MD as the contact PI. MCC is joined by four highly productive Academic Organizations (AO) including Princes...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jeffrey Lancet

UNIVERSITY HEALTH NETWORK, TORONTO, ON, CANADA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$1,720,919

FY 2025

Project Title

North American Star Consortium

Grant Number:

5UM1CA186644-09

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/7/2014

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

This UM1 renewal application is designated the North American Star Consortium (NASC), which includes Moffitt Cancer Center (MCC) as the Lead Academic Organization (LAO) with Daniel Sullivan, MD as the contact PI. MCC is joined by four highly productive Academic Organizations (AO) including Princes...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Devalingam Mahalingam

UNIVERSITY HEALTH NETWORK, TORONTO, ON, CANADA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$1,720,919

FY 2025

Project Title

North American Star Consortium

Grant Number:

5UM1CA186644-09

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/7/2014

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

This UM1 renewal application is designated the North American Star Consortium (NASC), which includes Moffitt Cancer Center (MCC) as the Lead Academic Organization (LAO) with Daniel Sullivan, MD as the contact PI. MCC is joined by four highly productive Academic Organizations (AO) including Princes...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Lillian L Siu

UNIVERSITY HEALTH NETWORK, TORONTO, ON, CANADA

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$1,720,919

FY 2025

Project Title

North American Star Consortium

Grant Number:

5UM1CA186644-09

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/7/2014

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

This UM1 renewal application is designated the North American Star Consortium (NASC), which includes Moffitt Cancer Center (MCC) as the Lead Academic Organization (LAO) with Daniel Sullivan, MD as the contact PI. MCC is joined by four highly productive Academic Organizations (AO) including Princes...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Patricia M. LoRusso

YALE UNIVERSITY, NEW HAVEN, CT

Good lead · 68/100

Likely hiring

Large award

Active award

Team-scale grant

$1,249,062

FY 2025

Project Title

VICKtOrY Early Clinical Trials Consortium

Grant Number:

5UM1CA186689-09

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/10/2014

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

The new era in cancer drug development represents a paradigm shift in how early phase studies are conducted relative to the “conventional” approach of treating without consideration to underlying tumor genomics, biology and immunology. Translational endpoints, including levels of target expression,...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Angelica Cifuentes Kottkamp

NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NEW YORK, NY

Good lead · 68/100

Likely hiring

Above-average budget

Active award

Team-scale grant

$864,459

FY 2026

Project Title

Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU)

Grant Number:

5UM1AI148574-07

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/10/2020

End Date:

11/30/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Establishment of New York University (NYU) Vaccine and Treatment Evaluation Unit (VTEU) is proposed in response to RFA-AI-18-046 entitled “Vaccine and Treatment Evaluation Units (VTEUs) (UM1 Clinical Trial Required)”. NYU VTEU will be one of the 10 fixed sites that will participate i...

Research Terms

<0-11 years old><21+ years old><AIDS><AIDS/HIV><Academic Medical Centers><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immunodeficiency Syndrome><Address><Admission><Admission activity><Adult><Adult Human><Advanced HIV><Airway infections><Anti-microbial Drug Resistance><Anti-microbial Drug Resistant><Antibiotic Agents><Antibiotic Drugs><Antibiotic Resistance><Antibiotics><Antigenic Determinants><Antimicrobial Drug Resistance><Antimicrobial Drug Resistant><Area><Assay><Avian Influenza><Award><Beds><Binding Determinants><Bioassay><Biological Agent><Biological Assay><Biological Markers><Biological Products><Biomedical Research><Bird Flu><Caring><Censuses><Cessation of life><Child><Child Youth><Childhood><Children (0-21)><Cities><Clinic><Clinical><Clinical Research><Clinical Study><Clinical Trials><Clinical Trials Unit><Clinics and Hospitals><Clinics or Hospitals><Communicable Diseases><Communities><Country><Death><Dedications><Dengue><Development><Devices><Diagnostic><Disease><Disorder><EHR system><Ebola><Educational process of instructing><Elements><Emerging infection><Enrollment><Enteral><Enteric><Epitopes><Evaluation><Facilities and Administrative Costs><Faculty><Fowl Pest><Fowl Plague><Funding><H1N1><H1N1 Virus><H5N1><H5N1 virus><H7N9><HIV/AIDS><Health><Health Care Systems><History><Hospitals><Human><IRB><IRBs><Immunology><Indirect Costs><Individual><Infection><Infectious Diseases><Infectious Diseases / Laboratory><Infectious Diseases Research><Infectious Disorder><Influenza A><Influenza A H5N1><Influenza A Virus, H1N1 Subtype><Influenza A Virus, H5N1 Subtype><Influenza A Virus, H7N9 Subtype><Influenza A virus><Influenza Vaccines><Influenza Viruses Type A><Influenzavirus A><Inpatients><Institution><Institutional Review Boards><International><Laboratories><Laboratory Research><Leadership><Long Island><M tuberculosis infection><M. tb infection><M. tuberculosis infection><M.tb infection><M.tuberculosis infection><MERS><MERS coronavirus disease><MERS-CoV disease><MTB infection><Malaria><Marriage><Medical Research><Microbial Drug Resistance><Middle East Respiratory Syndrome><Middle East Respiratory Syndrome CoV disease><Middle East Respiratory Syndrome coronavirus disease><Middle Eastern Respiratory Syndrome><Middle Eastern Respiratory Syndrome CoV disease><Middle Eastern Respiratory Syndrome coronavirus disease><Miscellaneous Antibiotic><Modeling><Modern Man><Molecular Epidemiology><Morbidity><Multi-Drug Resistance><Multidrug Resistance><Multiple Drug Resistance><Multiple Drug Resistant><Mycobacterium tuberculosis (MTB) infection><Mycobacterium tuberculosis infection><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><New York><New York City><Nipah><Norovirus><Norwalk-like Viruses><Orthomyxovirus Type A><Out-patients><Outpatients><PK/PD><Paludism><Participant><Patient Care><Patient Care Delivery><Patient Recruitments><Patients><Plasmodium Infections><Population><Predictive Value><Preparedness><Procedures><Public Health><Qualifying><Readiness><Recording of previous events><Reporting><Research><Research Activity><Research Priority><Research Resources><Research Support><Resistance to Multi-drug><Resistance to Multidrug><Resistance to Multiple Drug><Resistance to antibiotics><Resistant to Multiple Drug><Resistant to antibiotics><Resistant to multi-drug><Resistant to multidrug><Resources><Respiratory Infections><Respiratory Tract Infections><SARS><SARS coronavirus disease><SARS-CoV disease><Seasons><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome coronavirus disease><Severe HIV Disease><Sexually Transmitted Diseases><Sexually Transmitted Disorder><Sexually Transmitted Infection><Site><Speed><Study Subject><Study models><System><TB infection><Teaching><Therapeutic><Time><Tuberculosis><Type A Influenza><United States National Institutes of Health><Universities><University Medical Centers><Vaccination><Vaccines><Venereal Diseases><Venereal Disorders><Venereal Infections><Viral><Visit><Work><ZIKA><adulthood><anti-microbial agent><anti-microbial drug><antibiotic drug resistance><antibiotic resistant><avian flu><avian influenza H5N1><avian influenza H5N1 virus><avian strains of influenza><bio-markers><biologic marker><biologics><biomarker><biopharmaceutical><biotherapeutic agent><care for patients><care of patients><caring for patients><combat><comparative><demographics><developmental><disseminated TB><disseminated tuberculosis><electronic health record system><emergent infection><enroll><experience><flu><flu vaccine><flu virus pandemic><flu virus vaccine><histories><improved><infection due to Mycobacterium tuberculosis><influenza in birds><influenza virus pandemic><influenza virus vaccine><innovate><innovation><innovative><kids><medical college><medical countermeasure><medical schools><metropolitan><microbial><microbial drug resistant><microbial genomics><microbiome><mortality><multi-drug resistant><multidrug resistant><multiomics><multiple omics><neglected tropical diseases><new approaches><news><novel><novel approaches><novel strategies><novel strategy><operation><operations><outreach><pan influenza vaccine><pan influenza viral vaccine><pan influenza virus vaccine><pandemic flu><pandemic influenza><pandemic strain of influenza><panomics><participant recruitment><pathogen><pediatric><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><pharmacokinetics and pharmacodynamics><priority pathogen><recruit><response><school of medicine><seasonal flu><seasonal influenza><sexually acquired infection><systems research><tuberculosis infection><tuberculous spondyloarthropathy><universal flu vaccine><universal influenza vaccine><universal influenza virus vaccine><universal vaccine against flu><universal vaccine against influenza><vaccine against flu><vaccine against influenza><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Anoma Nellore

NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NEW YORK, NY

Good lead · 68/100

Likely hiring

Above-average budget

Active award

Team-scale grant

$864,459

FY 2026

Project Title

Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU)

Grant Number:

5UM1AI148574-07

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/10/2020

End Date:

11/30/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Establishment of New York University (NYU) Vaccine and Treatment Evaluation Unit (VTEU) is proposed in response to RFA-AI-18-046 entitled “Vaccine and Treatment Evaluation Units (VTEUs) (UM1 Clinical Trial Required)”. NYU VTEU will be one of the 10 fixed sites that will participate i...

Research Terms

<0-11 years old><21+ years old><AIDS><AIDS/HIV><Academic Medical Centers><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immunodeficiency Syndrome><Address><Admission><Admission activity><Adult><Adult Human><Advanced HIV><Airway infections><Anti-microbial Drug Resistance><Anti-microbial Drug Resistant><Antibiotic Agents><Antibiotic Drugs><Antibiotic Resistance><Antibiotics><Antigenic Determinants><Antimicrobial Drug Resistance><Antimicrobial Drug Resistant><Area><Assay><Avian Influenza><Award><Beds><Binding Determinants><Bioassay><Biological Agent><Biological Assay><Biological Markers><Biological Products><Biomedical Research><Bird Flu><Caring><Censuses><Cessation of life><Child><Child Youth><Childhood><Children (0-21)><Cities><Clinic><Clinical><Clinical Research><Clinical Study><Clinical Trials><Clinical Trials Unit><Clinics and Hospitals><Clinics or Hospitals><Communicable Diseases><Communities><Country><Death><Dedications><Dengue><Development><Devices><Diagnostic><Disease><Disorder><EHR system><Ebola><Educational process of instructing><Elements><Emerging infection><Enrollment><Enteral><Enteric><Epitopes><Evaluation><Facilities and Administrative Costs><Faculty><Fowl Pest><Fowl Plague><Funding><H1N1><H1N1 Virus><H5N1><H5N1 virus><H7N9><HIV/AIDS><Health><Health Care Systems><History><Hospitals><Human><IRB><IRBs><Immunology><Indirect Costs><Individual><Infection><Infectious Diseases><Infectious Diseases / Laboratory><Infectious Diseases Research><Infectious Disorder><Influenza A><Influenza A H5N1><Influenza A Virus, H1N1 Subtype><Influenza A Virus, H5N1 Subtype><Influenza A Virus, H7N9 Subtype><Influenza A virus><Influenza Vaccines><Influenza Viruses Type A><Influenzavirus A><Inpatients><Institution><Institutional Review Boards><International><Laboratories><Laboratory Research><Leadership><Long Island><M tuberculosis infection><M. tb infection><M. tuberculosis infection><M.tb infection><M.tuberculosis infection><MERS><MERS coronavirus disease><MERS-CoV disease><MTB infection><Malaria><Marriage><Medical Research><Microbial Drug Resistance><Middle East Respiratory Syndrome><Middle East Respiratory Syndrome CoV disease><Middle East Respiratory Syndrome coronavirus disease><Middle Eastern Respiratory Syndrome><Middle Eastern Respiratory Syndrome CoV disease><Middle Eastern Respiratory Syndrome coronavirus disease><Miscellaneous Antibiotic><Modeling><Modern Man><Molecular Epidemiology><Morbidity><Multi-Drug Resistance><Multidrug Resistance><Multiple Drug Resistance><Multiple Drug Resistant><Mycobacterium tuberculosis (MTB) infection><Mycobacterium tuberculosis infection><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><New York><New York City><Nipah><Norovirus><Norwalk-like Viruses><Orthomyxovirus Type A><Out-patients><Outpatients><PK/PD><Paludism><Participant><Patient Care><Patient Care Delivery><Patient Recruitments><Patients><Plasmodium Infections><Population><Predictive Value><Preparedness><Procedures><Public Health><Qualifying><Readiness><Recording of previous events><Reporting><Research><Research Activity><Research Priority><Research Resources><Research Support><Resistance to Multi-drug><Resistance to Multidrug><Resistance to Multiple Drug><Resistance to antibiotics><Resistant to Multiple Drug><Resistant to antibiotics><Resistant to multi-drug><Resistant to multidrug><Resources><Respiratory Infections><Respiratory Tract Infections><SARS><SARS coronavirus disease><SARS-CoV disease><Seasons><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome coronavirus disease><Severe HIV Disease><Sexually Transmitted Diseases><Sexually Transmitted Disorder><Sexually Transmitted Infection><Site><Speed><Study Subject><Study models><System><TB infection><Teaching><Therapeutic><Time><Tuberculosis><Type A Influenza><United States National Institutes of Health><Universities><University Medical Centers><Vaccination><Vaccines><Venereal Diseases><Venereal Disorders><Venereal Infections><Viral><Visit><Work><ZIKA><adulthood><anti-microbial agent><anti-microbial drug><antibiotic drug resistance><antibiotic resistant><avian flu><avian influenza H5N1><avian influenza H5N1 virus><avian strains of influenza><bio-markers><biologic marker><biologics><biomarker><biopharmaceutical><biotherapeutic agent><care for patients><care of patients><caring for patients><combat><comparative><demographics><developmental><disseminated TB><disseminated tuberculosis><electronic health record system><emergent infection><enroll><experience><flu><flu vaccine><flu virus pandemic><flu virus vaccine><histories><improved><infection due to Mycobacterium tuberculosis><influenza in birds><influenza virus pandemic><influenza virus vaccine><innovate><innovation><innovative><kids><medical college><medical countermeasure><medical schools><metropolitan><microbial><microbial drug resistant><microbial genomics><microbiome><mortality><multi-drug resistant><multidrug resistant><multiomics><multiple omics><neglected tropical diseases><new approaches><news><novel><novel approaches><novel strategies><novel strategy><operation><operations><outreach><pan influenza vaccine><pan influenza viral vaccine><pan influenza virus vaccine><pandemic flu><pandemic influenza><pandemic strain of influenza><panomics><participant recruitment><pathogen><pediatric><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><pharmacokinetics and pharmacodynamics><priority pathogen><recruit><response><school of medicine><seasonal flu><seasonal influenza><sexually acquired infection><systems research><tuberculosis infection><tuberculous spondyloarthropathy><universal flu vaccine><universal influenza vaccine><universal influenza virus vaccine><universal vaccine against flu><universal vaccine against influenza><vaccine against flu><vaccine against influenza><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Clarence Buddy Creech

VANDERBILT UNIVERSITY MEDICAL CENTER, NASHVILLE, TN

Good lead · 68/100

Likely hiring

Above-average budget

Active award

Team-scale grant

$613,257

FY 2026

Project Title

Vanderbilt Vaccine and Treatment Evaluation Unit

Grant Number:

5UM1AI148452-07

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/11/2019

End Date:

11/30/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT The goal of this UM1 proposal is to use the remarkable research infrastructure at Vanderbilt University Medical Center and collaborating sites (Washington University, University of Pittsburgh, and University of Pennsylvania) to conceptualize, design, implement, and analyze clinical research...

Research Terms

<0-11 years old><21+ years old><Academic Medical Centers><Adult><Adult Human><Age><Area><Articulation><Assay><Award><B. pertussis vaccine><Bacterial Infections><Bioassay><Biological Agent><Biological Assay><Biological Products><Body Tissues><Bordetella pertussis vaccine><Child><Child Youth><Childhood><Children (0-21)><Clinical><Clinical Investigator><Clinical Research><Clinical Study><Clinical Trials><Collaborations><Communicable Diseases><Conduct Clinical Trials><Data><Development><Disease><Disorder><Drugs><Education><Educational aspects><Elderly><Emerging Communicable Diseases><Emerging Infectious Diseases><Enrollment><Environment><Evaluation><Faculty><Feasibility Studies><Fellowship><Fostering><Funding><Fungus Diseases><Geography><Goals><Grippe><Home><Human><Immune response><Immunity><Immunization><Immunologist><Individual><Infant><Infection><Infectious Diseases><Infectious Disorder><Influenza><Influenza Vaccines><Institution><International><Intervention><Investigators><Laboratories><Laboratory Scientists><Lead><Leadership><Licensure><Malaria><Malaria Vaccines><Malarial Vaccines><Medical><Medical center><Medication><Mentors><Mentorship><Methods><Modeling><Modern Man><Mycoses><NIH><National Institutes of Health><Nurses><Paludism><Parasitic infection><Pathogenesis><Pb element><Pennsylvania><Pertussis Vaccine><Peru><Pharmaceutical Preparations><Phase><Physicians><Plasmodium Infections><Pneumococcal vaccine><Population><Population Heterogeneity><Position><Positioning Attribute><Pregnant Women><Prevention><Principal Investigator><Procedures><Process><Protocol><Protocols documentation><Qualifying><Research><Research Infrastructure><Research Personnel><Researchers><Safety><Scientist><Sexually Transmitted Diseases><Sexually Transmitted Disorder><Sexually Transmitted Infection><Site><Smallpox Vaccine><Special Population><Special Supplemental Nutrition Program for Women, Infants, and Children><Standardization><Streptococcus pneumoniae vaccine><Systems Biology><Tissues><Training><United States National Institutes of Health><Universities><University Medical Centers><Vaccination><Vaccine Research><Vaccine against B. pertussis><Vaccine against Bordetella pertussis><Vaccine against pertussis><Vaccines><Venereal Diseases><Venereal Disorders><Venereal Infections><Viral><Viral Diseases><Virus Diseases><Visit><WIC><WIC program><Washington><Women, Infants and Children><Work><adulthood><advanced age><ages><antibiotic resistant infections><bacteria infection><bacterial disease><biologics><biopharmaceutical><biotherapeutic agent><career><career development><clinical research site><clinical site><co-morbid><co-morbidity><comorbidity><design><designing><developmental><diverse populations><drug/agent><early clinical trial><early phase clinical trial><emerging pathogen><enroll><ethnic diversity><ethnically diverse><expectant mother><expectant women><expecting mother><expecting women><experience><flu vaccine><flu virus pandemic><flu virus vaccine><fungal infection><fungus infection><geriatric><heavy metal Pb><heavy metal lead><heterogeneous population><homes><host response><immune response to vaccination><immune response to vaccines><immune system response><immunogenicity><immunoresponse><individuals who are pregnant><infected with parasites><influenza virus pandemic><influenza virus vaccine><innovate><innovation><innovative><kids><life span><lifespan><new approaches><new drug treatments><new drugs><new pathogen><new pharmacological therapeutic><new therapeutics><new therapy><new vaccines><next generation><next generation therapeutics><next generation vaccines><novel><novel approaches><novel drug treatments><novel drugs><novel pathogen><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel strategies><novel strategy><novel therapeutics><novel therapy><novel vaccines><nurse><pandemic containment><pandemic control><pandemic flu><pandemic influenza><pandemic mitigation><pandemic response><pandemic strain of influenza><parasite infection><pathogen><pediatric><people who are pregnant><population diversity><pregnant females><pregnant mothers><pregnant people><pregnant populations><recruit><research study><respiratory><response><senior citizen><sexually acquired infection><those who are pregnant><tool><vaccination study><vaccination trial><vaccine against flu><vaccine against influenza><vaccine associated immune response><vaccine immune response><vaccine immunogenicity><vaccine induced immune response><vaccine study><vaccine trial><vaccine-related research><vaccines against malaria><vaccinology><viral infection><virus infection><virus-induced disease><volunteer><women who are pregnant><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Colin A. Depp

UNIVERSITY OF CALIFORNIA, SAN DIEGO, LA JOLLA, CA

Good lead · 62/100

Large award

Very recent

Active award

Career award

$1,612,278

FY 2026

Project Title

CTSA K12 Program at University of California San Diego Altman Clinical and Translational Research Institute

Grant Number:

5K12TR005441-02

Activity Code:

K12

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

8/1/2025

End Date:

4/30/2030

Why this may be worth a closer look

• Large budget suggests more room for personnel or project growth.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The overall goal of the University of California San Diego (UCSD) K12 program is to provide a supportive, and professional training environment that fosters new leaders in clinical and translational science (CTS). Graduates have been highly successful in sustaining academic research careers and many...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

ADRIANA H TREMOULET

UNIVERSITY OF CALIFORNIA, SAN DIEGO, LA JOLLA, CA

Good lead · 62/100

Large award

Very recent

Active award

Career award

$1,612,278

FY 2026

Project Title

CTSA K12 Program at University of California San Diego Altman Clinical and Translational Research Institute

Grant Number:

5K12TR005441-02

Activity Code:

K12

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

8/1/2025

End Date:

4/30/2030

Why this may be worth a closer look

• Large budget suggests more room for personnel or project growth.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The overall goal of the University of California San Diego (UCSD) K12 program is to provide a supportive, and professional training environment that fosters new leaders in clinical and translational science (CTS). Graduates have been highly successful in sustaining academic research careers and many...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

MICHAEL L BOEHNKE

BROAD INSTITUTE, INC., CAMBRIDGE, MA

Good lead · 62/100

Likely hiring

Above-average budget

Active award

Team-scale grant

$999,999

FY 2025

Project Title

Augmenting the CMDKP with advanced features for understanding biological mechanisms

Grant Number:

3UM1DK105554-10S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/1/2015

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Title: Augmenting the CMDKP with advanced features for understanding biological mechanisms Project Summary The Common Metabolic Diseases Knowledge Portal (CMDKP) aggregates genetic, genomic, and phenotypic data to accelerate discovery of therapies for type 2 diabetes and related common metabolic di...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Noel P Burtt

BROAD INSTITUTE, INC., CAMBRIDGE, MA

Good lead · 62/100

Likely hiring

Above-average budget

Active award

Team-scale grant

$999,999

FY 2025

Project Title

Augmenting the CMDKP with advanced features for understanding biological mechanisms

Grant Number:

3UM1DK105554-10S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/1/2015

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Title: Augmenting the CMDKP with advanced features for understanding biological mechanisms Project Summary The Common Metabolic Diseases Knowledge Portal (CMDKP) aggregates genetic, genomic, and phenotypic data to accelerate discovery of therapies for type 2 diabetes and related common metabolic di...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jason Flannick

BROAD INSTITUTE, INC., CAMBRIDGE, MA

Good lead · 62/100

Likely hiring

Above-average budget

Active award

Team-scale grant

$999,999

FY 2025

Project Title

Augmenting the CMDKP with advanced features for understanding biological mechanisms

Grant Number:

3UM1DK105554-10S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/1/2015

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Title: Augmenting the CMDKP with advanced features for understanding biological mechanisms Project Summary The Common Metabolic Diseases Knowledge Portal (CMDKP) aggregates genetic, genomic, and phenotypic data to accelerate discovery of therapies for type 2 diabetes and related common metabolic di...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Harry P. Selker

TUFTS UNIVERSITY BOSTON, BOSTON, MA

Good lead · 62/100

Likely hiring

Above-average budget

Active award

Team-scale grant

$975,053

FY 2023

Project Title

Tufts Clinical and Translational Science Institute (Clinical Trial Design Labs Supplement)

Grant Number:

3UM1TR004398-01S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/1/2023

End Date:

4/30/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary Tufts Clinical Trial Design Labs are structured multi-stakeholder events that support development of innovative solutions to improve the design and impact of clinical trials. During the first year of our UM1 Clinical and Translational Science Award that starts May 1, 2023, we will ho...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mark Joseph Mulligan

NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NEW YORK, NY

Good lead · 62/100

Likely hiring

Above-average budget

Active award

Team-scale grant

$804,593

FY 2024

Project Title

Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU)

Grant Number:

5UM1AI148574-05

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/10/2020

End Date:

11/30/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Establishment of New York University (NYU) Vaccine and Treatment Evaluation Unit (VTEU) is proposed in response to RFA-AI-18-046 entitled “Vaccine and Treatment Evaluation Units (VTEUs) (UM1 Clinical Trial Required)”. NYU VTEU will be one of the 10 fixed sites that will participate i...

Research Terms

<0-11 years old><21+ years old><AIDS><AIDS/HIV><Academic Medical Centers><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immunodeficiency Syndrome><Address><Admission><Admission activity><Adult><Adult Human><Airway infections><Anti-microbial Drug Resistance><Anti-microbial Drug Resistant><Antibiotic Agents><Antibiotic Drugs><Antibiotic Resistance><Antibiotics><Antigenic Determinants><Antimicrobial Drug Resistance><Antimicrobial Drug Resistant><Area><Assay><Avian Influenza><Award><Beds><Binding Determinants><Bioassay><Biological Agent><Biological Assay><Biological Markers><Biological Products><Biomedical Research><Bird Flu><Caring><Censuses><Cessation of life><Child><Child Youth><Childhood><Children (0-21)><Cities><Clinic><Clinical><Clinical Research><Clinical Study><Clinical Trials><Clinical Trials Unit><Clinics and Hospitals><Clinics or Hospitals><Communicable Diseases><Communities><Country><Death><Dedications><Dengue><Development><Devices><Diagnostic><Disease><Disorder><EHR system><Ebola><Educational process of instructing><Elements><Emerging infection><Enrollment><Enteral><Enteric><Epitopes><Evaluation><Facilities and Administrative Costs><Faculty><Fowl Pest><Fowl Plague><Funding><H1N1><H1N1 Virus><H5N1><H5N1 virus><H7N9><HIV/AIDS><Health><Health Care Systems><Healthcare Systems><History><Hospitals><Human><IRB><IRBs><Immunology><Indirect Costs><Individual><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Diseases / Laboratory><Infectious Diseases Research><Infectious Disorder><Influenza A><Influenza A H5N1><Influenza A Virus, H1N1 Subtype><Influenza A Virus, H5N1 Subtype><Influenza A Virus, H7N9 Subtype><Influenza A virus><Influenza Vaccines><Influenza Viruses Type A><Influenzavirus A><Inpatients><Institution><Institutional Review Boards><International><Laboratories><Laboratory Research><Leadership><Long Island><M tuberculosis infection><M. tb infection><M. tuberculosis infection><M.tb infection><M.tuberculosis infection><MERS><MERS coronavirus disease><MERS-CoV disease><MTB infection><Malaria><Marriage><Medical Research><Microbial Drug Resistance><Middle East Respiratory Syndrome><Middle East Respiratory Syndrome CoV disease><Middle East Respiratory Syndrome coronavirus disease><Middle Eastern Respiratory Syndrome><Middle Eastern Respiratory Syndrome CoV disease><Middle Eastern Respiratory Syndrome coronavirus disease><Miscellaneous Antibiotic><Modeling><Modern Man><Molecular Epidemiology><Morbidity><Morbidity - disease rate><Multi-Drug Resistance><Multidrug Resistance><Multiple Drug Resistance><Multiple Drug Resistant><Mycobacterium tuberculosis (MTB) infection><Mycobacterium tuberculosis infection><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><New York><New York City><Nipah><Norovirus><Norwalk-like Viruses><Orthomyxovirus Type A><Out-patients><Outpatients><PK/PD><Paludism><Participant><Patient Care><Patient Care Delivery><Patient Recruitments><Patients><Plasmodium Infections><Population><Predictive Value><Preparedness><Procedures><Public Health><Qualifying><Readiness><Recording of previous events><Reporting><Research><Research Activity><Research Priority><Research Resources><Research Support><Resistance to Multi-drug><Resistance to Multidrug><Resistance to Multiple Drug><Resistance to antibiotics><Resistant to Multiple Drug><Resistant to antibiotics><Resistant to multi-drug><Resistant to multidrug><Resources><Respiratory Infections><Respiratory Tract Infections><SARS><SARS coronavirus disease><SARS-CoV disease><Seasons><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome coronavirus disease><Sexually Transmitted Diseases><Sexually Transmitted Disorder><Sexually Transmitted Infection><Site><Speed><Study Subject><Study models><System><TB infection><Teaching><Therapeutic><Time><Tuberculosis><Type A Influenza><United States National Institutes of Health><Universities><University Medical Centers><Vaccination><Vaccines><Venereal Diseases><Venereal Disorders><Venereal Infections><Viral><Visit><Work><ZIKA><adulthood><anti-microbial agent><anti-microbial drug><antibiotic drug resistance><antibiotic resistant><avian flu><avian influenza H5N1><avian influenza H5N1 virus><avian strains of influenza><bio-markers><biologic marker><biologics><biomarker><biopharmaceutical><biotherapeutic agent><care for patients><care of patients><caring for patients><combat><comparative><demographics><developmental><disseminated TB><disseminated tuberculosis><electronic health record system><emergent infection><enroll><experience><flu><flu vaccine><flu virus pandemic><flu virus vaccine><histories><improved><infection due to Mycobacterium tuberculosis><influenza in birds><influenza virus pandemic><influenza virus vaccine><innovate><innovation><innovative><kids><medical college><medical countermeasure><medical schools><metropolitan><microbial><microbial drug resistant><microbial genomics><microbiome><mortality><multi-drug resistant><multidrug resistant><multiomics><multiple omics><neglected tropical diseases><new approaches><news><novel><novel approaches><novel strategies><novel strategy><operation><operations><outreach><pan influenza vaccine><pan influenza viral vaccine><pan influenza virus vaccine><pandemic flu><pandemic influenza><pandemic strain of influenza><panomics><participant recruitment><pathogen><pediatric><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><pharmacokinetics and pharmacodynamics><priority pathogen><recruit><response><school of medicine><seasonal flu><seasonal influenza><sexually acquired infection><systems research><tuberculosis infection><tuberculous spondyloarthropathy><universal flu vaccine><universal influenza vaccine><universal influenza virus vaccine><universal vaccine against flu><universal vaccine against influenza><vaccine against flu><vaccine against influenza><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

JUDITH A JAMES

OKLAHOMA MEDICAL RESEARCH FOUNDATION, OKLAHOMA CITY, OK

Good lead · 62/100

Likely hiring

Above-average budget

Active award

Team-scale grant

$767,250

FY 2025

Project Title

Oklahoma ACE: Molecular Destruction of Autoimmune Disease to Aid Clinical Trail Success

Grant Number:

5UM1AI144292-07

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/1/2019

End Date:

4/30/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary The Oklahoma ACE (OACE) aims to understand autoimmune disease biology through interdisciplinary, collaborative research integrating clinical and basic questions. Prior OACE work as both a Basic and Clinical ACE has significantly advanced our understanding of autoimmune disease genet...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Dan H. Barouch

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$55,953,346

FY 2022

Project Title

CoVPN 3008 - Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern

Grant Number:

3UM1AI068614-17S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/29/2006

End Date:

11/30/2024

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

FOA: PA-20-272: Administrative Supplements to Existing NIH Grants and Cooperative Agreements Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the ...

Research Terms

<2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><21+ years old><Abdominal Typhus><Address><Administrative Supplement><Adult><Adult Human><Africa South of the Sahara><Area><Assay><Award><B.1.351><Bioassay><Biologic Assays><Biological Assay><Biometrics><Biometry><Biostatistics><Blinded><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 Prevention Network><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 exposure><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 prevention><COVID-19 public health crisis><COVID-19 severity><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 outbreak><COVID19 pandemic><COVID19 prevention><COVID19 public health crisis><COVID19 severity><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cellular Assay><Cellular Immune Function><Clinical><Clinical Trials><Clinical Trials Network><CoV-2><CoV2><CoVPN><Code><Coding System><Cohort Studies><Communicable Diseases><Concurrent Studies><Constitution><Cooperative Agreements><Coronaviridae><Coronavirus><Country><Development><Diagnosis><Disease><Disorder><Dose><End Point Assay><Endpoint Assays><Enteric Fever><Exposure to><Eye><Eyeball><Future><Goals><Grant><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS Vaccines><HVTN><Health><High Prevalence><Immune><Immune Monitoring><Immune response><Immunes><Immunity><Immunologic Monitoring><Immunological Monitoring><Immunological response><Immunology><Immunomonitoring><Individual><Infection Control><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><International><Intervention><Intervention Strategies><Knowledge><Laboratories><Lead><Leadership><MAb Therapeutics><Malaria><Mediating><Messenger RNA><Moderna COVID-19 vaccine><Moderna coronavirus disease 2019 vaccine><Morbidity><Morbidity - disease rate><NIH><National Institutes of Health><Paludism><Parents><Pb element><Persons><Phase><Physicians><Placebo Control><Plasmodium Infections><Population><Preparation><Prevalence><Prevention><Preventive><Proliferating><Protocol><Protocols documentation><Quality Control><RNA vaccine><RNA-based vaccine><Randomized><Randomized Clinical Trials><Research Methodology><Research Methods><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 B.1.351><SARS-CoV-2 beta><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 exposure><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 severity><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 exposure><SARS-CoV2 infection><SARS-CoV2 outbreak><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Sampling><Scientist><Serology test><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 exposure><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Severities><Site><South Africa><South Africa strain><South Africa variant><South African strain><South African variant><Sub-Saharan Africa><Subsaharan Africa><System><Testing><Therapeutic Monoclonal Antibodies><Typhoid><Typhoid Fever><U-Series Cooperative Agreements><United States><United States National Institutes of Health><Vaccines><Validation><Wuhan coronavirus><adulthood><base><cell assay><clinical trial analysis><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 exposure><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 severity><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 prevention><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><design><designing><developmental><efficacy analysis><efficacy assessment><efficacy evaluation><efficacy examination><efficacy study><efficacy testing><efficacy trial><evaluate efficacy><examine efficacy><experience><exposure to COVID-19><exposure to SARS-CoV-2><exposure to SARS-CoV2><exposure to Severe acute respiratory syndrome coronavirus 2><exposure to coronavirus disease 2019><hCoV19><heavy metal Pb><heavy metal lead><host response><human immunodeficiency virus vaccine><immune function><immune system response><immunoresponse><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><interventional strategy><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><mRNA><mRNA vaccine><mRNA-1273><mRNA-based vaccine><mRNA1273><monoclonal antibody drugs><mortality><nCoV2><operation><placebo controlled><prevent><prevent COVID-19><prevent COVID19><prevent coronavirus disease 2019><preventing><programs><quality assurance><randomisation><randomization><randomly assigned><rational design><response><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><serology assay><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 B.1.351><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 severity><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><symptomatic COVID-19><symptomatic COVID19><symptomatic coronavirus disease 2019><therapeutic mAbs><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine efficacy><vaccine for novel coronavirus><vaccine study><vaccine trial><variants of concern>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Lawrence Corey

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$55,953,346

FY 2022

Project Title

CoVPN 3008 - Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern

Grant Number:

3UM1AI068614-17S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/29/2006

End Date:

11/30/2024

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

FOA: PA-20-272: Administrative Supplements to Existing NIH Grants and Cooperative Agreements Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the ...

Research Terms

<2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><21+ years old><Abdominal Typhus><Address><Administrative Supplement><Adult><Adult Human><Africa South of the Sahara><Area><Assay><Award><B.1.351><Bioassay><Biologic Assays><Biological Assay><Biometrics><Biometry><Biostatistics><Blinded><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 Prevention Network><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 exposure><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 prevention><COVID-19 public health crisis><COVID-19 severity><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 outbreak><COVID19 pandemic><COVID19 prevention><COVID19 public health crisis><COVID19 severity><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cellular Assay><Cellular Immune Function><Clinical><Clinical Trials><Clinical Trials Network><CoV-2><CoV2><CoVPN><Code><Coding System><Cohort Studies><Communicable Diseases><Concurrent Studies><Constitution><Cooperative Agreements><Coronaviridae><Coronavirus><Country><Development><Diagnosis><Disease><Disorder><Dose><End Point Assay><Endpoint Assays><Enteric Fever><Exposure to><Eye><Eyeball><Future><Goals><Grant><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS Vaccines><HVTN><Health><High Prevalence><Immune><Immune Monitoring><Immune response><Immunes><Immunity><Immunologic Monitoring><Immunological Monitoring><Immunological response><Immunology><Immunomonitoring><Individual><Infection Control><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><International><Intervention><Intervention Strategies><Knowledge><Laboratories><Lead><Leadership><MAb Therapeutics><Malaria><Mediating><Messenger RNA><Moderna COVID-19 vaccine><Moderna coronavirus disease 2019 vaccine><Morbidity><Morbidity - disease rate><NIH><National Institutes of Health><Paludism><Parents><Pb element><Persons><Phase><Physicians><Placebo Control><Plasmodium Infections><Population><Preparation><Prevalence><Prevention><Preventive><Proliferating><Protocol><Protocols documentation><Quality Control><RNA vaccine><RNA-based vaccine><Randomized><Randomized Clinical Trials><Research Methodology><Research Methods><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 B.1.351><SARS-CoV-2 beta><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 exposure><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 severity><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 exposure><SARS-CoV2 infection><SARS-CoV2 outbreak><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Sampling><Scientist><Serology test><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 exposure><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Severities><Site><South Africa><South Africa strain><South Africa variant><South African strain><South African variant><Sub-Saharan Africa><Subsaharan Africa><System><Testing><Therapeutic Monoclonal Antibodies><Typhoid><Typhoid Fever><U-Series Cooperative Agreements><United States><United States National Institutes of Health><Vaccines><Validation><Wuhan coronavirus><adulthood><base><cell assay><clinical trial analysis><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 exposure><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 severity><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 prevention><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><design><designing><developmental><efficacy analysis><efficacy assessment><efficacy evaluation><efficacy examination><efficacy study><efficacy testing><efficacy trial><evaluate efficacy><examine efficacy><experience><exposure to COVID-19><exposure to SARS-CoV-2><exposure to SARS-CoV2><exposure to Severe acute respiratory syndrome coronavirus 2><exposure to coronavirus disease 2019><hCoV19><heavy metal Pb><heavy metal lead><host response><human immunodeficiency virus vaccine><immune function><immune system response><immunoresponse><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><interventional strategy><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><mRNA><mRNA vaccine><mRNA-1273><mRNA-based vaccine><mRNA1273><monoclonal antibody drugs><mortality><nCoV2><operation><placebo controlled><prevent><prevent COVID-19><prevent COVID19><prevent coronavirus disease 2019><preventing><programs><quality assurance><randomisation><randomization><randomly assigned><rational design><response><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><serology assay><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 B.1.351><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 severity><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><symptomatic COVID-19><symptomatic COVID19><symptomatic coronavirus disease 2019><therapeutic mAbs><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine efficacy><vaccine for novel coronavirus><vaccine study><vaccine trial><variants of concern>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Glenda E Gray

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$55,953,346

FY 2022

Project Title

CoVPN 3008 - Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern

Grant Number:

3UM1AI068614-17S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/29/2006

End Date:

11/30/2024

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

FOA: PA-20-272: Administrative Supplements to Existing NIH Grants and Cooperative Agreements Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the ...

Research Terms

<2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><21+ years old><Abdominal Typhus><Address><Administrative Supplement><Adult><Adult Human><Africa South of the Sahara><Area><Assay><Award><B.1.351><Bioassay><Biologic Assays><Biological Assay><Biometrics><Biometry><Biostatistics><Blinded><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 Prevention Network><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 exposure><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 prevention><COVID-19 public health crisis><COVID-19 severity><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 outbreak><COVID19 pandemic><COVID19 prevention><COVID19 public health crisis><COVID19 severity><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cellular Assay><Cellular Immune Function><Clinical><Clinical Trials><Clinical Trials Network><CoV-2><CoV2><CoVPN><Code><Coding System><Cohort Studies><Communicable Diseases><Concurrent Studies><Constitution><Cooperative Agreements><Coronaviridae><Coronavirus><Country><Development><Diagnosis><Disease><Disorder><Dose><End Point Assay><Endpoint Assays><Enteric Fever><Exposure to><Eye><Eyeball><Future><Goals><Grant><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS Vaccines><HVTN><Health><High Prevalence><Immune><Immune Monitoring><Immune response><Immunes><Immunity><Immunologic Monitoring><Immunological Monitoring><Immunological response><Immunology><Immunomonitoring><Individual><Infection Control><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><International><Intervention><Intervention Strategies><Knowledge><Laboratories><Lead><Leadership><MAb Therapeutics><Malaria><Mediating><Messenger RNA><Moderna COVID-19 vaccine><Moderna coronavirus disease 2019 vaccine><Morbidity><Morbidity - disease rate><NIH><National Institutes of Health><Paludism><Parents><Pb element><Persons><Phase><Physicians><Placebo Control><Plasmodium Infections><Population><Preparation><Prevalence><Prevention><Preventive><Proliferating><Protocol><Protocols documentation><Quality Control><RNA vaccine><RNA-based vaccine><Randomized><Randomized Clinical Trials><Research Methodology><Research Methods><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 B.1.351><SARS-CoV-2 beta><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 exposure><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 severity><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 exposure><SARS-CoV2 infection><SARS-CoV2 outbreak><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Sampling><Scientist><Serology test><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 exposure><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Severities><Site><South Africa><South Africa strain><South Africa variant><South African strain><South African variant><Sub-Saharan Africa><Subsaharan Africa><System><Testing><Therapeutic Monoclonal Antibodies><Typhoid><Typhoid Fever><U-Series Cooperative Agreements><United States><United States National Institutes of Health><Vaccines><Validation><Wuhan coronavirus><adulthood><base><cell assay><clinical trial analysis><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 exposure><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 severity><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 prevention><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><design><designing><developmental><efficacy analysis><efficacy assessment><efficacy evaluation><efficacy examination><efficacy study><efficacy testing><efficacy trial><evaluate efficacy><examine efficacy><experience><exposure to COVID-19><exposure to SARS-CoV-2><exposure to SARS-CoV2><exposure to Severe acute respiratory syndrome coronavirus 2><exposure to coronavirus disease 2019><hCoV19><heavy metal Pb><heavy metal lead><host response><human immunodeficiency virus vaccine><immune function><immune system response><immunoresponse><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><interventional strategy><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><mRNA><mRNA vaccine><mRNA-1273><mRNA-based vaccine><mRNA1273><monoclonal antibody drugs><mortality><nCoV2><operation><placebo controlled><prevent><prevent COVID-19><prevent COVID19><prevent coronavirus disease 2019><preventing><programs><quality assurance><randomisation><randomization><randomly assigned><rational design><response><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><serology assay><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 B.1.351><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 severity><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><symptomatic COVID-19><symptomatic COVID19><symptomatic coronavirus disease 2019><therapeutic mAbs><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine efficacy><vaccine for novel coronavirus><vaccine study><vaccine trial><variants of concern>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

GEORGIA Doris TOMARAS

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$55,953,346

FY 2022

Project Title

CoVPN 3008 - Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern

Grant Number:

3UM1AI068614-17S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/29/2006

End Date:

11/30/2024

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

FOA: PA-20-272: Administrative Supplements to Existing NIH Grants and Cooperative Agreements Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the ...

Research Terms

<2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><21+ years old><Abdominal Typhus><Address><Administrative Supplement><Adult><Adult Human><Africa South of the Sahara><Area><Assay><Award><B.1.351><Bioassay><Biologic Assays><Biological Assay><Biometrics><Biometry><Biostatistics><Blinded><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 Prevention Network><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 exposure><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 prevention><COVID-19 public health crisis><COVID-19 severity><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 outbreak><COVID19 pandemic><COVID19 prevention><COVID19 public health crisis><COVID19 severity><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cellular Assay><Cellular Immune Function><Clinical><Clinical Trials><Clinical Trials Network><CoV-2><CoV2><CoVPN><Code><Coding System><Cohort Studies><Communicable Diseases><Concurrent Studies><Constitution><Cooperative Agreements><Coronaviridae><Coronavirus><Country><Development><Diagnosis><Disease><Disorder><Dose><End Point Assay><Endpoint Assays><Enteric Fever><Exposure to><Eye><Eyeball><Future><Goals><Grant><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS Vaccines><HVTN><Health><High Prevalence><Immune><Immune Monitoring><Immune response><Immunes><Immunity><Immunologic Monitoring><Immunological Monitoring><Immunological response><Immunology><Immunomonitoring><Individual><Infection Control><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><International><Intervention><Intervention Strategies><Knowledge><Laboratories><Lead><Leadership><MAb Therapeutics><Malaria><Mediating><Messenger RNA><Moderna COVID-19 vaccine><Moderna coronavirus disease 2019 vaccine><Morbidity><Morbidity - disease rate><NIH><National Institutes of Health><Paludism><Parents><Pb element><Persons><Phase><Physicians><Placebo Control><Plasmodium Infections><Population><Preparation><Prevalence><Prevention><Preventive><Proliferating><Protocol><Protocols documentation><Quality Control><RNA vaccine><RNA-based vaccine><Randomized><Randomized Clinical Trials><Research Methodology><Research Methods><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 B.1.351><SARS-CoV-2 beta><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 exposure><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 severity><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 exposure><SARS-CoV2 infection><SARS-CoV2 outbreak><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Sampling><Scientist><Serology test><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 exposure><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Severities><Site><South Africa><South Africa strain><South Africa variant><South African strain><South African variant><Sub-Saharan Africa><Subsaharan Africa><System><Testing><Therapeutic Monoclonal Antibodies><Typhoid><Typhoid Fever><U-Series Cooperative Agreements><United States><United States National Institutes of Health><Vaccines><Validation><Wuhan coronavirus><adulthood><base><cell assay><clinical trial analysis><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 exposure><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 severity><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 prevention><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><design><designing><developmental><efficacy analysis><efficacy assessment><efficacy evaluation><efficacy examination><efficacy study><efficacy testing><efficacy trial><evaluate efficacy><examine efficacy><experience><exposure to COVID-19><exposure to SARS-CoV-2><exposure to SARS-CoV2><exposure to Severe acute respiratory syndrome coronavirus 2><exposure to coronavirus disease 2019><hCoV19><heavy metal Pb><heavy metal lead><host response><human immunodeficiency virus vaccine><immune function><immune system response><immunoresponse><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><interventional strategy><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><mRNA><mRNA vaccine><mRNA-1273><mRNA-based vaccine><mRNA1273><monoclonal antibody drugs><mortality><nCoV2><operation><placebo controlled><prevent><prevent COVID-19><prevent COVID19><prevent coronavirus disease 2019><preventing><programs><quality assurance><randomisation><randomization><randomly assigned><rational design><response><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><serology assay><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 B.1.351><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 severity><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><symptomatic COVID-19><symptomatic COVID19><symptomatic coronavirus disease 2019><therapeutic mAbs><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine efficacy><vaccine for novel coronavirus><vaccine study><vaccine trial><variants of concern>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Clarence Buddy Creech

VANDERBILT UNIVERSITY MEDICAL CENTER, NASHVILLE, TN

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$13,319,092

FY 2022

Project Title

Vanderbilt Vaccine and Treatment Evaluation Unit

Grant Number:

3UM1AI148452-03S3

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/14/2021

End Date:

11/30/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

ABSTRACT The goal of this UM1 proposal is to use the remarkable research infrastructure at Vanderbilt University Medical Center and collaborating sites (Washington University, University of Pittsburgh, and University of Pennsylvania) to conceptualize, design, implement, and analyze clinical research...

Research Terms

<0-11 years old><21+ years old><Academic Medical Centers><Adult><Adult Human><Age><Area><Assay><Award><Bacterial Infections><Bioassay><Biologic Assays><Biologic Products><Biological Agent><Biological Assay><Biological Products><Body Tissues><Child><Child Youth><Childhood><Children (0-21)><Clinical><Clinical Investigator><Clinical Research><Clinical Study><Clinical Trials><Communicable Diseases><Conduct Clinical Trials><Data><Development><Disease><Disorder><Drugs><Education><Educational aspects><Elderly><Emerging Communicable Diseases><Emerging Infectious Diseases><Enrollment><Environment><Evaluation><Faculty><Feasibility Studies><Fellowship><Fostering><Funding><Fungus Diseases><Geography><Goals><Grippe><Home><Human><Immune response><Immunity><Immunization><Immunologic Sensitization><Immunologic Stimulation><Immunological Sensitization><Immunological Stimulation><Immunological response><Immunologist><Immunostimulation><Individual><Infant><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Influenza><Influenza Vaccines><Institution><International><Intervention><Intervention Strategies><Investigators><Laboratories><Laboratory Scientists><Lead><Leadership><Length of Life><Licensure><Longevity><Malaria><Malaria Vaccines><Malarial Vaccines><Medical><Medical center><Medication><Mentors><Mentorship><Methods><Modeling><Modern Man><Mycoses><NIH><National Institutes of Health><Nurses><Paludism><Parasitic infection><Pathogenesis><Pb element><Pennsylvania><Pertussis Vaccine><Peru><Pharmaceutic Preparations><Pharmaceutical Preparations><Phase><Physicians><Plasmodium Infections><Pneumococcal vaccine><Population><Population Heterogeneity><Position><Positioning Attribute><Pregnant Women><Prevention><Principal Investigator><Procedures><Process><Protocol><Protocols documentation><Research><Research Infrastructure><Research Personnel><Researchers><Safety><Scientist><Sexually Transmitted Diseases><Sexually Transmitted Disorder><Sexually Transmitted Infection><Site><Smallpox Vaccine><Special Population><Standardization><Streptococcus pneumoniae vaccine><Systems Biology><Tissues><Training><United States National Institutes of Health><Universities><University Medical Centers><Vaccination><Vaccine Research><Vaccines><Venereal Diseases><Venereal Disorders><Venereal Infections><Viral><Viral Diseases><Virus Diseases><Visit><Washington><Work><adulthood><advanced age><ages><antibiotic resistant infections><bacteria infection><bacterial disease><base><biologics><biopharmaceutical><biotherapeutic agent><career><career development><clinical research site><clinical site><co-morbid><co-morbidity><comorbidity><design><designing><developmental><diverse populations><drug/agent><early clinical trial><early phase clinical trial><elders><emerging pathogen><enroll><ethnic diversity><ethnically diverse><expectant mother><expecting mother><experience><flu vaccine><flu virus pandemic><flu virus vaccine><fungal infection><fungus infection><geriatric><heavy metal Pb><heavy metal lead><heterogeneous population><host response><immune system response><immunogenicity><immunoresponse><influenza virus pandemic><influenza virus vaccine><innovate><innovation><innovative><interventional strategy><late life><later life><life span><lifespan><new approaches><new drug treatments><new drugs><new pathogen><new therapeutics><new therapy><new vaccines><next generation><next generation therapeutics><next generation vaccines><novel><novel approaches><novel drug treatments><novel drugs><novel pathogen><novel strategies><novel strategy><novel therapeutics><novel therapy><novel vaccines><nurse><older adult><older person><pandemic flu><pandemic influenza><pandemic strain of influenza><parasite infection><pathogen><pediatric><population diversity><pregnant mothers><recruit><research study><respiratory><response><senior citizen><tool><vaccination study><vaccination trial><vaccine against flu><vaccine against influenza><vaccine study><vaccine trial><vaccines against malaria><vaccinology><viral infection><virus infection><virus-induced disease><volunteer><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Dan H. Barouch

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$9,754,127

FY 2022

Project Title

CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older

Grant Number:

3UM1AI068614-17S3

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/29/2006

End Date:

4/6/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

FOA: PA-20-272: Administrative Supplements to Existing NIH Grants and Cooperative Agreements Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the ...

Research Terms

<18 year old><18 years of age><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><21+ years old><Address><Adjuvant><Administrative Supplement><Adult><Adult Human><Assay><Award><B.1.351><Bioassay><Biologic Assays><Biological Assay><Biometrics><Biometry><Biostatistics><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 Prevention Network><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 screening><COVID-19 severity><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 outbreak><COVID19 pandemic><COVID19 public health crisis><COVID19 screening><COVID19 severity><COVID19 vaccine><COVID19 virus><CV-19><CV19><Clinical><Clinical Trials><Clinical Trials Network><CoV-2><CoV2><CoVPN><Code><Coding System><Constitution><Cooperative Agreements><Country><Data Analytics><Diagnosis><Disease><Disorder><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><End Point Assay><Endpoint Assays><Frequencies><Future Generations><Goals><Grant><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS Vaccines><HVTN><Health><Hospital Admission><Hospitalization><Immune Monitoring><Immune response><Immunity><Immunologic Monitoring><Immunological Monitoring><Immunological response><Immunomonitoring><Individual><Infection prevention><Injections><International><Investigation><Laboratories><Lead><Leadership><Monitor><NIH><National Institutes of Health><Parents><Participant><Pb element><Persons><Phase><Physicians><Placebo Control><Placebos><Population><Prevent infection><Prevention><Protocol><Protocols documentation><Recombinant Proteins><Recombinant Vaccines><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 B.1.351><SARS-CoV-2 beta><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 screening><SARS-CoV-2 severity><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 outbreak><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Scientist><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Sham Treatment><Site><South Africa strain><South Africa variant><South African strain><South African variant><U-Series Cooperative Agreements><United States><United States National Institutes of Health><Vaccines><Wuhan coronavirus><adulthood><age 18 years><clinical efficacy><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 screening><coronavirus disease 2019 severity><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><efficacy testing><efficacy trial><eighteen year old><eighteen years of age><ethnoracial><experience><hCoV19><heavy metal Pb><heavy metal lead><high risk><host response><human immunodeficiency virus vaccine><immune system response><immunogenicity><immunoresponse><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><nCoV2><operation><placebo controlled><prevent><preventing><racial and ethnic><racial diversity><racially diverse><recruit><remote monitoring><response><safety study><scale up><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 B.1.351><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 screening><severe acute respiratory syndrome coronavirus 2 severity><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><sham therapy><symptomatic COVID-19><symptomatic COVID19><symptomatic coronavirus disease 2019><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine for novel coronavirus><vaccine study><vaccine trial><variants of concern>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Lawrence Corey

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$9,754,127

FY 2022

Project Title

CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older

Grant Number:

3UM1AI068614-17S3

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/29/2006

End Date:

4/6/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

FOA: PA-20-272: Administrative Supplements to Existing NIH Grants and Cooperative Agreements Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the ...

Research Terms

<18 year old><18 years of age><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><21+ years old><Address><Adjuvant><Administrative Supplement><Adult><Adult Human><Assay><Award><B.1.351><Bioassay><Biologic Assays><Biological Assay><Biometrics><Biometry><Biostatistics><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 Prevention Network><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 screening><COVID-19 severity><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 outbreak><COVID19 pandemic><COVID19 public health crisis><COVID19 screening><COVID19 severity><COVID19 vaccine><COVID19 virus><CV-19><CV19><Clinical><Clinical Trials><Clinical Trials Network><CoV-2><CoV2><CoVPN><Code><Coding System><Constitution><Cooperative Agreements><Country><Data Analytics><Diagnosis><Disease><Disorder><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><End Point Assay><Endpoint Assays><Frequencies><Future Generations><Goals><Grant><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS Vaccines><HVTN><Health><Hospital Admission><Hospitalization><Immune Monitoring><Immune response><Immunity><Immunologic Monitoring><Immunological Monitoring><Immunological response><Immunomonitoring><Individual><Infection prevention><Injections><International><Investigation><Laboratories><Lead><Leadership><Monitor><NIH><National Institutes of Health><Parents><Participant><Pb element><Persons><Phase><Physicians><Placebo Control><Placebos><Population><Prevent infection><Prevention><Protocol><Protocols documentation><Recombinant Proteins><Recombinant Vaccines><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 B.1.351><SARS-CoV-2 beta><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 screening><SARS-CoV-2 severity><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 outbreak><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Scientist><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Sham Treatment><Site><South Africa strain><South Africa variant><South African strain><South African variant><U-Series Cooperative Agreements><United States><United States National Institutes of Health><Vaccines><Wuhan coronavirus><adulthood><age 18 years><clinical efficacy><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 screening><coronavirus disease 2019 severity><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><efficacy testing><efficacy trial><eighteen year old><eighteen years of age><ethnoracial><experience><hCoV19><heavy metal Pb><heavy metal lead><high risk><host response><human immunodeficiency virus vaccine><immune system response><immunogenicity><immunoresponse><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><nCoV2><operation><placebo controlled><prevent><preventing><racial and ethnic><racial diversity><racially diverse><recruit><remote monitoring><response><safety study><scale up><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 B.1.351><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 screening><severe acute respiratory syndrome coronavirus 2 severity><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><sham therapy><symptomatic COVID-19><symptomatic COVID19><symptomatic coronavirus disease 2019><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine for novel coronavirus><vaccine study><vaccine trial><variants of concern>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Glenda E Gray

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$9,754,127

FY 2022

Project Title

CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older

Grant Number:

3UM1AI068614-17S3

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/29/2006

End Date:

4/6/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

FOA: PA-20-272: Administrative Supplements to Existing NIH Grants and Cooperative Agreements Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the ...

Research Terms

<18 year old><18 years of age><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><21+ years old><Address><Adjuvant><Administrative Supplement><Adult><Adult Human><Assay><Award><B.1.351><Bioassay><Biologic Assays><Biological Assay><Biometrics><Biometry><Biostatistics><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 Prevention Network><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 screening><COVID-19 severity><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 outbreak><COVID19 pandemic><COVID19 public health crisis><COVID19 screening><COVID19 severity><COVID19 vaccine><COVID19 virus><CV-19><CV19><Clinical><Clinical Trials><Clinical Trials Network><CoV-2><CoV2><CoVPN><Code><Coding System><Constitution><Cooperative Agreements><Country><Data Analytics><Diagnosis><Disease><Disorder><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><End Point Assay><Endpoint Assays><Frequencies><Future Generations><Goals><Grant><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS Vaccines><HVTN><Health><Hospital Admission><Hospitalization><Immune Monitoring><Immune response><Immunity><Immunologic Monitoring><Immunological Monitoring><Immunological response><Immunomonitoring><Individual><Infection prevention><Injections><International><Investigation><Laboratories><Lead><Leadership><Monitor><NIH><National Institutes of Health><Parents><Participant><Pb element><Persons><Phase><Physicians><Placebo Control><Placebos><Population><Prevent infection><Prevention><Protocol><Protocols documentation><Recombinant Proteins><Recombinant Vaccines><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 B.1.351><SARS-CoV-2 beta><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 screening><SARS-CoV-2 severity><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 outbreak><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Scientist><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Sham Treatment><Site><South Africa strain><South Africa variant><South African strain><South African variant><U-Series Cooperative Agreements><United States><United States National Institutes of Health><Vaccines><Wuhan coronavirus><adulthood><age 18 years><clinical efficacy><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 screening><coronavirus disease 2019 severity><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><efficacy testing><efficacy trial><eighteen year old><eighteen years of age><ethnoracial><experience><hCoV19><heavy metal Pb><heavy metal lead><high risk><host response><human immunodeficiency virus vaccine><immune system response><immunogenicity><immunoresponse><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><nCoV2><operation><placebo controlled><prevent><preventing><racial and ethnic><racial diversity><racially diverse><recruit><remote monitoring><response><safety study><scale up><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 B.1.351><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 screening><severe acute respiratory syndrome coronavirus 2 severity><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><sham therapy><symptomatic COVID-19><symptomatic COVID19><symptomatic coronavirus disease 2019><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine for novel coronavirus><vaccine study><vaccine trial><variants of concern>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

GEORGIA Doris TOMARAS

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$9,754,127

FY 2022

Project Title

CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older

Grant Number:

3UM1AI068614-17S3

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/29/2006

End Date:

4/6/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

FOA: PA-20-272: Administrative Supplements to Existing NIH Grants and Cooperative Agreements Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the ...

Research Terms

<18 year old><18 years of age><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><21+ years old><Address><Adjuvant><Administrative Supplement><Adult><Adult Human><Assay><Award><B.1.351><Bioassay><Biologic Assays><Biological Assay><Biometrics><Biometry><Biostatistics><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 Prevention Network><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 screening><COVID-19 severity><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 outbreak><COVID19 pandemic><COVID19 public health crisis><COVID19 screening><COVID19 severity><COVID19 vaccine><COVID19 virus><CV-19><CV19><Clinical><Clinical Trials><Clinical Trials Network><CoV-2><CoV2><CoVPN><Code><Coding System><Constitution><Cooperative Agreements><Country><Data Analytics><Diagnosis><Disease><Disorder><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><End Point Assay><Endpoint Assays><Frequencies><Future Generations><Goals><Grant><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS Vaccines><HVTN><Health><Hospital Admission><Hospitalization><Immune Monitoring><Immune response><Immunity><Immunologic Monitoring><Immunological Monitoring><Immunological response><Immunomonitoring><Individual><Infection prevention><Injections><International><Investigation><Laboratories><Lead><Leadership><Monitor><NIH><National Institutes of Health><Parents><Participant><Pb element><Persons><Phase><Physicians><Placebo Control><Placebos><Population><Prevent infection><Prevention><Protocol><Protocols documentation><Recombinant Proteins><Recombinant Vaccines><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 B.1.351><SARS-CoV-2 beta><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 screening><SARS-CoV-2 severity><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 outbreak><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Scientist><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Sham Treatment><Site><South Africa strain><South Africa variant><South African strain><South African variant><U-Series Cooperative Agreements><United States><United States National Institutes of Health><Vaccines><Wuhan coronavirus><adulthood><age 18 years><clinical efficacy><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 screening><coronavirus disease 2019 severity><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><efficacy testing><efficacy trial><eighteen year old><eighteen years of age><ethnoracial><experience><hCoV19><heavy metal Pb><heavy metal lead><high risk><host response><human immunodeficiency virus vaccine><immune system response><immunogenicity><immunoresponse><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><nCoV2><operation><placebo controlled><prevent><preventing><racial and ethnic><racial diversity><racially diverse><recruit><remote monitoring><response><safety study><scale up><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 B.1.351><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 screening><severe acute respiratory syndrome coronavirus 2 severity><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><sham therapy><symptomatic COVID-19><symptomatic COVID19><symptomatic coronavirus disease 2019><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine for novel coronavirus><vaccine study><vaccine trial><variants of concern>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Nabila El-Bassel

COLUMBIA UNIV NEW YORK MORNINGSIDE, NEW YORK, NY

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$8,680,000

FY 2022

Project Title

CHASE: An Innovative County-Level Public Health Response to the Opioid Epidemic in New York State

Grant Number:

5UM1DA049415-04

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/17/2019

End Date:

3/31/2025

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

PROJECT SUMMARY New York State (NYS) ranks second in the nation in absolute numbers of opioid overdose deaths. From 2015- 2016, opioid overdose deaths in NYS increased by 32%, including an 88% increase in synthetic opioid-related deaths. The proposed research will develop and test a County-system Hu...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Daniel J Feaster

COLUMBIA UNIV NEW YORK MORNINGSIDE, NEW YORK, NY

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$8,680,000

FY 2022

Project Title

CHASE: An Innovative County-Level Public Health Response to the Opioid Epidemic in New York State

Grant Number:

5UM1DA049415-04

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/17/2019

End Date:

3/31/2025

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

PROJECT SUMMARY New York State (NYS) ranks second in the nation in absolute numbers of opioid overdose deaths. From 2015- 2016, opioid overdose deaths in NYS increased by 32%, including an 88% increase in synthetic opioid-related deaths. The proposed research will develop and test a County-system Hu...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Louisa Gilbert

COLUMBIA UNIV NEW YORK MORNINGSIDE, NEW YORK, NY

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$8,680,000

FY 2022

Project Title

CHASE: An Innovative County-Level Public Health Response to the Opioid Epidemic in New York State

Grant Number:

5UM1DA049415-04

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/17/2019

End Date:

3/31/2025

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

PROJECT SUMMARY New York State (NYS) ranks second in the nation in absolute numbers of opioid overdose deaths. From 2015- 2016, opioid overdose deaths in NYS increased by 32%, including an 88% increase in synthetic opioid-related deaths. The proposed research will develop and test a County-system Hu...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Edward V. Nunes

COLUMBIA UNIV NEW YORK MORNINGSIDE, NEW YORK, NY

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$8,680,000

FY 2022

Project Title

CHASE: An Innovative County-Level Public Health Response to the Opioid Epidemic in New York State

Grant Number:

5UM1DA049415-04

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/17/2019

End Date:

3/31/2025

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

PROJECT SUMMARY New York State (NYS) ranks second in the nation in absolute numbers of opioid overdose deaths. From 2015- 2016, opioid overdose deaths in NYS increased by 32%, including an 88% increase in synthetic opioid-related deaths. The proposed research will develop and test a County-system Hu...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Dan H. Barouch

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$5,663,427

FY 2022

Project Title

CoVPN 3004 - A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine LOC

Grant Number:

3UM1AI068614-17S6

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/29/2006

End Date:

11/30/2024

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

NOSI: NOT-AI-20-034 FOA: PA-20-135 – Emergency Competitive Revision to Existing NIH Awards Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the CO...

Research Terms

<18 year old><18 years of age><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><21+ years old><Abdominal Typhus><Address><Adjuvant><Adult><Adult Human><Antibodies><Antibody Response><Assay><Award><Binding><Bioassay><Biologic Assays><Biological Assay><Biometrics><Biometry><Biostatistics><Blinded><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 Prevention Network><COVID-19 antibody><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 screening><COVID-19 severity><COVID-19 vaccine><COVID-19 virus><COVID19><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 outbreak><COVID19 pandemic><COVID19 public health crisis><COVID19 screening><COVID19 severity><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cell Body><Cells><Cellular Assay><Cellular Immune Function><Characteristics><Clinical><Clinical Trials><Clinical Trials Network><CoV-2><CoV2><CoVPN><Code><Coding System><Cohort Studies><Communicable Diseases><Concurrent Studies><Constitution><Coronaviridae><Coronavirus><Country><Data Analytics><Development><Diabetes Mellitus><Diagnosis><Disease><Disorder><Dose><Emergencies><Emergency Situation><End Point Assay><Endpoint Assays><Enteric Fever><Ethnic Origin><Ethnicity><Eye><Eyeball><Follow-Up Studies><Followup Studies><Future><Goals><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS Vaccines><HVTN><Health><Hospital Admission><Hospitalization><Hypertension><Immune><Immune Monitoring><Immune response><Immunes><Immunity><Immunologic Monitoring><Immunological Monitoring><Immunological response><Immunology><Immunomonitoring><Individual><Infection Control><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><International><Intervention><Intervention Strategies><Knowledge><Laboratories><Lead><Leadership><MAb Therapeutics><Malaria><Mediating><Molecular Interaction><Monitor><Morbidity><Morbidity - disease rate><NIH><National Institutes of Health><Novavax COVID-19 vaccine><Novavax S protein vaccine><Novavax coronavirus disease 2019 vaccine><Obesity><Outcomes Research><Paludism><Parents><Participant><Pb element><Persons><Phase><Physicians><Placebo Control><Placebos><Plasmodium Infections><Population><Preparation><Prevention><Preventive><Proteins><Protocol><Protocols documentation><Quality Control><RS protein><Race><Racial Group><Racial Stocks><Randomized><Randomized Clinical Trials><Recombinants><Regimen><Research Methodology><Research Methods><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 antibody><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 rS><SARS-CoV-2 screening><SARS-CoV-2 severity><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 antibody><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 outbreak><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Sampling><Scientist><Serology test><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Severity of illness><Sham Treatment><Site><System><Testing><Therapeutic Monoclonal Antibodies><Typhoid><Typhoid Fever><United States><United States National Institutes of Health><Vaccination><Vaccines><Validation><Vascular Hypertensive Disease><Vascular Hypertensive Disorder><Virus><Wuhan coronavirus><adaptive immune response><adiposity><adulthood><age 18 years><antibody against COVID-19><antibody against SARS-CoV-2><antibody against SARS-CoV2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody to COVID-19><antibody to SARS-CoV-2><antibody to SARS-CoV2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><base><booster dose><booster shot><booster vaccine><cell assay><clinical trial analysis><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 antibody><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 screening><coronavirus disease 2019 severity><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><corpulence><design><designing><developmental><diabetes><disease severity><efficacy analysis><efficacy assessment><efficacy evaluation><efficacy examination><efficacy study><efficacy testing><efficacy trial><eighteen year old><eighteen years of age><ethnoracial><evaluate efficacy><examine efficacy><experience><hCoV19><health economics><heavy metal Pb><heavy metal lead><high blood pressure><high risk><host response><human immunodeficiency virus vaccine><hyperpiesia><hyperpiesis><hypertensive disease><hypertensive disorder><immune function><immune system response><immunogenicity><immunoresponse><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><interventional strategy><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><monoclonal antibody drugs><mortality><nCoV2><nano particle><nano-sized particle><nanoparticle><nanosized particle><neutralizing antibody><operation><placebo controlled><placebo controlled study><prevent><preventing><programs><quality assurance><racial and ethnic><racial diversity><racially diverse><randomisation><randomization><randomly assigned><rational design><recruit><remote monitoring><response><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><serology assay><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 screening><severe acute respiratory syndrome coronavirus 2 severity><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><sham therapy><symptomatic COVID-19><symptomatic COVID19><symptomatic coronavirus disease 2019><therapeutic mAbs><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine efficacy><vaccine for novel coronavirus><vaccine safety><vaccine study><vaccine trial>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Lawrence Corey

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$5,663,427

FY 2022

Project Title

CoVPN 3004 - A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine LOC

Grant Number:

3UM1AI068614-17S6

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/29/2006

End Date:

11/30/2024

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

NOSI: NOT-AI-20-034 FOA: PA-20-135 – Emergency Competitive Revision to Existing NIH Awards Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the CO...

Research Terms

<18 year old><18 years of age><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><21+ years old><Abdominal Typhus><Address><Adjuvant><Adult><Adult Human><Antibodies><Antibody Response><Assay><Award><Binding><Bioassay><Biologic Assays><Biological Assay><Biometrics><Biometry><Biostatistics><Blinded><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 Prevention Network><COVID-19 antibody><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 screening><COVID-19 severity><COVID-19 vaccine><COVID-19 virus><COVID19><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 outbreak><COVID19 pandemic><COVID19 public health crisis><COVID19 screening><COVID19 severity><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cell Body><Cells><Cellular Assay><Cellular Immune Function><Characteristics><Clinical><Clinical Trials><Clinical Trials Network><CoV-2><CoV2><CoVPN><Code><Coding System><Cohort Studies><Communicable Diseases><Concurrent Studies><Constitution><Coronaviridae><Coronavirus><Country><Data Analytics><Development><Diabetes Mellitus><Diagnosis><Disease><Disorder><Dose><Emergencies><Emergency Situation><End Point Assay><Endpoint Assays><Enteric Fever><Ethnic Origin><Ethnicity><Eye><Eyeball><Follow-Up Studies><Followup Studies><Future><Goals><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS Vaccines><HVTN><Health><Hospital Admission><Hospitalization><Hypertension><Immune><Immune Monitoring><Immune response><Immunes><Immunity><Immunologic Monitoring><Immunological Monitoring><Immunological response><Immunology><Immunomonitoring><Individual><Infection Control><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><International><Intervention><Intervention Strategies><Knowledge><Laboratories><Lead><Leadership><MAb Therapeutics><Malaria><Mediating><Molecular Interaction><Monitor><Morbidity><Morbidity - disease rate><NIH><National Institutes of Health><Novavax COVID-19 vaccine><Novavax S protein vaccine><Novavax coronavirus disease 2019 vaccine><Obesity><Outcomes Research><Paludism><Parents><Participant><Pb element><Persons><Phase><Physicians><Placebo Control><Placebos><Plasmodium Infections><Population><Preparation><Prevention><Preventive><Proteins><Protocol><Protocols documentation><Quality Control><RS protein><Race><Racial Group><Racial Stocks><Randomized><Randomized Clinical Trials><Recombinants><Regimen><Research Methodology><Research Methods><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 antibody><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 rS><SARS-CoV-2 screening><SARS-CoV-2 severity><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 antibody><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 outbreak><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Sampling><Scientist><Serology test><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Severity of illness><Sham Treatment><Site><System><Testing><Therapeutic Monoclonal Antibodies><Typhoid><Typhoid Fever><United States><United States National Institutes of Health><Vaccination><Vaccines><Validation><Vascular Hypertensive Disease><Vascular Hypertensive Disorder><Virus><Wuhan coronavirus><adaptive immune response><adiposity><adulthood><age 18 years><antibody against COVID-19><antibody against SARS-CoV-2><antibody against SARS-CoV2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody to COVID-19><antibody to SARS-CoV-2><antibody to SARS-CoV2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><base><booster dose><booster shot><booster vaccine><cell assay><clinical trial analysis><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 antibody><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 screening><coronavirus disease 2019 severity><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><corpulence><design><designing><developmental><diabetes><disease severity><efficacy analysis><efficacy assessment><efficacy evaluation><efficacy examination><efficacy study><efficacy testing><efficacy trial><eighteen year old><eighteen years of age><ethnoracial><evaluate efficacy><examine efficacy><experience><hCoV19><health economics><heavy metal Pb><heavy metal lead><high blood pressure><high risk><host response><human immunodeficiency virus vaccine><hyperpiesia><hyperpiesis><hypertensive disease><hypertensive disorder><immune function><immune system response><immunogenicity><immunoresponse><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><interventional strategy><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><monoclonal antibody drugs><mortality><nCoV2><nano particle><nano-sized particle><nanoparticle><nanosized particle><neutralizing antibody><operation><placebo controlled><placebo controlled study><prevent><preventing><programs><quality assurance><racial and ethnic><racial diversity><racially diverse><randomisation><randomization><randomly assigned><rational design><recruit><remote monitoring><response><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><serology assay><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 screening><severe acute respiratory syndrome coronavirus 2 severity><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><sham therapy><symptomatic COVID-19><symptomatic COVID19><symptomatic coronavirus disease 2019><therapeutic mAbs><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine efficacy><vaccine for novel coronavirus><vaccine safety><vaccine study><vaccine trial>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Glenda E Gray

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$5,663,427

FY 2022

Project Title

CoVPN 3004 - A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine LOC

Grant Number:

3UM1AI068614-17S6

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/29/2006

End Date:

11/30/2024

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

NOSI: NOT-AI-20-034 FOA: PA-20-135 – Emergency Competitive Revision to Existing NIH Awards Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the CO...

Research Terms

<18 year old><18 years of age><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><21+ years old><Abdominal Typhus><Address><Adjuvant><Adult><Adult Human><Antibodies><Antibody Response><Assay><Award><Binding><Bioassay><Biologic Assays><Biological Assay><Biometrics><Biometry><Biostatistics><Blinded><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 Prevention Network><COVID-19 antibody><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 screening><COVID-19 severity><COVID-19 vaccine><COVID-19 virus><COVID19><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 outbreak><COVID19 pandemic><COVID19 public health crisis><COVID19 screening><COVID19 severity><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cell Body><Cells><Cellular Assay><Cellular Immune Function><Characteristics><Clinical><Clinical Trials><Clinical Trials Network><CoV-2><CoV2><CoVPN><Code><Coding System><Cohort Studies><Communicable Diseases><Concurrent Studies><Constitution><Coronaviridae><Coronavirus><Country><Data Analytics><Development><Diabetes Mellitus><Diagnosis><Disease><Disorder><Dose><Emergencies><Emergency Situation><End Point Assay><Endpoint Assays><Enteric Fever><Ethnic Origin><Ethnicity><Eye><Eyeball><Follow-Up Studies><Followup Studies><Future><Goals><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS Vaccines><HVTN><Health><Hospital Admission><Hospitalization><Hypertension><Immune><Immune Monitoring><Immune response><Immunes><Immunity><Immunologic Monitoring><Immunological Monitoring><Immunological response><Immunology><Immunomonitoring><Individual><Infection Control><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><International><Intervention><Intervention Strategies><Knowledge><Laboratories><Lead><Leadership><MAb Therapeutics><Malaria><Mediating><Molecular Interaction><Monitor><Morbidity><Morbidity - disease rate><NIH><National Institutes of Health><Novavax COVID-19 vaccine><Novavax S protein vaccine><Novavax coronavirus disease 2019 vaccine><Obesity><Outcomes Research><Paludism><Parents><Participant><Pb element><Persons><Phase><Physicians><Placebo Control><Placebos><Plasmodium Infections><Population><Preparation><Prevention><Preventive><Proteins><Protocol><Protocols documentation><Quality Control><RS protein><Race><Racial Group><Racial Stocks><Randomized><Randomized Clinical Trials><Recombinants><Regimen><Research Methodology><Research Methods><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 antibody><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 rS><SARS-CoV-2 screening><SARS-CoV-2 severity><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 antibody><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 outbreak><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Sampling><Scientist><Serology test><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Severity of illness><Sham Treatment><Site><System><Testing><Therapeutic Monoclonal Antibodies><Typhoid><Typhoid Fever><United States><United States National Institutes of Health><Vaccination><Vaccines><Validation><Vascular Hypertensive Disease><Vascular Hypertensive Disorder><Virus><Wuhan coronavirus><adaptive immune response><adiposity><adulthood><age 18 years><antibody against COVID-19><antibody against SARS-CoV-2><antibody against SARS-CoV2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody to COVID-19><antibody to SARS-CoV-2><antibody to SARS-CoV2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><base><booster dose><booster shot><booster vaccine><cell assay><clinical trial analysis><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 antibody><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 screening><coronavirus disease 2019 severity><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><corpulence><design><designing><developmental><diabetes><disease severity><efficacy analysis><efficacy assessment><efficacy evaluation><efficacy examination><efficacy study><efficacy testing><efficacy trial><eighteen year old><eighteen years of age><ethnoracial><evaluate efficacy><examine efficacy><experience><hCoV19><health economics><heavy metal Pb><heavy metal lead><high blood pressure><high risk><host response><human immunodeficiency virus vaccine><hyperpiesia><hyperpiesis><hypertensive disease><hypertensive disorder><immune function><immune system response><immunogenicity><immunoresponse><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><interventional strategy><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><monoclonal antibody drugs><mortality><nCoV2><nano particle><nano-sized particle><nanoparticle><nanosized particle><neutralizing antibody><operation><placebo controlled><placebo controlled study><prevent><preventing><programs><quality assurance><racial and ethnic><racial diversity><racially diverse><randomisation><randomization><randomly assigned><rational design><recruit><remote monitoring><response><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><serology assay><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 screening><severe acute respiratory syndrome coronavirus 2 severity><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><sham therapy><symptomatic COVID-19><symptomatic COVID19><symptomatic coronavirus disease 2019><therapeutic mAbs><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine efficacy><vaccine for novel coronavirus><vaccine safety><vaccine study><vaccine trial>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

GEORGIA Doris TOMARAS

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$5,663,427

FY 2022

Project Title

CoVPN 3004 - A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine LOC

Grant Number:

3UM1AI068614-17S6

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/29/2006

End Date:

11/30/2024

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

NOSI: NOT-AI-20-034 FOA: PA-20-135 – Emergency Competitive Revision to Existing NIH Awards Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the CO...

Research Terms

<18 year old><18 years of age><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><21+ years old><Abdominal Typhus><Address><Adjuvant><Adult><Adult Human><Antibodies><Antibody Response><Assay><Award><Binding><Bioassay><Biologic Assays><Biological Assay><Biometrics><Biometry><Biostatistics><Blinded><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 Prevention Network><COVID-19 antibody><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 screening><COVID-19 severity><COVID-19 vaccine><COVID-19 virus><COVID19><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 outbreak><COVID19 pandemic><COVID19 public health crisis><COVID19 screening><COVID19 severity><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cell Body><Cells><Cellular Assay><Cellular Immune Function><Characteristics><Clinical><Clinical Trials><Clinical Trials Network><CoV-2><CoV2><CoVPN><Code><Coding System><Cohort Studies><Communicable Diseases><Concurrent Studies><Constitution><Coronaviridae><Coronavirus><Country><Data Analytics><Development><Diabetes Mellitus><Diagnosis><Disease><Disorder><Dose><Emergencies><Emergency Situation><End Point Assay><Endpoint Assays><Enteric Fever><Ethnic Origin><Ethnicity><Eye><Eyeball><Follow-Up Studies><Followup Studies><Future><Goals><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS Vaccines><HVTN><Health><Hospital Admission><Hospitalization><Hypertension><Immune><Immune Monitoring><Immune response><Immunes><Immunity><Immunologic Monitoring><Immunological Monitoring><Immunological response><Immunology><Immunomonitoring><Individual><Infection Control><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><International><Intervention><Intervention Strategies><Knowledge><Laboratories><Lead><Leadership><MAb Therapeutics><Malaria><Mediating><Molecular Interaction><Monitor><Morbidity><Morbidity - disease rate><NIH><National Institutes of Health><Novavax COVID-19 vaccine><Novavax S protein vaccine><Novavax coronavirus disease 2019 vaccine><Obesity><Outcomes Research><Paludism><Parents><Participant><Pb element><Persons><Phase><Physicians><Placebo Control><Placebos><Plasmodium Infections><Population><Preparation><Prevention><Preventive><Proteins><Protocol><Protocols documentation><Quality Control><RS protein><Race><Racial Group><Racial Stocks><Randomized><Randomized Clinical Trials><Recombinants><Regimen><Research Methodology><Research Methods><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 antibody><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 rS><SARS-CoV-2 screening><SARS-CoV-2 severity><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 antibody><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 outbreak><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Sampling><Scientist><Serology test><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Severity of illness><Sham Treatment><Site><System><Testing><Therapeutic Monoclonal Antibodies><Typhoid><Typhoid Fever><United States><United States National Institutes of Health><Vaccination><Vaccines><Validation><Vascular Hypertensive Disease><Vascular Hypertensive Disorder><Virus><Wuhan coronavirus><adaptive immune response><adiposity><adulthood><age 18 years><antibody against COVID-19><antibody against SARS-CoV-2><antibody against SARS-CoV2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody to COVID-19><antibody to SARS-CoV-2><antibody to SARS-CoV2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><base><booster dose><booster shot><booster vaccine><cell assay><clinical trial analysis><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 antibody><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 screening><coronavirus disease 2019 severity><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><corpulence><design><designing><developmental><diabetes><disease severity><efficacy analysis><efficacy assessment><efficacy evaluation><efficacy examination><efficacy study><efficacy testing><efficacy trial><eighteen year old><eighteen years of age><ethnoracial><evaluate efficacy><examine efficacy><experience><hCoV19><health economics><heavy metal Pb><heavy metal lead><high blood pressure><high risk><host response><human immunodeficiency virus vaccine><hyperpiesia><hyperpiesis><hypertensive disease><hypertensive disorder><immune function><immune system response><immunogenicity><immunoresponse><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><interventional strategy><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><monoclonal antibody drugs><mortality><nCoV2><nano particle><nano-sized particle><nanoparticle><nanosized particle><neutralizing antibody><operation><placebo controlled><placebo controlled study><prevent><preventing><programs><quality assurance><racial and ethnic><racial diversity><racially diverse><randomisation><randomization><randomly assigned><rational design><recruit><remote monitoring><response><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><serology assay><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 screening><severe acute respiratory syndrome coronavirus 2 severity><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><sham therapy><symptomatic COVID-19><symptomatic COVID19><symptomatic coronavirus disease 2019><therapeutic mAbs><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine efficacy><vaccine for novel coronavirus><vaccine safety><vaccine study><vaccine trial>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Dan H. Barouch

FRED HUTCHINSON CANCER RESEARCH CENTER, SEATTLE, WA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$5,323,993

FY 2022

Project Title

CoVPN LOC Cross-Protocol Infrastructure Supplement for GY15 and GY16

Grant Number:

3UM1AI068614-16S2

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/30/2022

End Date:

3/31/2022

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

NOSI: NOT-AI-20-034 FOA: PA-20-135 – Emergency Competitive Revision to Existing NIH Awards Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract Given the rapid spread of SARS-CoV-2 infection, the on-...

Research Terms

<2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><Africa><Africa South of the Sahara><Asia><Award><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 Prevention Network><COVID-19 affected><COVID-19 consequence><COVID-19 crisis><COVID-19 effect><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 impact><COVID-19 impacted><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 vaccine><COVID-19 virus><COVID19><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 outbreak><COVID19 pandemic><COVID19 public health crisis><COVID19 vaccine><COVID19 virus><CV-19><CV19><Clinic><Clinical><Clinical Trials><CoV-2><CoV2><CoVPN><Code><Coding System><Communities><Community Health><Data><Diagnostic><Disease Management><Disorder Management><Drug Industry><Emergencies><Emergency Situation><Enrollment><Ensure><Epidemic><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS Vaccines><HVTN><Immunochemical Immunologic><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunologic><Immunological><Immunologically><Immunologics><Immunosuppressed Host><Information Dissemination><Infrastructure><International><Laboratories><Latin America><Marketing><Monitor><NIH><National Institutes of Health><Parents><Persons><Pharmaceutic Industry><Pharmaceutical Industry><Phase><Population><Protocol><Protocols documentation><Public Health><Publishing><Recurrence><Recurrent><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 outbreak><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Series><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Site><Sub-Saharan Africa><Subsaharan Africa><Testing><Therapeutic><Time><United States><United States National Institutes of Health><Vaccines><Work><Wuhan coronavirus><clinical research site><clinical site><community-based health><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 consequence><coronavirus disease 2019 crisis><coronavirus disease 2019 effect><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 impact><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 impact><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><dissemination of results><efficacy trial><enroll><experience><hCoV19><health economics><high risk><high risk group><high risk population><human immunodeficiency virus vaccine><immunosuppressed patient><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><nCoV2><operation><pandemic><pandemic disease><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidate><vaccine for novel coronavirus>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Lawrence Corey

FRED HUTCHINSON CANCER RESEARCH CENTER, SEATTLE, WA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$5,323,993

FY 2022

Project Title

CoVPN LOC Cross-Protocol Infrastructure Supplement for GY15 and GY16

Grant Number:

3UM1AI068614-16S2

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/30/2022

End Date:

3/31/2022

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

NOSI: NOT-AI-20-034 FOA: PA-20-135 – Emergency Competitive Revision to Existing NIH Awards Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract Given the rapid spread of SARS-CoV-2 infection, the on-...

Research Terms

<2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><Africa><Africa South of the Sahara><Asia><Award><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 Prevention Network><COVID-19 affected><COVID-19 consequence><COVID-19 crisis><COVID-19 effect><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 impact><COVID-19 impacted><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 vaccine><COVID-19 virus><COVID19><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 outbreak><COVID19 pandemic><COVID19 public health crisis><COVID19 vaccine><COVID19 virus><CV-19><CV19><Clinic><Clinical><Clinical Trials><CoV-2><CoV2><CoVPN><Code><Coding System><Communities><Community Health><Data><Diagnostic><Disease Management><Disorder Management><Drug Industry><Emergencies><Emergency Situation><Enrollment><Ensure><Epidemic><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS Vaccines><HVTN><Immunochemical Immunologic><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunologic><Immunological><Immunologically><Immunologics><Immunosuppressed Host><Information Dissemination><Infrastructure><International><Laboratories><Latin America><Marketing><Monitor><NIH><National Institutes of Health><Parents><Persons><Pharmaceutic Industry><Pharmaceutical Industry><Phase><Population><Protocol><Protocols documentation><Public Health><Publishing><Recurrence><Recurrent><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 outbreak><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Series><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Site><Sub-Saharan Africa><Subsaharan Africa><Testing><Therapeutic><Time><United States><United States National Institutes of Health><Vaccines><Work><Wuhan coronavirus><clinical research site><clinical site><community-based health><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 consequence><coronavirus disease 2019 crisis><coronavirus disease 2019 effect><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 impact><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 impact><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><dissemination of results><efficacy trial><enroll><experience><hCoV19><health economics><high risk><high risk group><high risk population><human immunodeficiency virus vaccine><immunosuppressed patient><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><nCoV2><operation><pandemic><pandemic disease><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidate><vaccine for novel coronavirus>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Glenda E Gray

FRED HUTCHINSON CANCER RESEARCH CENTER, SEATTLE, WA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$5,323,993

FY 2022

Project Title

CoVPN LOC Cross-Protocol Infrastructure Supplement for GY15 and GY16

Grant Number:

3UM1AI068614-16S2

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/30/2022

End Date:

3/31/2022

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

NOSI: NOT-AI-20-034 FOA: PA-20-135 – Emergency Competitive Revision to Existing NIH Awards Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract Given the rapid spread of SARS-CoV-2 infection, the on-...

Research Terms

<2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><Africa><Africa South of the Sahara><Asia><Award><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 Prevention Network><COVID-19 affected><COVID-19 consequence><COVID-19 crisis><COVID-19 effect><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 impact><COVID-19 impacted><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 vaccine><COVID-19 virus><COVID19><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 outbreak><COVID19 pandemic><COVID19 public health crisis><COVID19 vaccine><COVID19 virus><CV-19><CV19><Clinic><Clinical><Clinical Trials><CoV-2><CoV2><CoVPN><Code><Coding System><Communities><Community Health><Data><Diagnostic><Disease Management><Disorder Management><Drug Industry><Emergencies><Emergency Situation><Enrollment><Ensure><Epidemic><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS Vaccines><HVTN><Immunochemical Immunologic><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunologic><Immunological><Immunologically><Immunologics><Immunosuppressed Host><Information Dissemination><Infrastructure><International><Laboratories><Latin America><Marketing><Monitor><NIH><National Institutes of Health><Parents><Persons><Pharmaceutic Industry><Pharmaceutical Industry><Phase><Population><Protocol><Protocols documentation><Public Health><Publishing><Recurrence><Recurrent><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 outbreak><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Series><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Site><Sub-Saharan Africa><Subsaharan Africa><Testing><Therapeutic><Time><United States><United States National Institutes of Health><Vaccines><Work><Wuhan coronavirus><clinical research site><clinical site><community-based health><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 consequence><coronavirus disease 2019 crisis><coronavirus disease 2019 effect><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 impact><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 impact><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><dissemination of results><efficacy trial><enroll><experience><hCoV19><health economics><high risk><high risk group><high risk population><human immunodeficiency virus vaccine><immunosuppressed patient><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><nCoV2><operation><pandemic><pandemic disease><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidate><vaccine for novel coronavirus>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

GEORGIA Doris TOMARAS

FRED HUTCHINSON CANCER RESEARCH CENTER, SEATTLE, WA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$5,323,993

FY 2022

Project Title

CoVPN LOC Cross-Protocol Infrastructure Supplement for GY15 and GY16

Grant Number:

3UM1AI068614-16S2

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/30/2022

End Date:

3/31/2022

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

NOSI: NOT-AI-20-034 FOA: PA-20-135 – Emergency Competitive Revision to Existing NIH Awards Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract Given the rapid spread of SARS-CoV-2 infection, the on-...

Research Terms

<2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><Africa><Africa South of the Sahara><Asia><Award><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 Prevention Network><COVID-19 affected><COVID-19 consequence><COVID-19 crisis><COVID-19 effect><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 impact><COVID-19 impacted><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 vaccine><COVID-19 virus><COVID19><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 outbreak><COVID19 pandemic><COVID19 public health crisis><COVID19 vaccine><COVID19 virus><CV-19><CV19><Clinic><Clinical><Clinical Trials><CoV-2><CoV2><CoVPN><Code><Coding System><Communities><Community Health><Data><Diagnostic><Disease Management><Disorder Management><Drug Industry><Emergencies><Emergency Situation><Enrollment><Ensure><Epidemic><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS Vaccines><HVTN><Immunochemical Immunologic><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunologic><Immunological><Immunologically><Immunologics><Immunosuppressed Host><Information Dissemination><Infrastructure><International><Laboratories><Latin America><Marketing><Monitor><NIH><National Institutes of Health><Parents><Persons><Pharmaceutic Industry><Pharmaceutical Industry><Phase><Population><Protocol><Protocols documentation><Public Health><Publishing><Recurrence><Recurrent><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 outbreak><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Series><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Site><Sub-Saharan Africa><Subsaharan Africa><Testing><Therapeutic><Time><United States><United States National Institutes of Health><Vaccines><Work><Wuhan coronavirus><clinical research site><clinical site><community-based health><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 consequence><coronavirus disease 2019 crisis><coronavirus disease 2019 effect><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 impact><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 impact><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><dissemination of results><efficacy trial><enroll><experience><hCoV19><health economics><high risk><high risk group><high risk population><human immunodeficiency virus vaccine><immunosuppressed patient><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><nCoV2><operation><pandemic><pandemic disease><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidate><vaccine for novel coronavirus>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jeffrey Michael Bethony

GEORGE WASHINGTON UNIVERSITY, WASHINGTON, DC

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$4,723,702

FY 2024

Project Title

AIDS and Cancer Specimen Resource (ACSR)

Grant Number:

3UM1CA181255-10S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/23/2013

End Date:

8/31/2025

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

Proposal Abstract The AIDS and Cancer Specimen Resource (ACSR) is a biorepository sponsored by the NCI, with a unique focus on cancer within the context of HIV/AIDS. Recent estimates indicate that 40.4 million people are living with HIV (PWH) worldwide, with two-thirds in sub-Saharan Africa (SSA) (2...

Research Terms

<21+ years old><AIDS><AIDS Malignancy Consortium><AIDS Virus><AIDS associated cancer><AIDS related cancer><AIDS-Related Malignancy><AIDS-Related Malignant Neoplasm><AIDS-associated malignancies><AIDS/HIV><Accountability><Accreditation><Achievement><Achievement Attainment><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome><Acquired Immunodeficiency Syndrome Virus><Adult><Adult Human><Africa South of the Sahara><African American><Afro American><Afroamerican><Aging><Arizona><Biological><Biological Specimen Banks><Biological Substance Banks><Blood Sample><Blood specimen><Brazil><Cancer Center><Cancers><Caribbean><Caribbean Sea Region><Caribbean region><Cessation of life><Clinic><Clinical Data><Clinical Trials><Collaborations><Collection><Complex><Data><Data Commons><Data Pooling><Data Set><Death><Eligibility><Eligibility Determination><Equipment and supply inventories><Equity><Exhibits><Funding><General Population><General Public><Goals><HIV><HIV Infections><HIV-Associated Cancer><HIV-associated malignancy><HIV-related malignancy><HIV/AIDS><HIV/AIDS-associated malignancy><HIV/AIDS-related cancer><HTLV-III Infections><HTLV-III-LAV Infections><Human><Human Immunodeficiency Viruses><Human T-Lymphotropic Virus Type III Infections><Incidence><Individual><Infection><Informatics><Inventory><Investigators><LAV-HTLV-III><Latin America><Latin American><Leadership><Link><Liquid substance><Lymphadenopathy-Associated Virus><Malignant Neoplasms><Malignant Tumor><Medicine><Modern Man><NCI Organization><NIH><National Cancer Institute><National Institutes of Health><Participant><Patients><Persons><Population><Protocol><Protocol Screening><Protocols documentation><Research Personnel><Research Resources><Research Specimen><Research Support><Researchers><Residual><Residual state><Resources><Sample Size><Sampling><Secure><Site><Source><South Africa><Specimen><Standardization><Structure><Sub-Saharan Africa><Subsaharan Africa><System><Testing><Time><Tissue Sample><Tumor Tissue><United States><United States National Institutes of Health><Universities><Virus-HIV><Washington><West Indies Region><accredited><adulthood><anti-cancer research><antiretroviral therapy><antiretroviral treatment><biobank><biologic><biological specimen repository><biorepository><biosample repository><biospecimen bank><biospecimen repository><cancer research><cancer risk><cancer specimen resource><college><collegiate><design><designing><experience><fluid><improved><internet portal><liquid><malignancy><member><men><neoplasm/cancer><novel><on-line portal><online portal><pandemic><pandemic disease><preservation><programs><response><specimen bank><specimen repository><trend><web portal><web-based portal>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Anna Coghill

GEORGE WASHINGTON UNIVERSITY, WASHINGTON, DC

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$4,723,702

FY 2024

Project Title

AIDS and Cancer Specimen Resource (ACSR)

Grant Number:

3UM1CA181255-10S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/23/2013

End Date:

8/31/2025

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

Proposal Abstract The AIDS and Cancer Specimen Resource (ACSR) is a biorepository sponsored by the NCI, with a unique focus on cancer within the context of HIV/AIDS. Recent estimates indicate that 40.4 million people are living with HIV (PWH) worldwide, with two-thirds in sub-Saharan Africa (SSA) (2...

Research Terms

<21+ years old><AIDS><AIDS Malignancy Consortium><AIDS Virus><AIDS associated cancer><AIDS related cancer><AIDS-Related Malignancy><AIDS-Related Malignant Neoplasm><AIDS-associated malignancies><AIDS/HIV><Accountability><Accreditation><Achievement><Achievement Attainment><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome><Acquired Immunodeficiency Syndrome Virus><Adult><Adult Human><Africa South of the Sahara><African American><Afro American><Afroamerican><Aging><Arizona><Biological><Biological Specimen Banks><Biological Substance Banks><Blood Sample><Blood specimen><Brazil><Cancer Center><Cancers><Caribbean><Caribbean Sea Region><Caribbean region><Cessation of life><Clinic><Clinical Data><Clinical Trials><Collaborations><Collection><Complex><Data><Data Commons><Data Pooling><Data Set><Death><Eligibility><Eligibility Determination><Equipment and supply inventories><Equity><Exhibits><Funding><General Population><General Public><Goals><HIV><HIV Infections><HIV-Associated Cancer><HIV-associated malignancy><HIV-related malignancy><HIV/AIDS><HIV/AIDS-associated malignancy><HIV/AIDS-related cancer><HTLV-III Infections><HTLV-III-LAV Infections><Human><Human Immunodeficiency Viruses><Human T-Lymphotropic Virus Type III Infections><Incidence><Individual><Infection><Informatics><Inventory><Investigators><LAV-HTLV-III><Latin America><Latin American><Leadership><Link><Liquid substance><Lymphadenopathy-Associated Virus><Malignant Neoplasms><Malignant Tumor><Medicine><Modern Man><NCI Organization><NIH><National Cancer Institute><National Institutes of Health><Participant><Patients><Persons><Population><Protocol><Protocol Screening><Protocols documentation><Research Personnel><Research Resources><Research Specimen><Research Support><Researchers><Residual><Residual state><Resources><Sample Size><Sampling><Secure><Site><Source><South Africa><Specimen><Standardization><Structure><Sub-Saharan Africa><Subsaharan Africa><System><Testing><Time><Tissue Sample><Tumor Tissue><United States><United States National Institutes of Health><Universities><Virus-HIV><Washington><West Indies Region><accredited><adulthood><anti-cancer research><antiretroviral therapy><antiretroviral treatment><biobank><biologic><biological specimen repository><biorepository><biosample repository><biospecimen bank><biospecimen repository><cancer research><cancer risk><cancer specimen resource><college><collegiate><design><designing><experience><fluid><improved><internet portal><liquid><malignancy><member><men><neoplasm/cancer><novel><on-line portal><online portal><pandemic><pandemic disease><preservation><programs><response><specimen bank><specimen repository><trend><web portal><web-based portal>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Lisa Rimsza

GEORGE WASHINGTON UNIVERSITY, WASHINGTON, DC

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$4,723,702

FY 2024

Project Title

AIDS and Cancer Specimen Resource (ACSR)

Grant Number:

3UM1CA181255-10S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/23/2013

End Date:

8/31/2025

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

Proposal Abstract The AIDS and Cancer Specimen Resource (ACSR) is a biorepository sponsored by the NCI, with a unique focus on cancer within the context of HIV/AIDS. Recent estimates indicate that 40.4 million people are living with HIV (PWH) worldwide, with two-thirds in sub-Saharan Africa (SSA) (2...

Research Terms

<21+ years old><AIDS><AIDS Malignancy Consortium><AIDS Virus><AIDS associated cancer><AIDS related cancer><AIDS-Related Malignancy><AIDS-Related Malignant Neoplasm><AIDS-associated malignancies><AIDS/HIV><Accountability><Accreditation><Achievement><Achievement Attainment><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome><Acquired Immunodeficiency Syndrome Virus><Adult><Adult Human><Africa South of the Sahara><African American><Afro American><Afroamerican><Aging><Arizona><Biological><Biological Specimen Banks><Biological Substance Banks><Blood Sample><Blood specimen><Brazil><Cancer Center><Cancers><Caribbean><Caribbean Sea Region><Caribbean region><Cessation of life><Clinic><Clinical Data><Clinical Trials><Collaborations><Collection><Complex><Data><Data Commons><Data Pooling><Data Set><Death><Eligibility><Eligibility Determination><Equipment and supply inventories><Equity><Exhibits><Funding><General Population><General Public><Goals><HIV><HIV Infections><HIV-Associated Cancer><HIV-associated malignancy><HIV-related malignancy><HIV/AIDS><HIV/AIDS-associated malignancy><HIV/AIDS-related cancer><HTLV-III Infections><HTLV-III-LAV Infections><Human><Human Immunodeficiency Viruses><Human T-Lymphotropic Virus Type III Infections><Incidence><Individual><Infection><Informatics><Inventory><Investigators><LAV-HTLV-III><Latin America><Latin American><Leadership><Link><Liquid substance><Lymphadenopathy-Associated Virus><Malignant Neoplasms><Malignant Tumor><Medicine><Modern Man><NCI Organization><NIH><National Cancer Institute><National Institutes of Health><Participant><Patients><Persons><Population><Protocol><Protocol Screening><Protocols documentation><Research Personnel><Research Resources><Research Specimen><Research Support><Researchers><Residual><Residual state><Resources><Sample Size><Sampling><Secure><Site><Source><South Africa><Specimen><Standardization><Structure><Sub-Saharan Africa><Subsaharan Africa><System><Testing><Time><Tissue Sample><Tumor Tissue><United States><United States National Institutes of Health><Universities><Virus-HIV><Washington><West Indies Region><accredited><adulthood><anti-cancer research><antiretroviral therapy><antiretroviral treatment><biobank><biologic><biological specimen repository><biorepository><biosample repository><biospecimen bank><biospecimen repository><cancer research><cancer risk><cancer specimen resource><college><collegiate><design><designing><experience><fluid><improved><internet portal><liquid><malignancy><member><men><neoplasm/cancer><novel><on-line portal><online portal><pandemic><pandemic disease><preservation><programs><response><specimen bank><specimen repository><trend><web portal><web-based portal>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Clarence Buddy Creech

VANDERBILT UNIVERSITY MEDICAL CENTER, NASHVILLE, TN

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$4,613,138

FY 2021

Project Title

Vanderbilt Vaccine and Treatment Evaluation Unit

Grant Number:

3UM1AI148452-02S2

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/14/2020

End Date:

11/30/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

ABSTRACT The goal of this UM1 proposal is to use the remarkable research infrastructure at Vanderbilt University Medical Center and collaborating sites (Washington University, University of Pittsburgh, and University of Pennsylvania) to conceptualize, design, implement, and analyze clinical research...

Research Terms

<0-11 years old><21+ years old><Academic Medical Centers><Adult><Adult Human><Age><Area><Assay><Award><Bacterial Infections><Bioassay><Biologic Assays><Biological><Biological Assay><Body Tissues><Child><Child Youth><Childhood><Children (0-21)><Clinical><Clinical Investigator><Clinical Research><Clinical Study><Clinical Trials><Communicable Diseases><Conduct Clinical Trials><Data><Development><Disease><Disorder><Drugs><Education><Educational aspects><Elderly><Emerging Communicable Diseases><Emerging Infectious Diseases><Enrollment><Environment><Evaluation><Faculty><Feasibility Studies><Fellowship><Fostering><Funding><Fungus Diseases><Geography><Goals><Grippe><Home><Human><Immune response><Immunity><Immunization><Immunologic Sensitization><Immunologic Stimulation><Immunological Sensitization><Immunological Stimulation><Immunological response><Immunologist><Immunostimulation><Individual><Infant><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Influenza><Influenza Vaccines><Institution><International><Intervention><Intervention Strategies><Investigators><Laboratories><Laboratory Scientists><Lead><Leadership><Length of Life><Licensure><Longevity><Malaria><Malaria Vaccines><Malarial Vaccines><Medical><Medical center><Medication><Mentors><Mentorship><Methods><Modeling><Modern Man><Mycoses><NIH><National Institutes of Health><Nurses><Paludism><Parasitic infection><Pathogenesis><Pb element><Pennsylvania><Pertussis Vaccine><Peru><Pharmaceutic Preparations><Pharmaceutical Preparations><Phase><Physicians><Plasmodium Infections><Pneumococcal vaccine><Population><Population Heterogeneity><Position><Positioning Attribute><Pregnant Women><Prevention><Principal Investigator><Procedures><Process><Protocol><Protocols documentation><Research><Research Infrastructure><Research Personnel><Researchers><Safety><Scientist><Sexually Transmitted Diseases><Sexually Transmitted Disorder><Sexually Transmitted Infection><Site><Smallpox Vaccine><Special Population><Standardization><Streptococcus pneumoniae vaccine><Systems Biology><Tissues><Training><United States National Institutes of Health><Universities><University Medical Centers><Vaccination><Vaccine Research><Vaccines><Venereal Diseases><Venereal Disorders><Venereal Infections><Viral><Viral Diseases><Virus Diseases><Visit><Washington><Work><adulthood><advanced age><ages><antibiotic resistant infections><bacteria infection><bacterial disease><base><career><career development><clinical research site><clinical site><co-morbid><co-morbidity><comorbidity><design><designing><developmental><diverse populations><drug/agent><early clinical trial><early phase clinical trial><elders><emerging pathogen><enroll><ethnic diversity><ethnically diverse><expectant mother><expecting mother><experience><flu vaccine><flu virus pandemic><flu virus vaccine><fungal infection><fungus infection><geriatric><heavy metal Pb><heavy metal lead><heterogeneous population><host response><immune system response><immunogenicity><immunoresponse><influenza virus pandemic><influenza virus vaccine><innovate><innovation><innovative><interventional strategy><late life><later life><life span><lifespan><new approaches><new drug treatments><new drugs><new pathogen><new therapeutics><new therapy><new vaccines><next generation><next generation therapeutics><next generation vaccines><novel><novel approaches><novel drug treatments><novel drugs><novel pathogen><novel strategies><novel strategy><novel therapeutics><novel therapy><novel vaccines><nurse><older adult><older person><pandemic flu><pandemic influenza><pandemic strain of influenza><parasite infection><pathogen><pediatric><population diversity><pregnant mothers><recruit><research study><respiratory><response><senior citizen><tool><vaccination study><vaccination trial><vaccine against flu><vaccine against influenza><vaccine study><vaccine trial><vaccines against malaria><vaccinology><viral infection><virus infection><virus-induced disease><volunteer><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Eric P. Winer

YALE UNIVERSITY, NEW HAVEN, CT

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$4,530,485

FY 2023

Project Title

Cancer Center Support Grant

Grant Number:

3P30CA016359-43S5

Activity Code:

P30

Mechanism:

Research Centers

Agency:

NIH

Start Date:

7/1/1997

End Date:

7/31/2024

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

OVERALL PROJECT SUMMARY/ABSTRACT! Now in its 43rd year as an NCI-Designated Comprehensive Cancer Center, Yale Cancer Center (YCC) has established a strong tradition of high-impact cancer research and a deep culture of communication and collaboration that unites 286 basic, translational, population, ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Eric P. Winer

YALE UNIVERSITY, NEW HAVEN, CT

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$4,530,485

FY 2022

Project Title

Cancer Center Support Grant

Grant Number:

5P30CA016359-43

Activity Code:

P30

Mechanism:

Research Centers

Agency:

NIH

Start Date:

7/1/1997

End Date:

7/31/2024

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

OVERALL PROJECT SUMMARY/ABSTRACT! Now in its 43rd year as an NCI-Designated Comprehensive Cancer Center, Yale Cancer Center (YCC) has established a strong tradition of high-impact cancer research and a deep culture of communication and collaboration that unites 286 basic, translational, population, ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Dan H. Barouch

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$3,879,990

FY 2022

Project Title

CoVPN 3001 GY16 PostMerger LOC

Grant Number:

3UM1AI068614-17S5

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/29/2006

End Date:

11/30/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

NOSI: NOT-AI-20-034 FOA: PA-20-135 – Emergency Competitive Revision to Existing NIH Awards Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the CO...

Research Terms

<18 year old><18 years of age><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><21+ years old><Address><Adult><Adult Human><Age-Years><Assay><Award><Bioassay><Biologic Assays><Biological Assay><Biometrics><Biometry><Biostatistics><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 Prevention Network><COVID-19 S protein><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 prevention><COVID-19 public health crisis><COVID-19 screening><COVID-19 severity><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 vaccine><COVID-19 virus><COVID19><COVID19 S protein><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 outbreak><COVID19 pandemic><COVID19 prevention><COVID19 public health crisis><COVID19 screening><COVID19 severity><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cardiomyopathies><Clinic><Clinical><Clinical Trials><Clinical Trials Network><CoV-2><CoV2><CoVPN><Code><Coding System><Communities><Data Analytics><Diagnosis><Disease><Disorder><Dose><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><Emergencies><Emergency Situation><End Point Assay><Endpoint Assays><Enrollment><Goals><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS Vaccines><HVTN><Health><Home><Hospital Admission><Hospitalization><Immune Monitoring><Immune response><Immunity><Immunologic Monitoring><Immunological Monitoring><Immunological response><Immunomonitoring><Individual><Infection prevention><Injections><Kinetics><Laboratories><Lead><Leadership><Lipids><Meat><Monitor><Myocardial Diseases><Myocardial Disorder><Myocardiopathies><NIH><National Institutes of Health><Non-Polyadenylated RNA><Parents><Participant><Pb element><Persons><Phase><Placebo Control><Plants><Population><Prevent infection><Protocol><Protocols documentation><RNA><RNA Gene Products><Randomized><Ribonucleic Acid><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 screening><SARS-CoV-2 severity><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 outbreak><SARS-CoV2 pandemic><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Series><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Site><United States National Institutes of Health><Vaccines><Viral Diseases><Virus Diseases><Wuhan coronavirus><adaptive immune response><adulthood><age 18 years><base><blind><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 screening><coronavirus disease 2019 severity><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 prevention><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><efficacy analysis><efficacy assessment><efficacy evaluation><efficacy examination><efficacy testing><efficacy trial><eighteen year old><eighteen years of age><enroll><ethnoracial><evaluate efficacy><evaluate vaccines><examine efficacy><experience><hCoV19><heavy metal Pb><heavy metal lead><high risk><host response><human immunodeficiency virus vaccine><immune system response><immunogenicity><immunoresponse><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><myocardium disease><myocardium disorder><nCoV2><operation><placebo controlled><placebo controlled study><prevent COVID-19><prevent COVID19><prevent coronavirus disease 2019><racial and ethnic><racial diversity><racially diverse><randomisation><randomization><randomly assigned><recruit><remote monitoring><response><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 screening><severe acute respiratory syndrome coronavirus 2 severity><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><side effect><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine evaluation><vaccine for novel coronavirus><vaccine screening><vaccine study><vaccine testing><vaccine trial><viral infection><virus infection><virus-induced disease>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Lawrence Corey

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$3,879,990

FY 2022

Project Title

CoVPN 3001 GY16 PostMerger LOC

Grant Number:

3UM1AI068614-17S5

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/29/2006

End Date:

11/30/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

NOSI: NOT-AI-20-034 FOA: PA-20-135 – Emergency Competitive Revision to Existing NIH Awards Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the CO...

Research Terms

<18 year old><18 years of age><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><21+ years old><Address><Adult><Adult Human><Age-Years><Assay><Award><Bioassay><Biologic Assays><Biological Assay><Biometrics><Biometry><Biostatistics><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 Prevention Network><COVID-19 S protein><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 prevention><COVID-19 public health crisis><COVID-19 screening><COVID-19 severity><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 vaccine><COVID-19 virus><COVID19><COVID19 S protein><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 outbreak><COVID19 pandemic><COVID19 prevention><COVID19 public health crisis><COVID19 screening><COVID19 severity><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cardiomyopathies><Clinic><Clinical><Clinical Trials><Clinical Trials Network><CoV-2><CoV2><CoVPN><Code><Coding System><Communities><Data Analytics><Diagnosis><Disease><Disorder><Dose><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><Emergencies><Emergency Situation><End Point Assay><Endpoint Assays><Enrollment><Goals><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS Vaccines><HVTN><Health><Home><Hospital Admission><Hospitalization><Immune Monitoring><Immune response><Immunity><Immunologic Monitoring><Immunological Monitoring><Immunological response><Immunomonitoring><Individual><Infection prevention><Injections><Kinetics><Laboratories><Lead><Leadership><Lipids><Meat><Monitor><Myocardial Diseases><Myocardial Disorder><Myocardiopathies><NIH><National Institutes of Health><Non-Polyadenylated RNA><Parents><Participant><Pb element><Persons><Phase><Placebo Control><Plants><Population><Prevent infection><Protocol><Protocols documentation><RNA><RNA Gene Products><Randomized><Ribonucleic Acid><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 screening><SARS-CoV-2 severity><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 outbreak><SARS-CoV2 pandemic><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Series><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Site><United States National Institutes of Health><Vaccines><Viral Diseases><Virus Diseases><Wuhan coronavirus><adaptive immune response><adulthood><age 18 years><base><blind><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 screening><coronavirus disease 2019 severity><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 prevention><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><efficacy analysis><efficacy assessment><efficacy evaluation><efficacy examination><efficacy testing><efficacy trial><eighteen year old><eighteen years of age><enroll><ethnoracial><evaluate efficacy><evaluate vaccines><examine efficacy><experience><hCoV19><heavy metal Pb><heavy metal lead><high risk><host response><human immunodeficiency virus vaccine><immune system response><immunogenicity><immunoresponse><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><myocardium disease><myocardium disorder><nCoV2><operation><placebo controlled><placebo controlled study><prevent COVID-19><prevent COVID19><prevent coronavirus disease 2019><racial and ethnic><racial diversity><racially diverse><randomisation><randomization><randomly assigned><recruit><remote monitoring><response><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 screening><severe acute respiratory syndrome coronavirus 2 severity><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><side effect><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine evaluation><vaccine for novel coronavirus><vaccine screening><vaccine study><vaccine testing><vaccine trial><viral infection><virus infection><virus-induced disease>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Glenda E Gray

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$3,879,990

FY 2022

Project Title

CoVPN 3001 GY16 PostMerger LOC

Grant Number:

3UM1AI068614-17S5

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/29/2006

End Date:

11/30/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

NOSI: NOT-AI-20-034 FOA: PA-20-135 – Emergency Competitive Revision to Existing NIH Awards Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the CO...

Research Terms

<18 year old><18 years of age><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><21+ years old><Address><Adult><Adult Human><Age-Years><Assay><Award><Bioassay><Biologic Assays><Biological Assay><Biometrics><Biometry><Biostatistics><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 Prevention Network><COVID-19 S protein><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 prevention><COVID-19 public health crisis><COVID-19 screening><COVID-19 severity><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 vaccine><COVID-19 virus><COVID19><COVID19 S protein><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 outbreak><COVID19 pandemic><COVID19 prevention><COVID19 public health crisis><COVID19 screening><COVID19 severity><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cardiomyopathies><Clinic><Clinical><Clinical Trials><Clinical Trials Network><CoV-2><CoV2><CoVPN><Code><Coding System><Communities><Data Analytics><Diagnosis><Disease><Disorder><Dose><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><Emergencies><Emergency Situation><End Point Assay><Endpoint Assays><Enrollment><Goals><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS Vaccines><HVTN><Health><Home><Hospital Admission><Hospitalization><Immune Monitoring><Immune response><Immunity><Immunologic Monitoring><Immunological Monitoring><Immunological response><Immunomonitoring><Individual><Infection prevention><Injections><Kinetics><Laboratories><Lead><Leadership><Lipids><Meat><Monitor><Myocardial Diseases><Myocardial Disorder><Myocardiopathies><NIH><National Institutes of Health><Non-Polyadenylated RNA><Parents><Participant><Pb element><Persons><Phase><Placebo Control><Plants><Population><Prevent infection><Protocol><Protocols documentation><RNA><RNA Gene Products><Randomized><Ribonucleic Acid><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 screening><SARS-CoV-2 severity><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 outbreak><SARS-CoV2 pandemic><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Series><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Site><United States National Institutes of Health><Vaccines><Viral Diseases><Virus Diseases><Wuhan coronavirus><adaptive immune response><adulthood><age 18 years><base><blind><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 screening><coronavirus disease 2019 severity><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 prevention><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><efficacy analysis><efficacy assessment><efficacy evaluation><efficacy examination><efficacy testing><efficacy trial><eighteen year old><eighteen years of age><enroll><ethnoracial><evaluate efficacy><evaluate vaccines><examine efficacy><experience><hCoV19><heavy metal Pb><heavy metal lead><high risk><host response><human immunodeficiency virus vaccine><immune system response><immunogenicity><immunoresponse><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><myocardium disease><myocardium disorder><nCoV2><operation><placebo controlled><placebo controlled study><prevent COVID-19><prevent COVID19><prevent coronavirus disease 2019><racial and ethnic><racial diversity><racially diverse><randomisation><randomization><randomly assigned><recruit><remote monitoring><response><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 screening><severe acute respiratory syndrome coronavirus 2 severity><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><side effect><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine evaluation><vaccine for novel coronavirus><vaccine screening><vaccine study><vaccine testing><vaccine trial><viral infection><virus infection><virus-induced disease>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

GEORGIA Doris TOMARAS

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$3,879,990

FY 2022

Project Title

CoVPN 3001 GY16 PostMerger LOC

Grant Number:

3UM1AI068614-17S5

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/29/2006

End Date:

11/30/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

NOSI: NOT-AI-20-034 FOA: PA-20-135 – Emergency Competitive Revision to Existing NIH Awards Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the CO...

Research Terms

<18 year old><18 years of age><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><21+ years old><Address><Adult><Adult Human><Age-Years><Assay><Award><Bioassay><Biologic Assays><Biological Assay><Biometrics><Biometry><Biostatistics><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 Prevention Network><COVID-19 S protein><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 prevention><COVID-19 public health crisis><COVID-19 screening><COVID-19 severity><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 vaccine><COVID-19 virus><COVID19><COVID19 S protein><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 outbreak><COVID19 pandemic><COVID19 prevention><COVID19 public health crisis><COVID19 screening><COVID19 severity><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cardiomyopathies><Clinic><Clinical><Clinical Trials><Clinical Trials Network><CoV-2><CoV2><CoVPN><Code><Coding System><Communities><Data Analytics><Diagnosis><Disease><Disorder><Dose><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><Emergencies><Emergency Situation><End Point Assay><Endpoint Assays><Enrollment><Goals><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS Vaccines><HVTN><Health><Home><Hospital Admission><Hospitalization><Immune Monitoring><Immune response><Immunity><Immunologic Monitoring><Immunological Monitoring><Immunological response><Immunomonitoring><Individual><Infection prevention><Injections><Kinetics><Laboratories><Lead><Leadership><Lipids><Meat><Monitor><Myocardial Diseases><Myocardial Disorder><Myocardiopathies><NIH><National Institutes of Health><Non-Polyadenylated RNA><Parents><Participant><Pb element><Persons><Phase><Placebo Control><Plants><Population><Prevent infection><Protocol><Protocols documentation><RNA><RNA Gene Products><Randomized><Ribonucleic Acid><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 screening><SARS-CoV-2 severity><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 outbreak><SARS-CoV2 pandemic><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Series><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Site><United States National Institutes of Health><Vaccines><Viral Diseases><Virus Diseases><Wuhan coronavirus><adaptive immune response><adulthood><age 18 years><base><blind><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 screening><coronavirus disease 2019 severity><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 prevention><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><efficacy analysis><efficacy assessment><efficacy evaluation><efficacy examination><efficacy testing><efficacy trial><eighteen year old><eighteen years of age><enroll><ethnoracial><evaluate efficacy><evaluate vaccines><examine efficacy><experience><hCoV19><heavy metal Pb><heavy metal lead><high risk><host response><human immunodeficiency virus vaccine><immune system response><immunogenicity><immunoresponse><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><myocardium disease><myocardium disorder><nCoV2><operation><placebo controlled><placebo controlled study><prevent COVID-19><prevent COVID19><prevent coronavirus disease 2019><racial and ethnic><racial diversity><racially diverse><randomisation><randomization><randomly assigned><recruit><remote monitoring><response><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 screening><severe acute respiratory syndrome coronavirus 2 severity><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><side effect><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine evaluation><vaccine for novel coronavirus><vaccine screening><vaccine study><vaccine testing><vaccine trial><viral infection><virus infection><virus-induced disease>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Margaret Juliana McElrath

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$3,544,100

FY 2022

Project Title

CoVPN 3005: Efficacy, Immunogenicity, and Safety of Two SARS-CoV-2 Recombinant Protein Vaccines with Adjuvant in Adults 18 Years of Age and Older - LC 3

Grant Number:

3UM1AI068618-17S2

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/29/2006

End Date:

11/30/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

FOA: PA-20-272: Administrative Supplements to Existing NIH Grants and Cooperative Agreements Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the ...

Research Terms

<18 year old><18 years of age><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><21+ years old><Abdominal Typhus><Address><Adjuvant><Administrative Supplement><Adult><Adult Human><Antigens><Assay><Award><B.1.351><Bioassay><Biologic Assays><Biological Assay><Biometrics><Biometry><Biostatistics><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 Prevention Network><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 screening><COVID-19 severity><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 outbreak><COVID19 pandemic><COVID19 public health crisis><COVID19 screening><COVID19 severity><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cellular Assay><Cellular Immune Function><Clinical><Clinical Trials><Clinical Trials Network><CoV-2><CoV2><CoVPN><Code><Coding System><Cohort Studies><Communicable Diseases><Concurrent Studies><Constitution><Cooperative Agreements><Coronaviridae><Coronavirus><Country><Data Analytics><Development><Diagnosis><Disease><Disorder><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><End Point Assay><Endpoint Assays><Enteric Fever><Eye><Eyeball><Frequencies><Future Generations><Goals><Grant><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS Vaccines><HVTN><Health><Hospital Admission><Hospitalization><Immune><Immune Monitoring><Immune response><Immunes><Immunity><Immunologic Monitoring><Immunological Monitoring><Immunological response><Immunology><Immunomonitoring><Individual><Infection Control><Infection prevention><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Injections><International><Investigation><Knowledge><Laboratories><Lead><Leadership><Malaria><Mediating><Monitor><Morbidity><Morbidity - disease rate><NIH><National Institutes of Health><Paludism><Parents><Participant><Pb element><Persons><Phase><Physicians><Placebo Control><Placebos><Plasmodium Infections><Population><Preparation><Prevent infection><Prevention><Protocol><Protocols documentation><Quality Control><Randomized Clinical Trials><Recombinant Proteins><Recombinant Vaccines><Research Methodology><Research Methods><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 B.1.351><SARS-CoV-2 beta><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 screening><SARS-CoV-2 severity><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 outbreak><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Sampling><Scientist><Serology test><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Sham Treatment><Site><South Africa strain><South Africa variant><South African strain><South African variant><System><Testing><Typhoid><Typhoid Fever><U-Series Cooperative Agreements><United States><United States National Institutes of Health><Vaccines><Validation><Wuhan coronavirus><adulthood><age 18 years><cell assay><clinical efficacy><clinical trial analysis><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 screening><coronavirus disease 2019 severity><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><design><designing><developmental><efficacy study><efficacy testing><efficacy trial><eighteen year old><eighteen years of age><ethnoracial><experience><hCoV19><heavy metal Pb><heavy metal lead><high risk><host response><human immunodeficiency virus vaccine><immune function><immune system response><immunogen><immunogenicity><immunoresponse><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><mortality><nCoV2><operation><placebo controlled><prevent><preventing><programs><quality assurance><racial and ethnic><racial diversity><racially diverse><recruit><remote monitoring><response><safety study><scale up><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><serology assay><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 B.1.351><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 screening><severe acute respiratory syndrome coronavirus 2 severity><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><sham therapy><symptomatic COVID-19><symptomatic COVID19><symptomatic coronavirus disease 2019><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine for novel coronavirus><vaccine study><vaccine trial><variants of concern>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Dan H. Barouch

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$2,683,830

FY 2023

Project Title

CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older

Grant Number:

3UM1AI068614-18S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/29/2006

End Date:

11/30/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

FOA: PA-20-272: Administrative Supplements to Existing NIH Grants and Cooperative Agreements Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the ...

Research Terms

<18 year old><18 years of age><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><21+ years old><Address><Adjuvant><Administrative Supplement><Adult><Adult Human><Assay><Award><B.1.351><Bioassay><Biologic Assays><Biological Assay><Biometrics><Biometry><Biostatistics><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 Prevention Network><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 screening><COVID-19 severity><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID-19 virus infection><COVID19><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 outbreak><COVID19 pandemic><COVID19 public health crisis><COVID19 screening><COVID19 severity><COVID19 vaccine><COVID19 virus><CV-19><CV19><Clinical><Clinical Trials><Clinical Trials Network><CoV-2><CoV2><CoVPN><Code><Coding System><Constitution><Constitutional><Cooperative Agreements><Country><Data Analytics><Dedications><Diagnosis><Disease><Disorder><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><End Point Assay><Endpoint Assays><Ethnic Origin><Ethnicity><Frequencies><Future Generations><Goals><Grant><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS Vaccines><HVTN><Health><Hospital Admission><Hospitalization><Immune Monitoring><Immune response><Immunity><Immunologic Monitoring><Immunological Monitoring><Immunological response><Immunomonitoring><Individual><Injections><International><Laboratories><Lead><Leadership><Monitor><NIH><National Institutes of Health><Parents><Participant><Pb element><Persons><Phase><Physicians><Placebo Control><Placebos><Population><Prevention><Protocol><Protocols documentation><Qualifying><Recombinant Proteins><Recombinant Vaccines><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 B.1.351><SARS-CoV-2 beta><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 screening><SARS-CoV-2 severity><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Scientist><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Sham Treatment><Site><South Africa strain><South Africa variant><South African strain><South African variant><U-Series Cooperative Agreements><United States><United States National Institutes of Health><Vaccines><Wuhan coronavirus><adulthood><age 18 years><clinical efficacy><clinical trial recruitment><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 screening><coronavirus disease 2019 severity><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><determine efficacy><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><efficacy testing><efficacy trial><eighteen year old><eighteen years of age><evaluate efficacy><examine efficacy><experience><hCoV19><heavy metal Pb><heavy metal lead><high risk group><high risk individual><high risk people><high risk population><host response><human immunodeficiency virus vaccine><immune system response><immunogenicity><immunoresponse><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><operation><operations><outbreak of SARS-CoV-2><parent><placebo controlled><prevent><preventing><racial diversity><racially diverse><remote monitoring><response><safety assessment><scale up><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 B.1.351><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 screening><severe acute respiratory syndrome coronavirus 2 severity><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><sham therapy><symptomatic COVID-19><symptomatic COVID19><symptomatic coronavirus disease 2019><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine for novel coronavirus><vaccine study><vaccine trial><variants of concern>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Lawrence Corey

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$2,683,830

FY 2023

Project Title

CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older

Grant Number:

3UM1AI068614-18S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/29/2006

End Date:

11/30/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

FOA: PA-20-272: Administrative Supplements to Existing NIH Grants and Cooperative Agreements Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the ...

Research Terms

<18 year old><18 years of age><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><21+ years old><Address><Adjuvant><Administrative Supplement><Adult><Adult Human><Assay><Award><B.1.351><Bioassay><Biologic Assays><Biological Assay><Biometrics><Biometry><Biostatistics><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 Prevention Network><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 screening><COVID-19 severity><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID-19 virus infection><COVID19><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 outbreak><COVID19 pandemic><COVID19 public health crisis><COVID19 screening><COVID19 severity><COVID19 vaccine><COVID19 virus><CV-19><CV19><Clinical><Clinical Trials><Clinical Trials Network><CoV-2><CoV2><CoVPN><Code><Coding System><Constitution><Constitutional><Cooperative Agreements><Country><Data Analytics><Dedications><Diagnosis><Disease><Disorder><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><End Point Assay><Endpoint Assays><Ethnic Origin><Ethnicity><Frequencies><Future Generations><Goals><Grant><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS Vaccines><HVTN><Health><Hospital Admission><Hospitalization><Immune Monitoring><Immune response><Immunity><Immunologic Monitoring><Immunological Monitoring><Immunological response><Immunomonitoring><Individual><Injections><International><Laboratories><Lead><Leadership><Monitor><NIH><National Institutes of Health><Parents><Participant><Pb element><Persons><Phase><Physicians><Placebo Control><Placebos><Population><Prevention><Protocol><Protocols documentation><Qualifying><Recombinant Proteins><Recombinant Vaccines><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 B.1.351><SARS-CoV-2 beta><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 screening><SARS-CoV-2 severity><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Scientist><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Sham Treatment><Site><South Africa strain><South Africa variant><South African strain><South African variant><U-Series Cooperative Agreements><United States><United States National Institutes of Health><Vaccines><Wuhan coronavirus><adulthood><age 18 years><clinical efficacy><clinical trial recruitment><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 screening><coronavirus disease 2019 severity><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><determine efficacy><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><efficacy testing><efficacy trial><eighteen year old><eighteen years of age><evaluate efficacy><examine efficacy><experience><hCoV19><heavy metal Pb><heavy metal lead><high risk group><high risk individual><high risk people><high risk population><host response><human immunodeficiency virus vaccine><immune system response><immunogenicity><immunoresponse><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><operation><operations><outbreak of SARS-CoV-2><parent><placebo controlled><prevent><preventing><racial diversity><racially diverse><remote monitoring><response><safety assessment><scale up><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 B.1.351><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 screening><severe acute respiratory syndrome coronavirus 2 severity><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><sham therapy><symptomatic COVID-19><symptomatic COVID19><symptomatic coronavirus disease 2019><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine for novel coronavirus><vaccine study><vaccine trial><variants of concern>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Glenda E Gray

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$2,683,830

FY 2023

Project Title

CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older

Grant Number:

3UM1AI068614-18S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/29/2006

End Date:

11/30/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

FOA: PA-20-272: Administrative Supplements to Existing NIH Grants and Cooperative Agreements Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the ...

Research Terms

<18 year old><18 years of age><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><21+ years old><Address><Adjuvant><Administrative Supplement><Adult><Adult Human><Assay><Award><B.1.351><Bioassay><Biologic Assays><Biological Assay><Biometrics><Biometry><Biostatistics><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 Prevention Network><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 screening><COVID-19 severity><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID-19 virus infection><COVID19><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 outbreak><COVID19 pandemic><COVID19 public health crisis><COVID19 screening><COVID19 severity><COVID19 vaccine><COVID19 virus><CV-19><CV19><Clinical><Clinical Trials><Clinical Trials Network><CoV-2><CoV2><CoVPN><Code><Coding System><Constitution><Constitutional><Cooperative Agreements><Country><Data Analytics><Dedications><Diagnosis><Disease><Disorder><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><End Point Assay><Endpoint Assays><Ethnic Origin><Ethnicity><Frequencies><Future Generations><Goals><Grant><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS Vaccines><HVTN><Health><Hospital Admission><Hospitalization><Immune Monitoring><Immune response><Immunity><Immunologic Monitoring><Immunological Monitoring><Immunological response><Immunomonitoring><Individual><Injections><International><Laboratories><Lead><Leadership><Monitor><NIH><National Institutes of Health><Parents><Participant><Pb element><Persons><Phase><Physicians><Placebo Control><Placebos><Population><Prevention><Protocol><Protocols documentation><Qualifying><Recombinant Proteins><Recombinant Vaccines><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 B.1.351><SARS-CoV-2 beta><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 screening><SARS-CoV-2 severity><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Scientist><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Sham Treatment><Site><South Africa strain><South Africa variant><South African strain><South African variant><U-Series Cooperative Agreements><United States><United States National Institutes of Health><Vaccines><Wuhan coronavirus><adulthood><age 18 years><clinical efficacy><clinical trial recruitment><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 screening><coronavirus disease 2019 severity><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><determine efficacy><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><efficacy testing><efficacy trial><eighteen year old><eighteen years of age><evaluate efficacy><examine efficacy><experience><hCoV19><heavy metal Pb><heavy metal lead><high risk group><high risk individual><high risk people><high risk population><host response><human immunodeficiency virus vaccine><immune system response><immunogenicity><immunoresponse><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><operation><operations><outbreak of SARS-CoV-2><parent><placebo controlled><prevent><preventing><racial diversity><racially diverse><remote monitoring><response><safety assessment><scale up><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 B.1.351><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 screening><severe acute respiratory syndrome coronavirus 2 severity><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><sham therapy><symptomatic COVID-19><symptomatic COVID19><symptomatic coronavirus disease 2019><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine for novel coronavirus><vaccine study><vaccine trial><variants of concern>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

GEORGIA Doris TOMARAS

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$2,683,830

FY 2023

Project Title

CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older

Grant Number:

3UM1AI068614-18S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/29/2006

End Date:

11/30/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

FOA: PA-20-272: Administrative Supplements to Existing NIH Grants and Cooperative Agreements Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the ...

Research Terms

<18 year old><18 years of age><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><21+ years old><Address><Adjuvant><Administrative Supplement><Adult><Adult Human><Assay><Award><B.1.351><Bioassay><Biologic Assays><Biological Assay><Biometrics><Biometry><Biostatistics><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 Prevention Network><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 screening><COVID-19 severity><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID-19 virus infection><COVID19><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 outbreak><COVID19 pandemic><COVID19 public health crisis><COVID19 screening><COVID19 severity><COVID19 vaccine><COVID19 virus><CV-19><CV19><Clinical><Clinical Trials><Clinical Trials Network><CoV-2><CoV2><CoVPN><Code><Coding System><Constitution><Constitutional><Cooperative Agreements><Country><Data Analytics><Dedications><Diagnosis><Disease><Disorder><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><End Point Assay><Endpoint Assays><Ethnic Origin><Ethnicity><Frequencies><Future Generations><Goals><Grant><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS Vaccines><HVTN><Health><Hospital Admission><Hospitalization><Immune Monitoring><Immune response><Immunity><Immunologic Monitoring><Immunological Monitoring><Immunological response><Immunomonitoring><Individual><Injections><International><Laboratories><Lead><Leadership><Monitor><NIH><National Institutes of Health><Parents><Participant><Pb element><Persons><Phase><Physicians><Placebo Control><Placebos><Population><Prevention><Protocol><Protocols documentation><Qualifying><Recombinant Proteins><Recombinant Vaccines><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 B.1.351><SARS-CoV-2 beta><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 screening><SARS-CoV-2 severity><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Scientist><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Sham Treatment><Site><South Africa strain><South Africa variant><South African strain><South African variant><U-Series Cooperative Agreements><United States><United States National Institutes of Health><Vaccines><Wuhan coronavirus><adulthood><age 18 years><clinical efficacy><clinical trial recruitment><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 screening><coronavirus disease 2019 severity><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><determine efficacy><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><efficacy testing><efficacy trial><eighteen year old><eighteen years of age><evaluate efficacy><examine efficacy><experience><hCoV19><heavy metal Pb><heavy metal lead><high risk group><high risk individual><high risk people><high risk population><host response><human immunodeficiency virus vaccine><immune system response><immunogenicity><immunoresponse><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><operation><operations><outbreak of SARS-CoV-2><parent><placebo controlled><prevent><preventing><racial diversity><racially diverse><remote monitoring><response><safety assessment><scale up><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 B.1.351><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 screening><severe acute respiratory syndrome coronavirus 2 severity><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><sham therapy><symptomatic COVID-19><symptomatic COVID19><symptomatic coronavirus disease 2019><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine for novel coronavirus><vaccine study><vaccine trial><variants of concern>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Clarence Buddy Creech

VANDERBILT UNIVERSITY MEDICAL CENTER, NASHVILLE, TN

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$2,059,956

FY 2022

Project Title

Vanderbilt Vaccine and Treatment Evaluation Unit

Grant Number:

3UM1AI148452-03S4

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/13/2022

End Date:

4/26/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

ABSTRACT The goal of this UM1 proposal is to use the remarkable research infrastructure at Vanderbilt University Medical Center and collaborating sites (Washington University, University of Pittsburgh, and University of Pennsylvania) to conceptualize, design, implement, and analyze clinical research...

Research Terms

<0-11 years old><21+ years old><Academic Medical Centers><Adult><Adult Human><Age><Area><Assay><Award><Bacterial Infections><Bioassay><Biologic Assays><Biologic Products><Biological Agent><Biological Assay><Biological Products><Body Tissues><Child><Child Youth><Childhood><Children (0-21)><Clinical><Clinical Investigator><Clinical Research><Clinical Study><Clinical Trials><Communicable Diseases><Conduct Clinical Trials><Data><Development><Disease><Disorder><Drugs><Education><Educational aspects><Elderly><Emerging Communicable Diseases><Emerging Infectious Diseases><Enrollment><Environment><Evaluation><Faculty><Feasibility Studies><Fellowship><Fostering><Funding><Fungus Diseases><Geography><Goals><Grippe><Home><Human><Immune response><Immunity><Immunization><Immunologic Sensitization><Immunologic Stimulation><Immunological Sensitization><Immunological Stimulation><Immunological response><Immunologist><Immunostimulation><Individual><Infant><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Influenza><Influenza Vaccines><Institution><International><Intervention><Intervention Strategies><Investigators><Laboratories><Laboratory Scientists><Lead><Leadership><Length of Life><Licensure><Longevity><Malaria><Malaria Vaccines><Malarial Vaccines><Medical><Medical center><Medication><Mentors><Mentorship><Methods><Modeling><Modern Man><Mycoses><NIH><National Institutes of Health><Nurses><Paludism><Parasitic infection><Pathogenesis><Pb element><Pennsylvania><Pertussis Vaccine><Peru><Pharmaceutic Preparations><Pharmaceutical Preparations><Phase><Physicians><Plasmodium Infections><Pneumococcal vaccine><Population><Population Heterogeneity><Position><Positioning Attribute><Pregnant Women><Prevention><Principal Investigator><Procedures><Process><Protocol><Protocols documentation><Research><Research Infrastructure><Research Personnel><Researchers><Safety><Scientist><Sexually Transmitted Diseases><Sexually Transmitted Disorder><Sexually Transmitted Infection><Site><Smallpox Vaccine><Special Population><Standardization><Streptococcus pneumoniae vaccine><Systems Biology><Tissues><Training><United States National Institutes of Health><Universities><University Medical Centers><Vaccination><Vaccine Research><Vaccines><Venereal Diseases><Venereal Disorders><Venereal Infections><Viral><Viral Diseases><Virus Diseases><Visit><Washington><Work><adulthood><advanced age><ages><antibiotic resistant infections><bacteria infection><bacterial disease><base><biologics><biopharmaceutical><biotherapeutic agent><career><career development><clinical research site><clinical site><co-morbid><co-morbidity><comorbidity><design><designing><developmental><diverse populations><drug/agent><early clinical trial><early phase clinical trial><elders><emerging pathogen><enroll><ethnic diversity><ethnically diverse><expectant mother><expecting mother><experience><flu vaccine><flu virus pandemic><flu virus vaccine><fungal infection><fungus infection><geriatric><heavy metal Pb><heavy metal lead><heterogeneous population><host response><immune system response><immunogenicity><immunoresponse><influenza virus pandemic><influenza virus vaccine><innovate><innovation><innovative><interventional strategy><late life><later life><life span><lifespan><new approaches><new drug treatments><new drugs><new pathogen><new therapeutics><new therapy><new vaccines><next generation><next generation therapeutics><next generation vaccines><novel><novel approaches><novel drug treatments><novel drugs><novel pathogen><novel strategies><novel strategy><novel therapeutics><novel therapy><novel vaccines><nurse><older adult><older person><pandemic flu><pandemic influenza><pandemic strain of influenza><parasite infection><pathogen><pediatric><population diversity><pregnant mothers><recruit><research study><respiratory><response><senior citizen><tool><vaccination study><vaccination trial><vaccine against flu><vaccine against influenza><vaccine study><vaccine trial><vaccines against malaria><vaccinology><viral infection><virus infection><virus-induced disease><volunteer><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Clarence Buddy Creech

VANDERBILT UNIVERSITY MEDICAL CENTER, NASHVILLE, TN

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$1,972,714

FY 2023

Project Title

Vanderbilt Vaccine and Treatment Evaluation Unit

Grant Number:

3UM1AI148452-04S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/11/2019

End Date:

11/30/2024

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

ABSTRACT The goal of this UM1 proposal is to use the remarkable research infrastructure at Vanderbilt University Medical Center and collaborating sites (Washington University, University of Pittsburgh, and University of Pennsylvania) to conceptualize, design, implement, and analyze clinical research...

Research Terms

<0-11 years old><21+ years old><Academic Medical Centers><Adult><Adult Human><Age><Area><Articulation><Assay><Award><Bacterial Infections><Bioassay><Biologic Assays><Biologic Products><Biological Agent><Biological Assay><Biological Products><Body Tissues><Child><Child Youth><Childhood><Children (0-21)><Clinical><Clinical Investigator><Clinical Research><Clinical Study><Clinical Trials><Collaborations><Communicable Diseases><Conduct Clinical Trials><Data><Development><Disease><Disorder><Drugs><Education><Educational aspects><Elderly><Emerging Communicable Diseases><Emerging Infectious Diseases><Enrollment><Environment><Evaluation><Faculty><Feasibility Studies><Fellowship><Fostering><Funding><Fungus Diseases><Geography><Goals><Grippe><Home><Human><Immune response><Immunity><Immunization><Immunological response><Immunologist><Individual><Infant><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Influenza><Influenza Vaccines><Institution><International><Intervention><Intervention Strategies><Investigators><Laboratories><Laboratory Scientists><Lead><Leadership><Length of Life><Licensure><Longevity><Malaria><Malaria Vaccines><Malarial Vaccines><Medical><Medical center><Medication><Mentors><Mentorship><Methods><Modeling><Modern Man><Mycoses><NIH><National Institutes of Health><Nurses><Paludism><Parasitic infection><Pathogenesis><Pb element><Pennsylvania><Pertussis Vaccine><Peru><Pharmaceutic Preparations><Pharmaceutical Preparations><Phase><Physicians><Plasmodium Infections><Pneumococcal vaccine><Population><Population Heterogeneity><Position><Positioning Attribute><Pregnant Women><Prevention><Principal Investigator><Procedures><Process><Protocol><Protocols documentation><Qualifying><Research><Research Infrastructure><Research Personnel><Researchers><Safety><Scientist><Sexually Transmitted Diseases><Sexually Transmitted Disorder><Sexually Transmitted Infection><Site><Smallpox Vaccine><Special Population><Standardization><Streptococcus pneumoniae vaccine><Systems Biology><Tissues><Training><United States National Institutes of Health><Universities><University Medical Centers><Vaccination><Vaccine Research><Vaccines><Venereal Diseases><Venereal Disorders><Venereal Infections><Viral><Viral Diseases><Virus Diseases><Visit><Washington><Work><adulthood><advanced age><ages><antibiotic resistant infections><bacteria infection><bacterial disease><biologics><biopharmaceutical><biotherapeutic agent><career><career development><clinical research site><clinical site><co-morbid><co-morbidity><comorbidity><design><designing><developmental><diverse populations><drug/agent><early clinical trial><early phase clinical trial><elders><emerging pathogen><enroll><ethnic diversity><ethnically diverse><expectant mother><expecting mother><experience><flu vaccine><flu virus pandemic><flu virus vaccine><fungal infection><fungus infection><geriatric><heavy metal Pb><heavy metal lead><heterogeneous population><homes><host response><immune system response><immunogenicity><immunoresponse><influenza virus pandemic><influenza virus vaccine><innovate><innovation><innovative><interventional strategy><kids><late life><later life><life span><lifespan><new approaches><new drug treatments><new drugs><new pathogen><new pharmacological therapeutic><new therapeutics><new therapy><new vaccines><next generation><next generation therapeutics><next generation vaccines><novel><novel approaches><novel drug treatments><novel drugs><novel pathogen><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel strategies><novel strategy><novel therapeutics><novel therapy><novel vaccines><nurse><older adult><older person><pandemic containment><pandemic control><pandemic flu><pandemic influenza><pandemic mitigation><pandemic response><pandemic strain of influenza><parasite infection><pathogen><pediatric><population diversity><pregnant mothers><recruit><research study><respiratory><response><senior citizen><tool><vaccination study><vaccination trial><vaccine against flu><vaccine against influenza><vaccine study><vaccine trial><vaccine-related research><vaccines against malaria><vaccinology><viral infection><virus infection><virus-induced disease><volunteer><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Margaret Juliana McElrath

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$1,748,110

FY 2023

Project Title

CoVPN 3008 Multi-Center, Randomized, Efficacy Study of Early vs Deferred Vaccination with COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern - LC Repository

Grant Number:

3UM1AI068618-18S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/29/2006

End Date:

11/30/2025

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

FOA: PA-20-272: Administrative Supplements to Existing NIH Grants and Cooperative Agreements Activity Code/Award: UM1/A1068618 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the COV...

Research Terms

<2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><21+ years old><Abdominal Typhus><Address><Administrative Supplement><Adult><Adult Human><Africa South of the Sahara><Area><Assay><Award><B.1.351><Bioassay><Biologic Assays><Biological Assay><Biometrics><Biometry><Biostatistics><Blinded><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 Prevention Network><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 exposure><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 prevention><COVID-19 public health crisis><COVID-19 severity><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID-19 virus infection><COVID19><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 outbreak><COVID19 pandemic><COVID19 prevention><COVID19 public health crisis><COVID19 severity><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cellular Assay><Cellular Immune Function><Clinical><Clinical Trials><Clinical Trials Network><CoV-2><CoV2><CoVPN><Code><Coding System><Communicable Diseases><Constitution><Constitutional><Cooperative Agreements><Coronaviridae><Coronavirus><Country><Dedications><Development><Diagnosis><Disease><Disorder><Dose><End Point Assay><Endpoint Assays><Enteric Fever><Exposure to><Future><Goals><Grant><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS Vaccines><HVTN><Health><High Prevalence><Immune><Immune Monitoring><Immune response><Immunes><Immunity><Immunologic Monitoring><Immunological Monitoring><Immunological response><Immunology><Immunomonitoring><Individual><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><International><Intervention><Intervention Strategies><Knowledge><Laboratories><Lead><Leadership><MAb Therapeutics><Malaria><Mediating><Moderna COVID-19 vaccine><Moderna coronavirus disease 2019 vaccine><Morbidity><Morbidity - disease rate><NIH><National Institutes of Health><Paludism><Parents><Pb element><Persons><Phase><Physicians><Placebo Control><Plasmodium Infections><Population><Preparation><Prevalence><Prevention><Preventive><Proliferating><Protocol><Protocols documentation><Qualifying><Quality Control><Randomized><Research Methodology><Research Methods><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 B.1.351><SARS-CoV-2 beta><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 exposure><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 severity><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 exposure><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Scientist><Serology test><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 exposure><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Severities><Site><South Africa><South Africa strain><South Africa variant><South African strain><South African variant><Sub-Saharan Africa><Subsaharan Africa><System><Testing><Therapeutic Monoclonal Antibodies><Typhoid><Typhoid Fever><U-Series Cooperative Agreements><United States><United States National Institutes of Health><Vaccination><Vaccines><Validation><Wuhan coronavirus><adulthood><cell assay><clinical trial analysis><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 exposure><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 severity><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 prevention><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><depository><design><designing><determine efficacy><developmental><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><efficacy study><efficacy testing><efficacy trial><evaluate efficacy><examine efficacy><experience><exposure to COVID-19><exposure to SARS-CoV-2><exposure to SARS-CoV2><exposure to Severe acute respiratory syndrome coronavirus 2><exposure to coronavirus disease 2019><hCoV19><heavy metal Pb><heavy metal lead><host response><human immunodeficiency virus vaccine><immune function><immune system response><immunoresponse><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><interventional strategy><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><mRNA-1273><mRNA1273><monoclonal antibody drugs><mortality><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><observational cohort study><operation><operations><outbreak of SARS-CoV-2><parent><placebo controlled><preparations><prevent><prevent COVID-19><prevent COVID19><prevent coronavirus disease 2019><preventing><programs><quality assurance><randomisation><randomization><randomized, clinical trials><randomly assigned><rational design><repository><research and methods><response><safety assessment><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><serology assay><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 B.1.351><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 severity><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><symptomatic COVID-19><symptomatic COVID19><symptomatic coronavirus disease 2019><therapeutic mAbs><trial planning><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine efficacy><vaccine for novel coronavirus><vaccine study><vaccine trial><validations><variants of concern>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ignacio Garrido-Laguna

OHIO STATE UNIVERSITY, Columbus, OH

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$1,607,030

FY 2024

Project Title

The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network

Grant Number:

5UM1CA186712-08

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/28/2014

End Date:

2/28/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

PROJECT SUMMARY This project encompasses a multi-disciplinary team of basic scientists and clinical investigators dedicated to finding effective new therapies for patients with cancer. The Ohio State University Comprehensive Cancer Center (OSUCCC) is a comprehensive biomedical research campus with...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Miguel A Villalona

BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, DUARTE, CA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$1,594,203

FY 2023

Project Title

Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN

Grant Number:

4UM1CA186717-07

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/28/2014

End Date:

2/28/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

PROJECT SUMMARY As the California Cancer Consortium (CCC), four National Cancer Institute (NCI)-Designated Cancer Centers propose to participate in the NCI Experimental Therapeutics Clinical Trials Network (ETCTN) to conduct early phase clinical trials of experimental therapeutics. The CCC compris...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Bing Ren

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, SAN FRANCISCO, CA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$1,571,946

FY 2021

Project Title

High throughput CRISPR-mediated functional validation of regulatory elements

Grant Number:

3UM1HG009402-04S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2021

End Date:

7/31/2022

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

Project Summary The overarching goal of the proposed study is to functionally characterize a large number of candidate functional elements in the mammalian genome. The ENCODE projects have revealed millions of putative regulatory elements across more than one hundred cell types and tissues. While th...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Yin Shen

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, SAN FRANCISCO, CA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$1,571,946

FY 2021

Project Title

High throughput CRISPR-mediated functional validation of regulatory elements

Grant Number:

3UM1HG009402-04S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2021

End Date:

7/31/2022

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

Project Summary The overarching goal of the proposed study is to functionally characterize a large number of candidate functional elements in the mammalian genome. The ENCODE projects have revealed millions of putative regulatory elements across more than one hundred cell types and tissues. While th...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Clarence Buddy Creech

VANDERBILT UNIVERSITY MEDICAL CENTER, NASHVILLE, TN

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$1,543,286

FY 2022

Project Title

Vanderbilt Vaccine and Treatment Evaluation Unit

Grant Number:

3UM1AI148452-03S5

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/11/2019

End Date:

11/30/2022

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

ABSTRACT The goal of this UM1 proposal is to use the remarkable research infrastructure at Vanderbilt University Medical Center and collaborating sites (Washington University, University of Pittsburgh, and University of Pennsylvania) to conceptualize, design, implement, and analyze clinical research...

Research Terms

<0-11 years old><21+ years old><Academic Medical Centers><Adult><Adult Human><Age><Area><Assay><Award><Bacterial Infections><Bioassay><Biologic Assays><Biologic Products><Biological Agent><Biological Assay><Biological Products><Body Tissues><Child><Child Youth><Childhood><Children (0-21)><Clinical><Clinical Investigator><Clinical Research><Clinical Study><Clinical Trials><Communicable Diseases><Conduct Clinical Trials><Data><Development><Disease><Disorder><Drugs><Education><Educational aspects><Elderly><Emerging Communicable Diseases><Emerging Infectious Diseases><Enrollment><Environment><Evaluation><Faculty><Feasibility Studies><Fellowship><Fostering><Funding><Fungus Diseases><Geography><Goals><Grippe><Home><Human><Immune response><Immunity><Immunization><Immunologic Sensitization><Immunologic Stimulation><Immunological Sensitization><Immunological Stimulation><Immunological response><Immunologist><Immunostimulation><Individual><Infant><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Influenza><Influenza Vaccines><Institution><International><Intervention><Intervention Strategies><Investigators><Laboratories><Laboratory Scientists><Lead><Leadership><Length of Life><Licensure><Longevity><Malaria><Malaria Vaccines><Malarial Vaccines><Medical><Medical center><Medication><Mentors><Mentorship><Methods><Modeling><Modern Man><Mycoses><NIH><National Institutes of Health><Nurses><Paludism><Parasitic infection><Pathogenesis><Pb element><Pennsylvania><Pertussis Vaccine><Peru><Pharmaceutic Preparations><Pharmaceutical Preparations><Phase><Physicians><Plasmodium Infections><Pneumococcal vaccine><Population><Population Heterogeneity><Position><Positioning Attribute><Pregnant Women><Prevention><Principal Investigator><Procedures><Process><Protocol><Protocols documentation><Research><Research Infrastructure><Research Personnel><Researchers><Safety><Scientist><Sexually Transmitted Diseases><Sexually Transmitted Disorder><Sexually Transmitted Infection><Site><Smallpox Vaccine><Special Population><Standardization><Streptococcus pneumoniae vaccine><Systems Biology><Tissues><Training><United States National Institutes of Health><Universities><University Medical Centers><Vaccination><Vaccine Research><Vaccines><Venereal Diseases><Venereal Disorders><Venereal Infections><Viral><Viral Diseases><Virus Diseases><Visit><Washington><Work><adulthood><advanced age><ages><antibiotic resistant infections><bacteria infection><bacterial disease><base><biologics><biopharmaceutical><biotherapeutic agent><career><career development><clinical research site><clinical site><co-morbid><co-morbidity><comorbidity><design><designing><developmental><diverse populations><drug/agent><early clinical trial><early phase clinical trial><elders><emerging pathogen><enroll><ethnic diversity><ethnically diverse><expectant mother><expecting mother><experience><flu vaccine><flu virus pandemic><flu virus vaccine><fungal infection><fungus infection><geriatric><heavy metal Pb><heavy metal lead><heterogeneous population><host response><immune system response><immunogenicity><immunoresponse><influenza virus pandemic><influenza virus vaccine><innovate><innovation><innovative><interventional strategy><late life><later life><life span><lifespan><new approaches><new drug treatments><new drugs><new pathogen><new therapeutics><new therapy><new vaccines><next generation><next generation therapeutics><next generation vaccines><novel><novel approaches><novel drug treatments><novel drugs><novel pathogen><novel strategies><novel strategy><novel therapeutics><novel therapy><novel vaccines><nurse><older adult><older person><pandemic flu><pandemic influenza><pandemic strain of influenza><parasite infection><pathogen><pediatric><population diversity><pregnant mothers><recruit><research study><respiratory><response><senior citizen><tool><vaccination study><vaccination trial><vaccine against flu><vaccine against influenza><vaccine study><vaccine trial><vaccines against malaria><vaccinology><viral infection><virus infection><virus-induced disease><volunteer><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

A. Heather Eliassen

BRIGHAM AND WOMEN'S HOSPITAL, BOSTON, MA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$1,500,747

FY 2023

Project Title

Long Term Multidisciplinary Study of Cancer in Women: The Nurses Health Study

Grant Number:

5UM1CA186107-10

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/22/2014

End Date:

6/30/2025

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

ABSTRACT This is a competing renewal of a UM1 application to support the infrastructure of the original Nurses’ Health Study (NHS), begun in 1976. The accumulated resources of NHS provide exceptional opportunities for identifying new paradigms in cancer prevention, etiology and survival. The resourc...

Research Terms

<65+ years old><Active Follow-up><Address><Adjuvant Therapy><Age><Age Years><Aged 65 and Over><Aging><Archives><Behavior><Behavioral><Behavioral Research><Biological><Biological Markers><Blood><Blood Plasma><Blood Reticuloendothelial System><Blood Sample><Blood erythrocyte><Blood specimen><Body Tissues><Brain><Brain Nervous System><Cancer Cause><Cancer Etiology><Cancer Patient><Cancer Survivor><Cancer Survivorship><Cancer Treatment><Cancers><Caring><Causality><Cell Body><Cells><Cessation of life><Collaborations><Collection><Communities><DNA><Data><Data Analyses><Data Analysis><Data Bases><Data Element><Data Systems><Databases><Death><Deoxyribonucleic Acid><Diagnostic><Diet><Documentation><Educational Materials><Encephalon><Enrollment><Environment><Erythrocytes><Erythrocytic><Etiology><Fostering><Funding><GTEx><Genetic Predisposition><Genetic Predisposition to Disease><Genetic Susceptibility><Genetic propensity><Genomics><Genotype-Tissue Expression Project><Goals><Guidelines><Health><Health Policy><IT Systems><Incidence><Information Systems><Information Technology Systems><Infrastructure><Inherited Predisposition><Inherited Susceptibility><International><Investigators><Life Cycle><Life Cycle Stages><Life Style><Lifestyle><Link><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Ovarian Neoplasm><Malignant Ovarian Tumor><Malignant Tumor><Malignant Tumor of the Ovary><Malignant neoplasm of ovary><Mammogram><Mammography><Marrow erythrocyte><Measures><Mediating><Medicare claim><Modernization><Multiple Cancer Sites><Neighborhoods><Nurses' Health Study><Nursing Research><Outcome><Ovary Cancer><Participant><Patients><Phase><Phenotype><Physical activity><Plasma><Plasma Serum><Population><Process><Publications><QOL><Quality of life><Questionnaires><Recurrence><Recurrent><Red Blood Cells><Red Cell><Registries><Research><Research Personnel><Research Resources><Research Specimen><Researchers><Resource Sharing><Resources><Reticuloendothelial System, Serum, Plasma><Sampling><Scientific Publication><Scientist><Serous><Specimen><Structure of nail of toe><System><TCGA><The Cancer Genome Atlas><Tissue Banks><Tissue Collection><Tissue repository><Tissues><Toe Nail><Toenail><Tumor Tissue><Update><Urine><Visualization><Woman><active followup><adjuvant treatment><age 65 and greater><age 65 and older><aged 65 and greater><aged ≥65><ages><anti-cancer therapy><anticancer therapy><bio-markers><biobank><biologic><biologic marker><biological research><biomarker><biorepository><blood corpuscles><cancer epidemiology><cancer location><cancer prevention><cancer registry><cancer resource><cancer risk><cancer site><cancer survival><cancer therapy><cancer-directed therapy><causation><clinical practice><cohort><complex data><cost><data base><data interpretation><data management><data resource><data sharing><data tools><data visualization><depository><diets><disease causation><enroll><follow up><follow-up><followed up><followup><genetic etiology><genetic mechanism of disease><genetic vulnerability><genetically predisposed><genomic data><genomic data-set><genomic dataset><health care policy><health data><healthcare policy><human old age (65+)><indexing><large data sets><large datasets><life course><malignancy><mammographic Imaging><mammographic examinations><mammographic exams><mid life><mid-life><middle age><middle aged><midlife><mortality><multidisciplinary><neoplasm registry><neoplasm resource><neoplasm/cancer><novel><old age><ovarian cancer><repository><research study><screening><screenings><tool><tumor><user-friendly><virtual>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Meir Stampfer

BRIGHAM AND WOMEN'S HOSPITAL, BOSTON, MA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$1,500,747

FY 2023

Project Title

Long Term Multidisciplinary Study of Cancer in Women: The Nurses Health Study

Grant Number:

5UM1CA186107-10

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/22/2014

End Date:

6/30/2025

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

ABSTRACT This is a competing renewal of a UM1 application to support the infrastructure of the original Nurses’ Health Study (NHS), begun in 1976. The accumulated resources of NHS provide exceptional opportunities for identifying new paradigms in cancer prevention, etiology and survival. The resourc...

Research Terms

<65+ years old><Active Follow-up><Address><Adjuvant Therapy><Age><Age Years><Aged 65 and Over><Aging><Archives><Behavior><Behavioral><Behavioral Research><Biological><Biological Markers><Blood><Blood Plasma><Blood Reticuloendothelial System><Blood Sample><Blood erythrocyte><Blood specimen><Body Tissues><Brain><Brain Nervous System><Cancer Cause><Cancer Etiology><Cancer Patient><Cancer Survivor><Cancer Survivorship><Cancer Treatment><Cancers><Caring><Causality><Cell Body><Cells><Cessation of life><Collaborations><Collection><Communities><DNA><Data><Data Analyses><Data Analysis><Data Bases><Data Element><Data Systems><Databases><Death><Deoxyribonucleic Acid><Diagnostic><Diet><Documentation><Educational Materials><Encephalon><Enrollment><Environment><Erythrocytes><Erythrocytic><Etiology><Fostering><Funding><GTEx><Genetic Predisposition><Genetic Predisposition to Disease><Genetic Susceptibility><Genetic propensity><Genomics><Genotype-Tissue Expression Project><Goals><Guidelines><Health><Health Policy><IT Systems><Incidence><Information Systems><Information Technology Systems><Infrastructure><Inherited Predisposition><Inherited Susceptibility><International><Investigators><Life Cycle><Life Cycle Stages><Life Style><Lifestyle><Link><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Ovarian Neoplasm><Malignant Ovarian Tumor><Malignant Tumor><Malignant Tumor of the Ovary><Malignant neoplasm of ovary><Mammogram><Mammography><Marrow erythrocyte><Measures><Mediating><Medicare claim><Modernization><Multiple Cancer Sites><Neighborhoods><Nurses' Health Study><Nursing Research><Outcome><Ovary Cancer><Participant><Patients><Phase><Phenotype><Physical activity><Plasma><Plasma Serum><Population><Process><Publications><QOL><Quality of life><Questionnaires><Recurrence><Recurrent><Red Blood Cells><Red Cell><Registries><Research><Research Personnel><Research Resources><Research Specimen><Researchers><Resource Sharing><Resources><Reticuloendothelial System, Serum, Plasma><Sampling><Scientific Publication><Scientist><Serous><Specimen><Structure of nail of toe><System><TCGA><The Cancer Genome Atlas><Tissue Banks><Tissue Collection><Tissue repository><Tissues><Toe Nail><Toenail><Tumor Tissue><Update><Urine><Visualization><Woman><active followup><adjuvant treatment><age 65 and greater><age 65 and older><aged 65 and greater><aged ≥65><ages><anti-cancer therapy><anticancer therapy><bio-markers><biobank><biologic><biologic marker><biological research><biomarker><biorepository><blood corpuscles><cancer epidemiology><cancer location><cancer prevention><cancer registry><cancer resource><cancer risk><cancer site><cancer survival><cancer therapy><cancer-directed therapy><causation><clinical practice><cohort><complex data><cost><data base><data interpretation><data management><data resource><data sharing><data tools><data visualization><depository><diets><disease causation><enroll><follow up><follow-up><followed up><followup><genetic etiology><genetic mechanism of disease><genetic vulnerability><genetically predisposed><genomic data><genomic data-set><genomic dataset><health care policy><health data><healthcare policy><human old age (65+)><indexing><large data sets><large datasets><life course><malignancy><mammographic Imaging><mammographic examinations><mammographic exams><mid life><mid-life><middle age><middle aged><midlife><mortality><multidisciplinary><neoplasm registry><neoplasm resource><neoplasm/cancer><novel><old age><ovarian cancer><repository><research study><screening><screenings><tool><tumor><user-friendly><virtual>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Margaret Juliana McElrath

FRED HUTCHINSON CANCER RESEARCH CENTER, SEATTLE, WA

Good lead · 58/100

Likely hiring

Large award

Team-scale grant

$1,324,786

FY 2022

Project Title

HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals: LC 3

Grant Number:

3UM1AI068618-16S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/18/2022

End Date:

3/31/2022

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

FOA: PA-20-272: Administrative Supplements to Existing NIH Grants and Cooperative Agreements Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the ...

Research Terms

<18 year old><18 years of age><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><21+ years old><Abdominal Typhus><Address><Adjuvant><Administrative Supplement><Adult><Adult Human><Antigens><Assay><Award><B.1.351><Bioassay><Biologic Assays><Biological Assay><Biometrics><Biometry><Biostatistics><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 Prevention Network><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 screening><COVID-19 severity><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 outbreak><COVID19 pandemic><COVID19 public health crisis><COVID19 screening><COVID19 severity><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cellular Assay><Cellular Immune Function><Clinical><Clinical Trials><Clinical Trials Network><CoV-2><CoV2><CoVPN><Code><Coding System><Cohort Studies><Communicable Diseases><Concurrent Studies><Constitution><Cooperative Agreements><Coronaviridae><Coronavirus><Country><Data Analytics><Development><Diagnosis><Disease><Disorder><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><End Point Assay><Endpoint Assays><Enteric Fever><Eye><Eyeball><Frequencies><Future Generations><Goals><Grant><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS Vaccines><HVTN><Health><Hospital Admission><Hospitalization><Immune><Immune Monitoring><Immune response><Immunes><Immunity><Immunologic Monitoring><Immunological Monitoring><Immunological response><Immunology><Immunomonitoring><Individual><Infection Control><Infection prevention><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Injections><International><Investigation><Knowledge><Laboratories><Lead><Leadership><Malaria><Mediating><Monitor><Morbidity><Morbidity - disease rate><NIH><National Institutes of Health><Paludism><Parents><Participant><Pb element><Persons><Phase><Physicians><Placebo Control><Placebos><Plasmodium Infections><Population><Preparation><Prevent infection><Prevention><Protocol><Protocols documentation><Quality Control><Randomized Clinical Trials><Recombinant Proteins><Recombinant Vaccines><Research Methodology><Research Methods><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 B.1.351><SARS-CoV-2 beta><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 screening><SARS-CoV-2 severity><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 outbreak><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Sampling><Scientist><Serology test><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Sham Treatment><Site><South Africa strain><South Africa variant><South African strain><South African variant><System><Testing><Typhoid><Typhoid Fever><U-Series Cooperative Agreements><United States><United States National Institutes of Health><Vaccines><Validation><Wuhan coronavirus><adulthood><age 18 years><cell assay><clinical efficacy><clinical trial analysis><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 screening><coronavirus disease 2019 severity><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><design><designing><developmental><efficacy study><efficacy testing><efficacy trial><eighteen year old><eighteen years of age><ethnoracial><experience><hCoV19><heavy metal Pb><heavy metal lead><high risk><host response><human immunodeficiency virus vaccine><immune function><immune system response><immunogen><immunogenicity><immunoresponse><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><mortality><nCoV2><operation><placebo controlled><prevent><preventing><programs><quality assurance><racial and ethnic><racial diversity><racially diverse><recruit><remote monitoring><response><safety study><scale up><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><serology assay><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 B.1.351><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 screening><severe acute respiratory syndrome coronavirus 2 severity><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><sham therapy><symptomatic COVID-19><symptomatic COVID19><symptomatic coronavirus disease 2019><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine for novel coronavirus><vaccine study><vaccine trial><variants of concern>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

JUDITH A JAMES

OKLAHOMA MEDICAL RESEARCH FOUNDATION, OKLAHOMA CITY, OK

Good lead · 54/100

Likely hiring

Solid budget

Active award

Team-scale grant

$400,579

FY 2025

Project Title

Oklahoma ACE: Molecular Destruction of Autoimmune Disease to Aid Clinical Trail Success

Grant Number:

3UM1AI144292-07S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

8/1/2025

End Date:

4/30/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary The Oklahoma Autoimmunity Center of Excellence aims to understand autoimmune disease biology through interdisciplinary, collaborative research integrating clinical and basic questions. Prior Oklahoma Autoimmunity Center of Excellence (ACE) work as both a Basic and Clinical ACE has s...

Research Terms

<2'-Deoxy-2-chloroadenosine><2-CDA><2-Chloro-2'-deoxyadenosine><2-Chlorodeoxyadenosine><2-chloro-2'-deoxy-adenosine><2CDA><Agreement><American><Autoimmune Diseases><Autoimmune Status><Autoimmunity><Biology><CdA><Certification><Cladribina><Cladribine><Clinical><Clinical Trials><Clinical Trials Design><Clinical Trials Network><Collaborations><Data><Dedications><Development><Disease><Disorder><Employee><Equipment><Equipment and supply inventories><Flare><Floor><Foundations><Funding><Future><Genetic Diseases><Heterogeneity><Human Resources><IRB><IRBs><Infrastructure><Institutional Review Boards><Inventory><Investments><Lead><Liquid substance><Location><Logistics><Maintenance><Manpower><Medical Research><Modeling><Molecular><Monitor><Morbidity><Morbidity - disease rate><NIH RFA><Nitrogen><O element><O2 element><Oklahoma><Oxygen><Participant><Pathologist><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Patients><Pb element><Phase><Policies><Population><Preventive><Procedures><Protocol><Protocols documentation><Reporting><Request for Applications><Research><Robotics><Rural Community><Safety><Sampling><Selection for Treatments><Services><Shelter facility><Shipping><Site><Standardization><System><Testing><Tornadoes><Training><Tube><Urban Community><Work><autoimmune attack><autoimmune condition><autoimmune destruction><autoimmune disorder><autoimmune pathogenesis><autoimmunity disease><biobank><biorepository><chlorodeoxyadenosine><cohort><college><collegiate><cost effective><depository><developmental><energy efficiency><experience><fluid><genetic condition><genetic disorder><heavy metal Pb><heavy metal lead><improved><liquid><minority communities><mortality><patient oriented outcomes><patient subclass><patient subcluster><patient subgroups><patient subpopulations><patient subsets><patient subtypes><personnel><programs><recruit><repository><rho><sample collection><selection of treatment><shelter><shelter housing><shelters><specimen collection><success><therapeutically effective><therapy selection><treatment selection><vapor>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mark Joseph Mulligan

NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NEW YORK, NY

Good lead · 54/100

Likely hiring

Solid budget

Active award

Team-scale grant

$375,787

FY 2022

Project Title

Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU)

Grant Number:

3UM1AI148574-03S2

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/14/2021

End Date:

11/30/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY Establishment of New York University (NYU) Vaccine and Treatment Evaluation Unit (VTEU) is proposed in response to RFA-AI-18-046 entitled “Vaccine and Treatment Evaluation Units (VTEUs) (UM1 Clinical Trial Required)”. NYU VTEU will be one of the 10 fixed sites that will participate i...

Research Terms

<0-11 years old><21+ years old><AIDS><AIDS/HIV><AIDS/HIV problem><Academic Medical Centers><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immuno-Deficiency Syndrome><Acquired Immunodeficiency Syndrome><Acquired Immunologic Deficiency Syndrome><Address><Admission><Admission activity><Adult><Adult Human><Airway infections><Anti-microbial Drug Resistance><Anti-microbial Drug Resistant><Antibiotic Agents><Antibiotic Drugs><Antibiotic Resistance><Antibiotics><Antigenic Determinants><Antimicrobial Drug Resistance><Antimicrobial Drug Resistant><Area><Assay><Avian Influenza><Award><Beds><Binding Determinants><Bioassay><Biologic Assays><Biologic Products><Biological Agent><Biological Assay><Biological Markers><Biological Products><Biomedical Research><Bird Flu><Caring><Censuses><Cessation of life><Child><Child Youth><Childhood><Children (0-21)><Cities><Clinic><Clinical><Clinical Research><Clinical Study><Clinical Trials><Clinical Trials Unit><Clinics and Hospitals><Clinics or Hospitals><Communicable Diseases><Communities><Country><Death><Dengue><Development><Devices><Diagnostic><Disease><Disorder><Ebola><Electronic Health Record><Elements><Enrollment><Enteral><Enteric><Epitopes><Evaluation><Facilities and Administrative Costs><Faculty><Fowl Pest><Fowl Plague><Funding><H1N1><H1N1 Virus><H5N1><H5N1 virus><H7N9><HIV/AIDS><HIV/AIDS problem><Health><Health Care Systems><Healthcare Systems><History><Hospitals><Human><IRB><IRBs><Immunology><Indirect Costs><Individual><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Diseases / Laboratory><Infectious Diseases Research><Infectious Disorder><Influenza A><Influenza A Virus, H1N1 Subtype><Influenza A Virus, H5N1 Subtype><Influenza A Virus, H7N9 Subtype><Influenza A virus><Influenza Vaccines><Influenza Viruses Type A><Influenzavirus A><Inpatients><Institutional Review Boards><International><Laboratories><Laboratory Research><Leadership><Long Island><M tuberculosis infection><M. tb infection><M. tuberculosis infection><M.tb infection><M.tuberculosis infection><MERS><MERS coronavirus disease><MERS-CoV disease><MTB infection><Malaria><Marriage><Medical Research><Microbial Drug Resistance><Middle East Respiratory Syndrome><Middle East Respiratory Syndrome CoV disease><Middle East Respiratory Syndrome coronavirus disease><Middle Eastern Respiratory Syndrome><Middle Eastern Respiratory Syndrome CoV disease><Middle Eastern Respiratory Syndrome coronavirus disease><Miscellaneous Antibiotic><Modeling><Modern Man><Molecular Epidemiology><Morbidity><Morbidity - disease rate><Multi-Drug Resistance><Multidrug Resistance><Multiple Drug Resistance><Multiple Drug Resistant><Mycobacterium tuberculosis (MTB) infection><Mycobacterium tuberculosis infection><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><New York><New York City><Norovirus><Norwalk-like Viruses><Orthomyxovirus Type A><Out-patients><Outpatients><PK/PD><Paludism><Participant><Patient Care><Patient Care Delivery><Patient Recruitments><Patients><Plasmodium Infections><Population><Predictive Value><Preparedness><Procedures><Public Health><Readiness><Recording of previous events><Reporting><Research><Research Activity><Research Priority><Research Resources><Research Support><Resistance to Multi-drug><Resistance to Multidrug><Resistance to Multiple Drug><Resistance to antibiotics><Resistant to Multiple Drug><Resistant to antibiotics><Resistant to multi-drug><Resistant to multidrug><Resources><Respiratory Infections><Respiratory Tract Infections><SARS><SARS coronavirus disease><SARS-CoV disease><Seasons><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome coronavirus disease><Sexually Transmitted Diseases><Sexually Transmitted Disorder><Sexually Transmitted Infection><Site><Speed><Study Subject><Study models><System><TB infection><Therapeutic><Time><Tuberculosis><Type A Influenza><United States National Institutes of Health><Universities><University Medical Centers><Vaccination><Vaccines><Venereal Diseases><Venereal Disorders><Venereal Infections><Viral><Visit><Work><ZIKA><adulthood><anti-microbial agent><anti-microbial drug><antibiotic drug resistance><antibiotic resistant><antimicrobial agent><antimicrobial drug><avian flu><avian influenza H5N1><avian influenza H5N1 virus><bio-markers><biologic marker><biologics><biomarker><biopharmaceutical><biotherapeutic agent><combat><comparative><demographics><developmental><disseminated TB><disseminated tuberculosis><electronic health care record><electronic healthcare record><enroll><experience><flu><flu vaccine><flu virus pandemic><flu virus vaccine><individual patient><infection due to Mycobacterium tuberculosis><influenza in birds><influenza virus pandemic><influenza virus vaccine><innovate><innovation><innovative><medical college><medical countermeasure><medical schools><metropolitan><microbial><microbial drug resistant><microbial genomics><microbiome><mortality><multi-drug resistant><multidrug resistant><multiomics><multiple omics><neglected tropical diseases><new approaches><news><novel><novel approaches><novel strategies><novel strategy><operation><outreach><pandemic flu><pandemic influenza><pandemic strain of influenza><participant recruitment><pathogen><pediatric><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><pharmacokinetics and pharmacodynamics><priority pathogen><recruit><response><school of medicine><seasonal flu><seasonal influenza><systems research><tuberculosis infection><tuberculous spondyloarthropathy><universal flu vaccine><universal influenza vaccine><universal influenza virus vaccine><universal vaccine against flu><universal vaccine against influenza><vaccine against flu><vaccine against influenza><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Robert Wilson Frenck

CINCINNATI CHILDRENS HOSP MED CTR, CINCINNATI, OH

Good lead · 52/100

Likely hiring

Above-average budget

Team-scale grant

$674,143

FY 2022

Project Title

Cincinnati Children's Hospital Medical Center Vaccine and Treatment Evaluation Units (UM1 Clinical Trial Required)

Grant Number:

3UM1AI148372-03S2

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/11/2019

End Date:

11/30/2024

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Throughout history, infectious diseases have been, and continue to be, a leading cause of morbidity and mortality throughout the world. While all ages are affected by infectious diseases, the ends of the spectrum of life (young children and elderly) are particularly vulnerable. Thus,...

Research Terms

<0-11 years old><21+ years old><Address><Adolescent><Adolescent Youth><Adult><Adult Human><Affect><Age><Airway infections><Applied Research><Applied Science><Area><Assay><Award><Bioassay><Biologic Assays><Biologic Products><Biological Agent><Biological Assay><Biological Products><Budgets><Child><Child Youth><Children (0-21)><Children's Hospital><Clinical><Clinical Research><Clinical Study><Clinical Trials><Collaborations><Communicable Diseases><Consent Documents><Consent Forms><Cooperative Agreements><Data Analyses><Data Analysis><Development><Devices><Diagnostic><Diagnostic Device><Diagnostic Equipment><Disease><Disease Outbreaks><Disorder><Elderly><Emerging Communicable Diseases><Emerging Infectious Diseases><Enrollment><Ensure><Enteral><Enteric><Epidemiology><Evaluation><Faculty><Future><Goals><Grippe><Group Structure><H1N1><H1N1 Virus><H5N1><H5N1 virus><History><Human><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunosuppressed Host><Infant><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Influenza><Influenza A Virus, H1N1 Subtype><Influenza A Virus, H5N1 Subtype><Influenza Vaccines><Informed Consent Documents><Informed Consent Forms><Intervention Trial><Interventional trial><Investigators><Laboratories><Leadership><Letters><Life><Manuals><Medical center><Mentors><Methods><Microbiology><Mission><Modeling><Modern Man><Modification><Morbidity><Morbidity - disease rate><Multi-center studies><Multicenter Studies><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><Norovirus><Norwalk-like Viruses><Ohio><Organization Charts><Out-patients><Outbreaks><Outpatients><Participant><Pediatric Hospitals><Performance><Persons><Phase><Population><Pregnant Women><Preparation><Prevention><Preventive><Prognostic Marker><Protocol><Protocols documentation><Public Health><Publications><Quality Control><Recording of previous events><Research Design><Research Personnel><Researchers><Respiratory Infections><Respiratory Tract Infections><S sonnei><S. sonnei><Scientific Publication><Sexually Transmitted Diseases><Sexually Transmitted Disorder><Sexually Transmitted Infection><Shigella sonnei><Site><Specialty><Study Type><Systems Biology><Technology><Testing><Therapeutic><Training><U-Series Cooperative Agreements><United States National Institutes of Health><Vaccines><Venereal Diseases><Venereal Disorders><Venereal Infections><adulthood><advanced age><ages><avian influenza H5N1><avian influenza H5N1 virus><biodefense><biologics><biopharmaceutical><biotherapeutic agent><clinical research site><clinical site><clinical trial implementation><data dissemination><data interpretation><data tools><design><designing><develop a vaccine><develop vaccines><development of a vaccine><developmental><elders><emerging pathogen><enroll><enteral pathogen><enteric pathogen><enteropathogen><epidemiologic><epidemiological><evaluate vaccines><expectant mother><expecting mother><flu vaccine><flu virus vaccine><geriatric><immunosuppressed patient><implementation of clinical trials><infectious disease treatment><influenza virus vaccine><innovate><innovation><innovative><intestinal pathogen><intestine pathogen><investigator-initiated trial><juvenile><juvenile human><late life><later life><medical specialties><mortality><neglected tropical diseases><new pathogen><novel><novel pathogen><older adult><older person><operation><organizational structure><predictive biomarkers><predictive marker><predictive molecular biomarker><pregnant mothers><prevent><preventing><prognostic biomarker><recruit><respiratory pathogen><response><senior citizen><study design><trial design><vaccination study><vaccination trial><vaccine against flu><vaccine against influenza><vaccine candidate><vaccine development><vaccine effectiveness><vaccine evaluation><vaccine screening><vaccine study><vaccine testing><vaccine trial><vaccine-induced immunity><vaccine-induced protection><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Clarence Buddy Creech

VANDERBILT UNIVERSITY MEDICAL CENTER, NASHVILLE, TN

Good lead · 52/100

Likely hiring

Above-average budget

Team-scale grant

$658,548

FY 2021

Project Title

Vanderbilt Vaccine and Treatment Evaluation Unit - DMID 21-0004

Grant Number:

3UM1AI148452-02S6

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

8/10/2021

End Date:

11/30/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Program Director/Principal Investigator (Last, First, Middle): Creech, Clarence B Supplement Abstract Observational, Prospective Cohort Study of the Immunogenicity and Safety of SARS-CoV-2 Vaccines Administered during Pregnancy or Postpartum and Evaluation of Antibody Transfer and Durability in Infa...

Research Terms

<2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><Award><COVID><COVID-19><COVID-19 vaccine><COVID-19 virus><COVID19><COVID19 vaccine><COVID19 virus><CV-19><CV19><Children's Hospital><Clinical Research><Clinical Study><Clinical Trials><CoV disease><CoV-2><CoV2><Coronaviridae><Coronavirus><Development><Evaluation><Faculty><Future><Gestation><Immune response><Immunological response><Infant><Infection><Intervention><Intervention Strategies><Laboratories><Manuscripts><Measures><Morbidity><Morbidity - disease rate><Pediatric Hospitals><Philadelphia><Postpartum><Postpartum Period><Pregnancy><Preparation><Principal Investigator><Prospective cohort study><Research><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Sampling><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Site><Training><Vaccines><Work><Wuhan coronavirus><antibody transfer><corona virus><corona virus disease><corona virus disease 2019><corona virus disease 2019 vaccine><coronavirus disease><coronavirus disease 2019><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><developmental><evaluate vaccines><hCoV19><host response><immune system response><immunogenicity><immunoresponse><interventional strategy><mortality><nCoV2><novel><pandemic><pandemic disease><participant enrollment><patient enrollment><post-partum><programs><protocol development><research study><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidate><vaccine evaluation><vaccine for novel coronavirus><vaccine screening><vaccine testing><vaccinology>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Clarence Buddy Creech

VANDERBILT UNIVERSITY MEDICAL CENTER, NASHVILLE, TN

Good lead · 52/100

Likely hiring

Above-average budget

Team-scale grant

$592,422

FY 2022

Project Title

Vanderbilt Vaccine and Treatment Evaluation Unit

Grant Number:

3UM1AI148452-03S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

8/10/2021

End Date:

4/26/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT The goal of this UM1 proposal is to use the remarkable research infrastructure at Vanderbilt University Medical Center and collaborating sites (Washington University, University of Pittsburgh, and University of Pennsylvania) to conceptualize, design, implement, and analyze clinical research...

Research Terms

<0-11 years old><21+ years old><Academic Medical Centers><Adult><Adult Human><Age><Area><Assay><Award><Bacterial Infections><Bioassay><Biologic Assays><Biologic Products><Biological Agent><Biological Assay><Biological Products><Body Tissues><Child><Child Youth><Childhood><Children (0-21)><Clinical><Clinical Investigator><Clinical Research><Clinical Study><Clinical Trials><Communicable Diseases><Conduct Clinical Trials><Data><Development><Disease><Disorder><Drugs><Education><Educational aspects><Elderly><Emerging Communicable Diseases><Emerging Infectious Diseases><Enrollment><Environment><Evaluation><Faculty><Feasibility Studies><Fellowship><Fostering><Funding><Fungus Diseases><Geography><Goals><Grippe><Home><Human><Immune response><Immunity><Immunization><Immunologic Sensitization><Immunologic Stimulation><Immunological Sensitization><Immunological Stimulation><Immunological response><Immunologist><Immunostimulation><Individual><Infant><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Influenza><Influenza Vaccines><Institution><International><Intervention><Intervention Strategies><Investigators><Laboratories><Laboratory Scientists><Lead><Leadership><Length of Life><Licensure><Longevity><Malaria><Malaria Vaccines><Malarial Vaccines><Medical><Medical center><Medication><Mentors><Mentorship><Methods><Modeling><Modern Man><Mycoses><NIH><National Institutes of Health><Nurses><Paludism><Parasitic infection><Pathogenesis><Pb element><Pennsylvania><Pertussis Vaccine><Peru><Pharmaceutic Preparations><Pharmaceutical Preparations><Phase><Physicians><Plasmodium Infections><Pneumococcal vaccine><Population><Population Heterogeneity><Position><Positioning Attribute><Pregnant Women><Prevention><Principal Investigator><Procedures><Process><Protocol><Protocols documentation><Research><Research Infrastructure><Research Personnel><Researchers><Safety><Scientist><Sexually Transmitted Diseases><Sexually Transmitted Disorder><Sexually Transmitted Infection><Site><Smallpox Vaccine><Special Population><Standardization><Streptococcus pneumoniae vaccine><Systems Biology><Tissues><Training><United States National Institutes of Health><Universities><University Medical Centers><Vaccination><Vaccine Research><Vaccines><Venereal Diseases><Venereal Disorders><Venereal Infections><Viral><Viral Diseases><Virus Diseases><Visit><Washington><Work><adulthood><advanced age><ages><antibiotic resistant infections><bacteria infection><bacterial disease><base><biologics><biopharmaceutical><biotherapeutic agent><career><career development><clinical research site><clinical site><co-morbid><co-morbidity><comorbidity><design><designing><developmental><diverse populations><drug/agent><early clinical trial><early phase clinical trial><elders><emerging pathogen><enroll><ethnic diversity><ethnically diverse><expectant mother><expecting mother><experience><flu vaccine><flu virus pandemic><flu virus vaccine><fungal infection><fungus infection><geriatric><heavy metal Pb><heavy metal lead><heterogeneous population><host response><immune system response><immunogenicity><immunoresponse><influenza virus pandemic><influenza virus vaccine><innovate><innovation><innovative><interventional strategy><late life><later life><life span><lifespan><new approaches><new drug treatments><new drugs><new pathogen><new therapeutics><new therapy><new vaccines><next generation><next generation therapeutics><next generation vaccines><novel><novel approaches><novel drug treatments><novel drugs><novel pathogen><novel strategies><novel strategy><novel therapeutics><novel therapy><novel vaccines><nurse><older adult><older person><pandemic flu><pandemic influenza><pandemic strain of influenza><parasite infection><pathogen><pediatric><population diversity><pregnant mothers><recruit><research study><respiratory><response><senior citizen><tool><vaccination study><vaccination trial><vaccine against flu><vaccine against influenza><vaccine study><vaccine trial><vaccines against malaria><vaccinology><viral infection><virus infection><virus-induced disease><volunteer><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ignacio E. Sanz

EMORY UNIVERSITY, ATLANTA, GA

Good lead · 52/100

Likely hiring

Above-average budget

Team-scale grant

$560,943

FY 2021

Project Title

Molecular Regulation of B cells and T cells in Human SLE

Grant Number:

3U19AI110483-08S1

Activity Code:

U19

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/6/2020

End Date:

4/30/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

The overarching objective of the Emory Autoimmunity Center of Excellence (ACE) U19 is to decipher the molecular programs responsible for the aberrant effector immune responses that lead to autoimmune disease. Specifically, based on the work performed by the Emory ACE during the current funding cycle...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mark Joseph Mulligan

NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NEW YORK, NY

Good lead · 52/100

Likely hiring

Above-average budget

Team-scale grant

$543,651

FY 2022

Project Title

Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU)

Grant Number:

3UM1AI148574-03S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/29/2021

End Date:

11/30/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Establishment of New York University (NYU) Vaccine and Treatment Evaluation Unit (VTEU) is proposed in response to RFA-AI-18-046 entitled “Vaccine and Treatment Evaluation Units (VTEUs) (UM1 Clinical Trial Required)”. NYU VTEU will be one of the 10 fixed sites that will participate i...

Research Terms

<0-11 years old><21+ years old><AIDS><AIDS/HIV><AIDS/HIV problem><Academic Medical Centers><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immuno-Deficiency Syndrome><Acquired Immunodeficiency Syndrome><Acquired Immunologic Deficiency Syndrome><Address><Admission><Admission activity><Adult><Adult Human><Airway infections><Anti-microbial Drug Resistance><Anti-microbial Drug Resistant><Antibiotic Agents><Antibiotic Drugs><Antibiotic Resistance><Antibiotics><Antigenic Determinants><Antimicrobial Drug Resistance><Antimicrobial Drug Resistant><Area><Assay><Avian Influenza><Award><Beds><Binding Determinants><Bioassay><Biologic Assays><Biologic Products><Biological Agent><Biological Assay><Biological Markers><Biological Products><Biomedical Research><Bird Flu><Caring><Censuses><Cessation of life><Child><Child Youth><Childhood><Children (0-21)><Cities><Clinic><Clinical><Clinical Research><Clinical Study><Clinical Trials><Clinical Trials Unit><Clinics and Hospitals><Clinics or Hospitals><Communicable Diseases><Communities><Country><Death><Dengue><Development><Devices><Diagnostic><Disease><Disorder><Ebola><Electronic Health Record><Elements><Enrollment><Enteral><Enteric><Epitopes><Evaluation><Facilities and Administrative Costs><Faculty><Fowl Pest><Fowl Plague><Funding><H1N1><H1N1 Virus><H5N1><H5N1 virus><H7N9><HIV/AIDS><HIV/AIDS problem><Health><Health Care Systems><Healthcare Systems><History><Hospitals><Human><IRB><IRBs><Immunology><Indirect Costs><Individual><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Diseases / Laboratory><Infectious Diseases Research><Infectious Disorder><Influenza A><Influenza A Virus, H1N1 Subtype><Influenza A Virus, H5N1 Subtype><Influenza A Virus, H7N9 Subtype><Influenza A virus><Influenza Vaccines><Influenza Viruses Type A><Influenzavirus A><Inpatients><Institutional Review Boards><International><Laboratories><Laboratory Research><Leadership><Long Island><M tuberculosis infection><M. tb infection><M. tuberculosis infection><M.tb infection><M.tuberculosis infection><MERS><MERS coronavirus disease><MERS-CoV disease><MTB infection><Malaria><Marriage><Medical Research><Microbial Drug Resistance><Middle East Respiratory Syndrome><Middle East Respiratory Syndrome CoV disease><Middle East Respiratory Syndrome coronavirus disease><Middle Eastern Respiratory Syndrome><Middle Eastern Respiratory Syndrome CoV disease><Middle Eastern Respiratory Syndrome coronavirus disease><Miscellaneous Antibiotic><Modeling><Modern Man><Molecular Epidemiology><Morbidity><Morbidity - disease rate><Multi-Drug Resistance><Multidrug Resistance><Multiple Drug Resistance><Multiple Drug Resistant><Mycobacterium tuberculosis (MTB) infection><Mycobacterium tuberculosis infection><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><New York><New York City><Norovirus><Norwalk-like Viruses><Orthomyxovirus Type A><Out-patients><Outpatients><PK/PD><Paludism><Participant><Patient Care><Patient Care Delivery><Patient Recruitments><Patients><Plasmodium Infections><Population><Predictive Value><Preparedness><Procedures><Public Health><Readiness><Recording of previous events><Reporting><Research><Research Activity><Research Priority><Research Resources><Research Support><Resistance to Multi-drug><Resistance to Multidrug><Resistance to Multiple Drug><Resistance to antibiotics><Resistant to Multiple Drug><Resistant to antibiotics><Resistant to multi-drug><Resistant to multidrug><Resources><Respiratory Infections><Respiratory Tract Infections><SARS><SARS coronavirus disease><SARS-CoV disease><Seasons><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome coronavirus disease><Sexually Transmitted Diseases><Sexually Transmitted Disorder><Sexually Transmitted Infection><Site><Speed><Study Subject><Study models><System><TB infection><Therapeutic><Time><Tuberculosis><Type A Influenza><United States National Institutes of Health><Universities><University Medical Centers><Vaccination><Vaccines><Venereal Diseases><Venereal Disorders><Venereal Infections><Viral><Visit><Work><ZIKA><adulthood><anti-microbial agent><anti-microbial drug><antibiotic drug resistance><antibiotic resistant><antimicrobial agent><antimicrobial drug><avian flu><avian influenza H5N1><avian influenza H5N1 virus><bio-markers><biologic marker><biologics><biomarker><biopharmaceutical><biotherapeutic agent><combat><comparative><demographics><developmental><disseminated TB><disseminated tuberculosis><electronic health care record><electronic healthcare record><enroll><experience><flu><flu vaccine><flu virus pandemic><flu virus vaccine><individual patient><infection due to Mycobacterium tuberculosis><influenza in birds><influenza virus pandemic><influenza virus vaccine><innovate><innovation><innovative><medical college><medical countermeasure><medical schools><metropolitan><microbial><microbial drug resistant><microbial genomics><microbiome><mortality><multi-drug resistant><multidrug resistant><multiomics><multiple omics><neglected tropical diseases><new approaches><news><novel><novel approaches><novel strategies><novel strategy><operation><outreach><pandemic flu><pandemic influenza><pandemic strain of influenza><participant recruitment><pathogen><pediatric><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><pharmacokinetics and pharmacodynamics><priority pathogen><recruit><response><school of medicine><seasonal flu><seasonal influenza><systems research><tuberculosis infection><tuberculous spondyloarthropathy><universal flu vaccine><universal influenza vaccine><universal influenza virus vaccine><universal vaccine against flu><universal vaccine against influenza><vaccine against flu><vaccine against influenza><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Patricia M. LoRusso

YALE UNIVERSITY, NEW HAVEN, CT

Good lead · 52/100

Likely hiring

Above-average budget

Team-scale grant

$500,000

FY 2022

Project Title

Supplement to UM1 grant for NCI's Early Therapeutics Clinical Trials Network (ETCTN)

Grant Number:

3UM1CA186689-06S5

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/1/2022

End Date:

2/28/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT: This application is being submitted to request the addition of University of Kansas Cancer Center (KUCC) as an Affiliated Organization (AO) to our NCI Experimental Therapeutics-Clinical Trials Network (ETCTN) UM1 Lead Academic Organization. KUCC, previously a “Create Access to Targeted Can...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

ELLEN L BURNHAM

UNIVERSITY OF COLORADO DENVER, Aurora, CO

Good lead · 48/100

Large award

Active award

Career award

$1,079,975

FY 2026

Project Title

CTSA K12 Program at University of Colorado Denver

Grant Number:

5K12TR004412-03

Activity Code:

K12

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

12/1/2023

End Date:

11/30/2028

Why this may be worth a closer look

• Large budget suggests more room for personnel or project growth.

Project Abstract

Effective clinical and translational research (CTR) requires teams of scientists who can move out of traditional siloes to engage in research across the translational ecosystem. Competencies in a discipline known as clinical and translational science (CTS) that includes an array of fundamental chara...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

CATARINA I. KIEFE

UNIV OF MASSACHUSETTS MED SCH WORCESTER, WORCESTER, MA

Good lead · 48/100

Above-average budget

Recent

Active award

Career award

$949,994

FY 2026

Project Title

2/3 CTSA K12 Program at University of Massachusetts

Grant Number:

1K12TR005450-01

Activity Code:

K12

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2031

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT Background: This K12 application is a required companion of the UMass CTSA (UM1) application. We build on the strengths of our KL2 program, which has trained 27 scholars since its inception in 2010. Collectively, they have published 978 peer-reviewed publications and garnere...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

VINCENT James CAIOZZO

UNIVERSITY OF CALIFORNIA-IRVINE, IRVINE, CA

Good lead · 48/100

Above-average budget

Recent

Active award

Career award

$756,000

FY 2026

Project Title

ICTS Mentored Career Development Core

Grant Number:

1K12TR006003-01

Activity Code:

K12

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

3/15/2026

End Date:

2/28/2031

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.

Project Abstract

K12 PROJECT SUMMARY The goal of the proposed K12 program is to provide a robust mentored career development environment that pursues the following specific aims. Specific Aim 1: Champion mentored career development by nurturing an integrated K12 program that consists of outstanding leadership and ov...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Anand K Ganesan

UNIVERSITY OF CALIFORNIA-IRVINE, IRVINE, CA

Good lead · 48/100

Above-average budget

Recent

Active award

Career award

$756,000

FY 2026

Project Title

ICTS Mentored Career Development Core

Grant Number:

1K12TR006003-01

Activity Code:

K12

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

3/15/2026

End Date:

2/28/2031

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.

Project Abstract

K12 PROJECT SUMMARY The goal of the proposed K12 program is to provide a robust mentored career development environment that pursues the following specific aims. Specific Aim 1: Champion mentored career development by nurturing an integrated K12 program that consists of outstanding leadership and ov...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Elizabeth Head

UNIVERSITY OF CALIFORNIA-IRVINE, IRVINE, CA

Good lead · 48/100

Above-average budget

Recent

Active award

Career award

$756,000

FY 2026

Project Title

ICTS Mentored Career Development Core

Grant Number:

1K12TR006003-01

Activity Code:

K12

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

3/15/2026

End Date:

2/28/2031

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.

Project Abstract

K12 PROJECT SUMMARY The goal of the proposed K12 program is to provide a robust mentored career development environment that pursues the following specific aims. Specific Aim 1: Champion mentored career development by nurturing an integrated K12 program that consists of outstanding leadership and ov...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Susan Marie Graham

UNIVERSITY OF WASHINGTON, SEATTLE, WA

Good lead · 46/100

Likely hiring

Solid budget

Active award

$367,416

FY 2023

Project Title

Acceptability of Sustained-Release Antiretrovirals for Treatment in the US and sub-Saharan Africa

Grant Number:

5R01MH121424-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/17/2019

End Date:

7/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary In 2017, UNAIDS estimated that 23% of diagnosed persons living with HIV (PLWH) were not accessing antiretroviral therapy (ART), and 18% of PLWH taking ART had unsuppressed viral loads. The development of sustained-release or long-acting injectable antiretroviral therapy (LAI ART) is ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jane M. Simoni

UNIVERSITY OF WASHINGTON, SEATTLE, WA

Exploratory lead · 44/100

Likely hiring

Above-average budget

$521,931

FY 2022

Project Title

Acceptability of Sustained-Release Antiretrovirals for Treatment in the US and sub-Saharan Africa

Grant Number:

5R01MH121424-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/17/2019

End Date:

7/31/2024

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary In 2017, UNAIDS estimated that 23% of diagnosed persons living with HIV (PLWH) were not accessing antiretroviral therapy (ART), and 18% of PLWH taking ART had unsuppressed viral loads. The development of sustained-release or long-acting injectable antiretroviral therapy (LAI ART) is ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jan Hendrik Beumer

UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PITTSBURGH, PA

Exploratory lead · 44/100

Likely hiring

Solid budget

Team-scale grant

$400,000

FY 2022

Project Title

CATCH-UP: NCI ETCTN Pittsburgh Cancer Consortium (PCC)

Grant Number:

3UM1CA186690-06S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/25/2014

End Date:

2/28/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

ABSTRACT This application is being submitted to request the addition of an Affiliated Organization(s) to the Early Therapeutics Clinical Trial Network (ETCTN) UM1 Lead Academic Organization. The Chao Family Comprehensive Cancer Center (CFCCC) of the University of California, Irvine (UCI) has demonst...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jason John Luke

UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PITTSBURGH, PA

Exploratory lead · 44/100

Likely hiring

Solid budget

Team-scale grant

$400,000

FY 2022

Project Title

CATCH-UP: NCI ETCTN Pittsburgh Cancer Consortium (PCC)

Grant Number:

3UM1CA186690-06S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/25/2014

End Date:

2/28/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

ABSTRACT This application is being submitted to request the addition of an Affiliated Organization(s) to the Early Therapeutics Clinical Trial Network (ETCTN) UM1 Lead Academic Organization. The Chao Family Comprehensive Cancer Center (CFCCC) of the University of California, Irvine (UCI) has demonst...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Liza Cosca Villaruz

UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PITTSBURGH, PA

Exploratory lead · 44/100

Likely hiring

Solid budget

Team-scale grant

$400,000

FY 2022

Project Title

CATCH-UP: NCI ETCTN Pittsburgh Cancer Consortium (PCC)

Grant Number:

3UM1CA186690-06S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/25/2014

End Date:

2/28/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

ABSTRACT This application is being submitted to request the addition of an Affiliated Organization(s) to the Early Therapeutics Clinical Trial Network (ETCTN) UM1 Lead Academic Organization. The Chao Family Comprehensive Cancer Center (CFCCC) of the University of California, Irvine (UCI) has demonst...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ignacio E. Sanz

EMORY UNIVERSITY, ATLANTA, GA

Exploratory lead · 44/100

Likely hiring

Solid budget

Team-scale grant

$374,678

FY 2021

Project Title

Molecular Regulation of B cells and T cells in Human SLE

Grant Number:

3U19AI110483-08S2

Activity Code:

U19

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

8/26/2020

End Date:

4/30/2024

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

The overarching objective of the Emory Autoimmunity Center of Excellence (ACE) U19 is to decipher the molecular programs responsible for the aberrant effector immune responses that lead to autoimmune disease. Specifically, based on the work performed by the Emory ACE during the current funding cycle...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Philippe Bedard

UNIVERSITY HEALTH NETWORK, TORONTO, ON, CANADA

Exploratory lead · 44/100

Likely hiring

Solid budget

Team-scale grant

$372,146

FY 2022

Project Title

North American Star Consortium

Grant Number:

3UM1CA186644-06S2

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2022

End Date:

2/28/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

North American Star Consortium (NASC) (CA-UM186644) is consisted of Princess Margaret Cancer Centre- University Health Network (PM-UHN) as its Lead Academic Organization (LAO) and 5 Affiliated Organizations (AOs): H. Lee Moffitt Cancer Center, Virginal Commonwealth University, University of Texas So...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Kevin D Courtney

UNIVERSITY HEALTH NETWORK, TORONTO, ON, CANADA

Exploratory lead · 44/100

Likely hiring

Solid budget

Team-scale grant

$372,146

FY 2022

Project Title

North American Star Consortium

Grant Number:

3UM1CA186644-06S2

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2022

End Date:

2/28/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

North American Star Consortium (NASC) (CA-UM186644) is consisted of Princess Margaret Cancer Centre- University Health Network (PM-UHN) as its Lead Academic Organization (LAO) and 5 Affiliated Organizations (AOs): H. Lee Moffitt Cancer Center, Virginal Commonwealth University, University of Texas So...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Steven Grant

UNIVERSITY HEALTH NETWORK, TORONTO, ON, CANADA

Exploratory lead · 44/100

Likely hiring

Solid budget

Team-scale grant

$372,146

FY 2022

Project Title

North American Star Consortium

Grant Number:

3UM1CA186644-06S2

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2022

End Date:

2/28/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

North American Star Consortium (NASC) (CA-UM186644) is consisted of Princess Margaret Cancer Centre- University Health Network (PM-UHN) as its Lead Academic Organization (LAO) and 5 Affiliated Organizations (AOs): H. Lee Moffitt Cancer Center, Virginal Commonwealth University, University of Texas So...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Salma Jabbour

UNIVERSITY HEALTH NETWORK, TORONTO, ON, CANADA

Exploratory lead · 44/100

Likely hiring

Solid budget

Team-scale grant

$372,146

FY 2022

Project Title

North American Star Consortium

Grant Number:

3UM1CA186644-06S2

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2022

End Date:

2/28/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

North American Star Consortium (NASC) (CA-UM186644) is consisted of Princess Margaret Cancer Centre- University Health Network (PM-UHN) as its Lead Academic Organization (LAO) and 5 Affiliated Organizations (AOs): H. Lee Moffitt Cancer Center, Virginal Commonwealth University, University of Texas So...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jeffrey Lancet

UNIVERSITY HEALTH NETWORK, TORONTO, ON, CANADA

Exploratory lead · 44/100

Likely hiring

Solid budget

Team-scale grant

$372,146

FY 2022

Project Title

North American Star Consortium

Grant Number:

3UM1CA186644-06S2

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2022

End Date:

2/28/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

North American Star Consortium (NASC) (CA-UM186644) is consisted of Princess Margaret Cancer Centre- University Health Network (PM-UHN) as its Lead Academic Organization (LAO) and 5 Affiliated Organizations (AOs): H. Lee Moffitt Cancer Center, Virginal Commonwealth University, University of Texas So...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Devalingam Mahalingam

UNIVERSITY HEALTH NETWORK, TORONTO, ON, CANADA

Exploratory lead · 44/100

Likely hiring

Solid budget

Team-scale grant

$372,146

FY 2022

Project Title

North American Star Consortium

Grant Number:

3UM1CA186644-06S2

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2022

End Date:

2/28/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

North American Star Consortium (NASC) (CA-UM186644) is consisted of Princess Margaret Cancer Centre- University Health Network (PM-UHN) as its Lead Academic Organization (LAO) and 5 Affiliated Organizations (AOs): H. Lee Moffitt Cancer Center, Virginal Commonwealth University, University of Texas So...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Lillian L Siu

UNIVERSITY HEALTH NETWORK, TORONTO, ON, CANADA

Exploratory lead · 44/100

Likely hiring

Solid budget

Team-scale grant

$372,146

FY 2022

Project Title

North American Star Consortium

Grant Number:

3UM1CA186644-06S2

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2022

End Date:

2/28/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

North American Star Consortium (NASC) (CA-UM186644) is consisted of Princess Margaret Cancer Centre- University Health Network (PM-UHN) as its Lead Academic Organization (LAO) and 5 Affiliated Organizations (AOs): H. Lee Moffitt Cancer Center, Virginal Commonwealth University, University of Texas So...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Robert Wilson Frenck

CINCINNATI CHILDRENS HOSP MED CTR, CINCINNATI, OH

Exploratory lead · 44/100

Likely hiring

Solid budget

Team-scale grant

$349,665

FY 2022

Project Title

Cincinnati Children's Hospital Medical Center Vaccine and Treatment Evaluation Units (UM1 Clinical Trial Required)

Grant Number:

3UM1AI148372-03S3

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/20/2021

End Date:

11/30/2024

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY Throughout history, infectious diseases have been, and continue to be, a leading cause of morbidity and mortality throughout the world. While all ages are affected by infectious diseases, the ends of the spectrum of life (young children and elderly) are particularly vulnerable. Thus,...

Research Terms

<0-11 years old><21+ years old><Address><Adolescent><Adolescent Youth><Adult><Adult Human><Affect><Age><Airway infections><Applied Research><Applied Science><Area><Assay><Award><Bioassay><Biologic Assays><Biologic Products><Biological Agent><Biological Assay><Biological Products><Budgets><Child><Child Youth><Children (0-21)><Children's Hospital><Clinical><Clinical Research><Clinical Study><Clinical Trials><Collaborations><Communicable Diseases><Consent Documents><Consent Forms><Cooperative Agreements><Data Analyses><Data Analysis><Development><Devices><Diagnostic><Diagnostic Device><Diagnostic Equipment><Disease><Disease Outbreaks><Disorder><Elderly><Emerging Communicable Diseases><Emerging Infectious Diseases><Enrollment><Ensure><Enteral><Enteric><Epidemiology><Evaluation><Faculty><Future><Goals><Grippe><Group Structure><H1N1><H1N1 Virus><H5N1><H5N1 virus><History><Human><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunosuppressed Host><Infant><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Influenza><Influenza A Virus, H1N1 Subtype><Influenza A Virus, H5N1 Subtype><Influenza Vaccines><Informed Consent Documents><Informed Consent Forms><Intervention Trial><Interventional trial><Investigators><Laboratories><Leadership><Letters><Life><Manuals><Medical center><Mentors><Methods><Microbiology><Mission><Modeling><Modern Man><Modification><Morbidity><Morbidity - disease rate><Multi-center studies><Multicenter Studies><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><Norovirus><Norwalk-like Viruses><Ohio><Organization Charts><Out-patients><Outbreaks><Outpatients><Participant><Pediatric Hospitals><Performance><Persons><Phase><Population><Pregnant Women><Preparation><Prevention><Preventive><Prognostic Marker><Protocol><Protocols documentation><Public Health><Publications><Quality Control><Recording of previous events><Research Design><Research Personnel><Researchers><Respiratory Infections><Respiratory Tract Infections><S sonnei><S. sonnei><Scientific Publication><Sexually Transmitted Diseases><Sexually Transmitted Disorder><Sexually Transmitted Infection><Shigella sonnei><Site><Specialty><Study Type><Systems Biology><Technology><Testing><Therapeutic><Training><U-Series Cooperative Agreements><United States National Institutes of Health><Vaccines><Venereal Diseases><Venereal Disorders><Venereal Infections><adulthood><advanced age><ages><avian influenza H5N1><avian influenza H5N1 virus><biodefense><biologics><biopharmaceutical><biotherapeutic agent><clinical research site><clinical site><clinical trial implementation><data dissemination><data interpretation><data tools><design><designing><develop a vaccine><develop vaccines><development of a vaccine><developmental><elders><emerging pathogen><enroll><enteral pathogen><enteric pathogen><enteropathogen><epidemiologic><epidemiological><evaluate vaccines><expectant mother><expecting mother><flu vaccine><flu virus vaccine><geriatric><immunosuppressed patient><implementation of clinical trials><infectious disease treatment><influenza virus vaccine><innovate><innovation><innovative><intestinal pathogen><intestine pathogen><investigator-initiated trial><juvenile><juvenile human><late life><later life><medical specialties><mortality><neglected tropical diseases><new pathogen><novel><novel pathogen><older adult><older person><operation><organizational structure><predictive biomarkers><predictive marker><predictive molecular biomarker><pregnant mothers><prevent><preventing><prognostic biomarker><recruit><respiratory pathogen><response><senior citizen><study design><trial design><vaccination study><vaccination trial><vaccine against flu><vaccine against influenza><vaccine candidate><vaccine development><vaccine effectiveness><vaccine evaluation><vaccine screening><vaccine study><vaccine testing><vaccine trial><vaccine-induced immunity><vaccine-induced protection><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

CHARLES S FUCHS

YALE UNIVERSITY, NEW HAVEN, CT

Exploratory lead · 44/100

Likely hiring

Solid budget

Team-scale grant

$327,124

FY 2022

Project Title

Cancer Center Support Grant

Grant Number:

3P30CA016359-40S5

Activity Code:

P30

Mechanism:

Research Centers

Agency:

NIH

Start Date:

7/1/1997

End Date:

7/31/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

OVERALL PROJECT SUMMARY/ABSTRACT! Now in its 43rd year as an NCI-Designated Comprehensive Cancer Center, Yale Cancer Center (YCC) has established a strong tradition of high-impact cancer research and a deep culture of communication and collaboration that unites 286 basic, translational, population, ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Clarence Buddy Creech

VANDERBILT UNIVERSITY MEDICAL CENTER, NASHVILLE, TN

Exploratory lead · 44/100

Likely hiring

Solid budget

Team-scale grant

$303,464

FY 2022

Project Title

Vanderbilt Vaccine and Treatment Evaluation Unit

Grant Number:

3UM1AI148452-03S2

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/7/2021

End Date:

4/26/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

ABSTRACT The goal of this UM1 proposal is to use the remarkable research infrastructure at Vanderbilt University Medical Center and collaborating sites (Washington University, University of Pittsburgh, and University of Pennsylvania) to conceptualize, design, implement, and analyze clinical research...

Research Terms

<0-11 years old><21+ years old><Academic Medical Centers><Adult><Adult Human><Age><Area><Assay><Award><Bacterial Infections><Bioassay><Biologic Assays><Biologic Products><Biological Agent><Biological Assay><Biological Products><Body Tissues><Child><Child Youth><Childhood><Children (0-21)><Clinical><Clinical Investigator><Clinical Research><Clinical Study><Clinical Trials><Communicable Diseases><Conduct Clinical Trials><Data><Development><Disease><Disorder><Drugs><Education><Educational aspects><Elderly><Emerging Communicable Diseases><Emerging Infectious Diseases><Enrollment><Environment><Evaluation><Faculty><Feasibility Studies><Fellowship><Fostering><Funding><Fungus Diseases><Geography><Goals><Grippe><Home><Human><Immune response><Immunity><Immunization><Immunologic Sensitization><Immunologic Stimulation><Immunological Sensitization><Immunological Stimulation><Immunological response><Immunologist><Immunostimulation><Individual><Infant><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Influenza><Influenza Vaccines><Institution><International><Intervention><Intervention Strategies><Investigators><Laboratories><Laboratory Scientists><Lead><Leadership><Length of Life><Licensure><Longevity><Malaria><Malaria Vaccines><Malarial Vaccines><Medical><Medical center><Medication><Mentors><Mentorship><Methods><Modeling><Modern Man><Mycoses><NIH><National Institutes of Health><Nurses><Paludism><Parasitic infection><Pathogenesis><Pb element><Pennsylvania><Pertussis Vaccine><Peru><Pharmaceutic Preparations><Pharmaceutical Preparations><Phase><Physicians><Plasmodium Infections><Pneumococcal vaccine><Population><Population Heterogeneity><Position><Positioning Attribute><Pregnant Women><Prevention><Principal Investigator><Procedures><Process><Protocol><Protocols documentation><Research><Research Infrastructure><Research Personnel><Researchers><Safety><Scientist><Sexually Transmitted Diseases><Sexually Transmitted Disorder><Sexually Transmitted Infection><Site><Smallpox Vaccine><Special Population><Standardization><Streptococcus pneumoniae vaccine><Systems Biology><Tissues><Training><United States National Institutes of Health><Universities><University Medical Centers><Vaccination><Vaccine Research><Vaccines><Venereal Diseases><Venereal Disorders><Venereal Infections><Viral><Viral Diseases><Virus Diseases><Visit><Washington><Work><adulthood><advanced age><ages><antibiotic resistant infections><bacteria infection><bacterial disease><base><biologics><biopharmaceutical><biotherapeutic agent><career><career development><clinical research site><clinical site><co-morbid><co-morbidity><comorbidity><design><designing><developmental><diverse populations><drug/agent><early clinical trial><early phase clinical trial><elders><emerging pathogen><enroll><ethnic diversity><ethnically diverse><expectant mother><expecting mother><experience><flu vaccine><flu virus pandemic><flu virus vaccine><fungal infection><fungus infection><geriatric><heavy metal Pb><heavy metal lead><heterogeneous population><host response><immune system response><immunogenicity><immunoresponse><influenza virus pandemic><influenza virus vaccine><innovate><innovation><innovative><interventional strategy><late life><later life><life span><lifespan><new approaches><new drug treatments><new drugs><new pathogen><new therapeutics><new therapy><new vaccines><next generation><next generation therapeutics><next generation vaccines><novel><novel approaches><novel drug treatments><novel drugs><novel pathogen><novel strategies><novel strategy><novel therapeutics><novel therapy><novel vaccines><nurse><older adult><older person><pandemic flu><pandemic influenza><pandemic strain of influenza><parasite infection><pathogen><pediatric><population diversity><pregnant mothers><recruit><research study><respiratory><response><senior citizen><tool><vaccination study><vaccination trial><vaccine against flu><vaccine against influenza><vaccine study><vaccine trial><vaccines against malaria><vaccinology><viral infection><virus infection><virus-induced disease><volunteer><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mark Joseph Mulligan

NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NEW YORK, NY

Exploratory lead · 44/100

Likely hiring

Active award

Team-scale grant

$249,587

FY 2025

Project Title

Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU)

Grant Number:

3UM1AI148574-06S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/10/2020

End Date:

11/30/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY Establishment of New York University (NYU) Vaccine and Treatment Evaluation Unit (VTEU) is proposed in response to RFA-AI-18-046 entitled “Vaccine and Treatment Evaluation Units (VTEUs) (UM1 Clinical Trial Required)”. NYU VTEU will be one of the 10 fixed sites that will participate i...

Research Terms

<0-11 years old><21+ years old><AIDS><AIDS/HIV><Academic Medical Centers><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immunodeficiency Syndrome><Address><Admission><Admission activity><Adult><Adult Human><Airway infections><Anti-microbial Drug Resistance><Anti-microbial Drug Resistant><Antibiotic Agents><Antibiotic Drugs><Antibiotic Resistance><Antibiotics><Antigenic Determinants><Antimicrobial Drug Resistance><Antimicrobial Drug Resistant><Area><Assay><Avian Influenza><Award><Beds><Binding Determinants><Bioassay><Biological Agent><Biological Assay><Biological Markers><Biological Products><Biomedical Research><Bird Flu><Caring><Censuses><Cessation of life><Child><Child Youth><Childhood><Children (0-21)><Cities><Clinic><Clinical><Clinical Research><Clinical Study><Clinical Trials><Clinical Trials Unit><Clinics and Hospitals><Clinics or Hospitals><Communicable Diseases><Communities><Country><Death><Dedications><Dengue><Development><Devices><Diagnostic><Disease><Disorder><EHR system><Ebola><Educational process of instructing><Elements><Emerging infection><Enrollment><Enteral><Enteric><Epitopes><Evaluation><Facilities and Administrative Costs><Faculty><Fowl Pest><Fowl Plague><Funding><H1N1><H1N1 Virus><H5N1><H5N1 virus><H7N9><HIV/AIDS><Health><Health Care Systems><History><Hospitals><Human><IRB><IRBs><Immunology><Indirect Costs><Individual><Infection><Infectious Diseases><Infectious Diseases / Laboratory><Infectious Diseases Research><Infectious Disorder><Influenza A><Influenza A H5N1><Influenza A Virus, H1N1 Subtype><Influenza A Virus, H5N1 Subtype><Influenza A Virus, H7N9 Subtype><Influenza A virus><Influenza Vaccines><Influenza Viruses Type A><Influenzavirus A><Inpatients><Institution><Institutional Review Boards><International><Laboratories><Laboratory Research><Leadership><Long Island><M tuberculosis infection><M. tb infection><M. tuberculosis infection><M.tb infection><M.tuberculosis infection><MERS><MERS coronavirus disease><MERS-CoV disease><MTB infection><Malaria><Marriage><Medical Research><Microbial Drug Resistance><Middle East Respiratory Syndrome><Middle East Respiratory Syndrome CoV disease><Middle East Respiratory Syndrome coronavirus disease><Middle Eastern Respiratory Syndrome><Middle Eastern Respiratory Syndrome CoV disease><Middle Eastern Respiratory Syndrome coronavirus disease><Miscellaneous Antibiotic><Modeling><Modern Man><Molecular Epidemiology><Morbidity><Morbidity - disease rate><Multi-Drug Resistance><Multidrug Resistance><Multiple Drug Resistance><Multiple Drug Resistant><Mycobacterium tuberculosis (MTB) infection><Mycobacterium tuberculosis infection><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><New York><New York City><Nipah><Norovirus><Norwalk-like Viruses><Orthomyxovirus Type A><Out-patients><Outpatients><PK/PD><Paludism><Participant><Patient Care><Patient Care Delivery><Patient Recruitments><Patients><Plasmodium Infections><Population><Predictive Value><Preparedness><Procedures><Public Health><Qualifying><Readiness><Recording of previous events><Reporting><Research><Research Activity><Research Priority><Research Resources><Research Support><Resistance to Multi-drug><Resistance to Multidrug><Resistance to Multiple Drug><Resistance to antibiotics><Resistant to Multiple Drug><Resistant to antibiotics><Resistant to multi-drug><Resistant to multidrug><Resources><Respiratory Infections><Respiratory Tract Infections><SARS><SARS coronavirus disease><SARS-CoV disease><Seasons><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome coronavirus disease><Sexually Transmitted Diseases><Sexually Transmitted Disorder><Sexually Transmitted Infection><Site><Speed><Study Subject><Study models><System><TB infection><Teaching><Therapeutic><Time><Tuberculosis><Type A Influenza><United States National Institutes of Health><Universities><University Medical Centers><Vaccination><Vaccines><Venereal Diseases><Venereal Disorders><Venereal Infections><Viral><Visit><Work><ZIKA><adulthood><anti-microbial agent><anti-microbial drug><antibiotic drug resistance><antibiotic resistant><avian flu><avian influenza H5N1><avian influenza H5N1 virus><avian strains of influenza><bio-markers><biologic marker><biologics><biomarker><biopharmaceutical><biotherapeutic agent><care for patients><care of patients><caring for patients><combat><comparative><demographics><developmental><disseminated TB><disseminated tuberculosis><electronic health record system><emergent infection><enroll><experience><flu><flu vaccine><flu virus pandemic><flu virus vaccine><histories><improved><infection due to Mycobacterium tuberculosis><influenza in birds><influenza virus pandemic><influenza virus vaccine><innovate><innovation><innovative><kids><medical college><medical countermeasure><medical schools><metropolitan><microbial><microbial drug resistant><microbial genomics><microbiome><mortality><multi-drug resistant><multidrug resistant><multiomics><multiple omics><neglected tropical diseases><new approaches><news><novel><novel approaches><novel strategies><novel strategy><operation><operations><outreach><pan influenza vaccine><pan influenza viral vaccine><pan influenza virus vaccine><pandemic flu><pandemic influenza><pandemic strain of influenza><panomics><participant recruitment><pathogen><pediatric><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><pharmacokinetics and pharmacodynamics><priority pathogen><recruit><response><school of medicine><seasonal flu><seasonal influenza><sexually acquired infection><systems research><tuberculosis infection><tuberculous spondyloarthropathy><universal flu vaccine><universal influenza vaccine><universal influenza virus vaccine><universal vaccine against flu><universal vaccine against influenza><vaccine against flu><vaccine against influenza><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

KEITH T FLAHERTY

DANA-FARBER CANCER INST, BOSTON, MA

Exploratory lead · 44/100

Likely hiring

Active award

Team-scale grant

$194,240

FY 2025

Project Title

DF/HCC Preclinical Translation-Focused Clinical Investigator to Bridge PDXNet and the ETCTN

Grant Number:

3UM1CA186709-09S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/13/2014

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

ABSTRACT This application is being submitted to request the addition of a Preclinical Translation-Focused Clinical Investigator (PT-FCI) to the Dana-Farber/Harvard Cancer Center (DF/HCC) ETCTN UM1 Lead Academic Organization (LAO). Dr. Geoffrey Shapiro will serve as the DF/HCC PT-FCI. He has expertis...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

DONALD W. KUFE

DANA-FARBER CANCER INST, BOSTON, MA

Exploratory lead · 44/100

Likely hiring

Active award

Team-scale grant

$194,240

FY 2025

Project Title

DF/HCC Preclinical Translation-Focused Clinical Investigator to Bridge PDXNet and the ETCTN

Grant Number:

3UM1CA186709-09S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/13/2014

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

ABSTRACT This application is being submitted to request the addition of a Preclinical Translation-Focused Clinical Investigator (PT-FCI) to the Dana-Farber/Harvard Cancer Center (DF/HCC) ETCTN UM1 Lead Academic Organization (LAO). Dr. Geoffrey Shapiro will serve as the DF/HCC PT-FCI. He has expertis...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Geoffrey I. Shapiro

DANA-FARBER CANCER INST, BOSTON, MA

Exploratory lead · 44/100

Likely hiring

Active award

Team-scale grant

$194,240

FY 2025

Project Title

DF/HCC Preclinical Translation-Focused Clinical Investigator to Bridge PDXNet and the ETCTN

Grant Number:

3UM1CA186709-09S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/13/2014

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

ABSTRACT This application is being submitted to request the addition of a Preclinical Translation-Focused Clinical Investigator (PT-FCI) to the Dana-Farber/Harvard Cancer Center (DF/HCC) ETCTN UM1 Lead Academic Organization (LAO). Dr. Geoffrey Shapiro will serve as the DF/HCC PT-FCI. He has expertis...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mark Joseph Mulligan

NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NEW YORK, NY

Exploratory lead · 44/100

Likely hiring

Active award

Team-scale grant

$46,709

FY 2025

Project Title

Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU)

Grant Number:

3UM1AI148574-06S2

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/10/2020

End Date:

11/30/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY Establishment of New York University (NYU) Vaccine and Treatment Evaluation Unit (VTEU) is proposed in response to RFA-AI-18-046 entitled “Vaccine and Treatment Evaluation Units (VTEUs) (UM1 Clinical Trial Required)”. NYU VTEU will be one of the 10 fixed sites that will participate i...

Research Terms

<0-11 years old><21+ years old><AIDS><AIDS/HIV><Academic Medical Centers><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immunodeficiency Syndrome><Address><Admission><Admission activity><Adult><Adult Human><Airway infections><Anti-microbial Drug Resistance><Anti-microbial Drug Resistant><Antibiotic Agents><Antibiotic Drugs><Antibiotic Resistance><Antibiotics><Antigenic Determinants><Antimicrobial Drug Resistance><Antimicrobial Drug Resistant><Area><Assay><Avian Influenza><Award><Beds><Binding Determinants><Bioassay><Biological Agent><Biological Assay><Biological Markers><Biological Products><Biomedical Research><Bird Flu><Caring><Censuses><Cessation of life><Child><Child Youth><Childhood><Children (0-21)><Cities><Clinic><Clinical><Clinical Research><Clinical Study><Clinical Trials><Clinical Trials Unit><Clinics and Hospitals><Clinics or Hospitals><Communicable Diseases><Communities><Country><Death><Dedications><Dengue><Development><Devices><Diagnostic><Disease><Disorder><EHR system><Ebola><Educational process of instructing><Elements><Emerging infection><Enrollment><Enteral><Enteric><Epitopes><Evaluation><Facilities and Administrative Costs><Faculty><Fowl Pest><Fowl Plague><Funding><H1N1><H1N1 Virus><H5N1><H5N1 virus><H7N9><HIV/AIDS><Health><Health Care Systems><History><Hospitals><Human><IRB><IRBs><Immunology><Indirect Costs><Individual><Infection><Infectious Diseases><Infectious Diseases / Laboratory><Infectious Diseases Research><Infectious Disorder><Influenza A><Influenza A H5N1><Influenza A Virus, H1N1 Subtype><Influenza A Virus, H5N1 Subtype><Influenza A Virus, H7N9 Subtype><Influenza A virus><Influenza Vaccines><Influenza Viruses Type A><Influenzavirus A><Inpatients><Institution><Institutional Review Boards><International><Laboratories><Laboratory Research><Leadership><Long Island><M tuberculosis infection><M. tb infection><M. tuberculosis infection><M.tb infection><M.tuberculosis infection><MERS><MERS coronavirus disease><MERS-CoV disease><MTB infection><Malaria><Marriage><Medical Research><Microbial Drug Resistance><Middle East Respiratory Syndrome><Middle East Respiratory Syndrome CoV disease><Middle East Respiratory Syndrome coronavirus disease><Middle Eastern Respiratory Syndrome><Middle Eastern Respiratory Syndrome CoV disease><Middle Eastern Respiratory Syndrome coronavirus disease><Miscellaneous Antibiotic><Modeling><Modern Man><Molecular Epidemiology><Morbidity><Morbidity - disease rate><Multi-Drug Resistance><Multidrug Resistance><Multiple Drug Resistance><Multiple Drug Resistant><Mycobacterium tuberculosis (MTB) infection><Mycobacterium tuberculosis infection><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><New York><New York City><Nipah><Norovirus><Norwalk-like Viruses><Orthomyxovirus Type A><Out-patients><Outpatients><PK/PD><Paludism><Participant><Patient Care><Patient Care Delivery><Patient Recruitments><Patients><Plasmodium Infections><Population><Predictive Value><Preparedness><Procedures><Public Health><Qualifying><Readiness><Recording of previous events><Reporting><Research><Research Activity><Research Priority><Research Resources><Research Support><Resistance to Multi-drug><Resistance to Multidrug><Resistance to Multiple Drug><Resistance to antibiotics><Resistant to Multiple Drug><Resistant to antibiotics><Resistant to multi-drug><Resistant to multidrug><Resources><Respiratory Infections><Respiratory Tract Infections><SARS><SARS coronavirus disease><SARS-CoV disease><Seasons><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome coronavirus disease><Sexually Transmitted Diseases><Sexually Transmitted Disorder><Sexually Transmitted Infection><Site><Speed><Study Subject><Study models><System><TB infection><Teaching><Therapeutic><Time><Tuberculosis><Type A Influenza><United States National Institutes of Health><Universities><University Medical Centers><Vaccination><Vaccines><Venereal Diseases><Venereal Disorders><Venereal Infections><Viral><Visit><Work><ZIKA><adulthood><anti-microbial agent><anti-microbial drug><antibiotic drug resistance><antibiotic resistant><avian flu><avian influenza H5N1><avian influenza H5N1 virus><avian strains of influenza><bio-markers><biologic marker><biologics><biomarker><biopharmaceutical><biotherapeutic agent><care for patients><care of patients><caring for patients><combat><comparative><demographics><developmental><disseminated TB><disseminated tuberculosis><electronic health record system><emergent infection><enroll><experience><flu><flu vaccine><flu virus pandemic><flu virus vaccine><histories><improved><infection due to Mycobacterium tuberculosis><influenza in birds><influenza virus pandemic><influenza virus vaccine><innovate><innovation><innovative><kids><medical college><medical countermeasure><medical schools><metropolitan><microbial><microbial drug resistant><microbial genomics><microbiome><mortality><multi-drug resistant><multidrug resistant><multiomics><multiple omics><neglected tropical diseases><new approaches><news><novel><novel approaches><novel strategies><novel strategy><operation><operations><outreach><pan influenza vaccine><pan influenza viral vaccine><pan influenza virus vaccine><pandemic flu><pandemic influenza><pandemic strain of influenza><panomics><participant recruitment><pathogen><pediatric><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><pharmacokinetics and pharmacodynamics><priority pathogen><recruit><response><school of medicine><seasonal flu><seasonal influenza><sexually acquired infection><systems research><tuberculosis infection><tuberculous spondyloarthropathy><universal flu vaccine><universal influenza vaccine><universal influenza virus vaccine><universal vaccine against flu><universal vaccine against influenza><vaccine against flu><vaccine against influenza><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Michelle Hernandez

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Exploratory lead · 42/100

Large award

Active award

Career award

$1,620,000

FY 2025

Project Title

CTSA K12 Program at UNC

Grant Number:

5K12TR004416-03

Activity Code:

K12

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

7/6/2023

End Date:

6/30/2028

Why this may be worth a closer look

• Large budget suggests more room for personnel or project growth.

Project Abstract

There is an urgent need to develop a new type of scientist, one who is motivated by a need to bring scientific advances to clinics and communities in a timely fashion, and to make a long-term impact by contributing to health policies. This scientist is fluent in the language of team science and coll...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jonathan J Juliano

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Exploratory lead · 42/100

Large award

Active award

Career award

$1,620,000

FY 2025

Project Title

CTSA K12 Program at UNC

Grant Number:

5K12TR004416-03

Activity Code:

K12

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

7/6/2023

End Date:

6/30/2028

Why this may be worth a closer look

• Large budget suggests more room for personnel or project growth.

Project Abstract

There is an urgent need to develop a new type of scientist, one who is motivated by a need to bring scientific advances to clinics and communities in a timely fashion, and to make a long-term impact by contributing to health policies. This scientist is fluent in the language of team science and coll...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Franco Pestilli

UNIVERSITY OF TEXAS AT AUSTIN, AUSTIN, TX

Exploratory lead · 42/100

Large award

Active award

Team-scale grant

$1,213,341

FY 2025

Project Title

BRAIN CONNECTS: The Axonal Projectome EXchange (APEX)

Grant Number:

1U24NS140384-01

Activity Code:

U24

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

1/21/2025

End Date:

12/31/2029

Why this may be worth a closer look

• Large budget suggests more room for personnel or project growth.

Project Abstract

Project Summary The brain is the most complex organ in the human body. Millions of interconnected cells communicate through an intricate network of pathways to give rise to our cognition, perception, and emotional experiences. At present we lack an accurate and complete map of the axonal projections...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Anastasia Yendiki

UNIVERSITY OF TEXAS AT AUSTIN, AUSTIN, TX

Exploratory lead · 42/100

Large award

Active award

Team-scale grant

$1,213,341

FY 2025

Project Title

BRAIN CONNECTS: The Axonal Projectome EXchange (APEX)

Grant Number:

1U24NS140384-01

Activity Code:

U24

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

1/21/2025

End Date:

12/31/2029

Why this may be worth a closer look

• Large budget suggests more room for personnel or project growth.

Project Abstract

Project Summary The brain is the most complex organ in the human body. Millions of interconnected cells communicate through an intricate network of pathways to give rise to our cognition, perception, and emotional experiences. At present we lack an accurate and complete map of the axonal projections...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Raed A. Dweik

CASE WESTERN RESERVE UNIVERSITY, CLEVELAND, OH

Exploratory lead · 42/100

Large award

Active award

Career award

$1,078,928

FY 2025

Project Title

Clinical and Translational Science Collaborative of Northern Ohio, CTSA K12 Program at Case Western Reserve University

Grant Number:

1K12TR005469-01

Activity Code:

K12

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

8/15/2025

End Date:

6/30/2030

Why this may be worth a closer look

• Large budget suggests more room for personnel or project growth.

Project Abstract

The K12 proposed by the Clinical and Translational Research Collaborative of Northern Ohio is an innovative, flexible program to prepare a highly skilled cohort in clinical and translational (C/T) research to address the lack of optimal management strategies for hundreds of diseases and conditions a...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ruth Farrell

CASE WESTERN RESERVE UNIVERSITY, CLEVELAND, OH

Exploratory lead · 42/100

Large award

Active award

Career award

$1,078,928

FY 2025

Project Title

Clinical and Translational Science Collaborative of Northern Ohio, CTSA K12 Program at Case Western Reserve University

Grant Number:

1K12TR005469-01

Activity Code:

K12

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

8/15/2025

End Date:

6/30/2030

Why this may be worth a closer look

• Large budget suggests more room for personnel or project growth.

Project Abstract

The K12 proposed by the Clinical and Translational Research Collaborative of Northern Ohio is an innovative, flexible program to prepare a highly skilled cohort in clinical and translational (C/T) research to address the lack of optimal management strategies for hundreds of diseases and conditions a...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Leena Sharma

NORTHWESTERN UNIVERSITY AT CHICAGO, CHICAGO, IL

Exploratory lead · 42/100

Large award

Active award

Career award

$1,078,410

FY 2025

Project Title

NUCATS CTSA K12 Program at Northwestern University

Grant Number:

5K12TR005104-02

Activity Code:

K12

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

9/1/2024

End Date:

7/31/2029

Why this may be worth a closer look

• Large budget suggests more room for personnel or project growth.

Project Abstract

Leveraging our experience as a KL2 program, we submit this Northwestern University Clinical and Translational Sciences Institute (NUCATS) K12 application in conjunction with the NUCATS UM1, T32, and R25 applications. Through a needs assessment, brainstorming sessions, and interviews, we identified k...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

BETINA YANEZ

NORTHWESTERN UNIVERSITY AT CHICAGO, CHICAGO, IL

Exploratory lead · 42/100

Large award

Active award

Career award

$1,078,410

FY 2025

Project Title

NUCATS CTSA K12 Program at Northwestern University

Grant Number:

5K12TR005104-02

Activity Code:

K12

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

9/1/2024

End Date:

7/31/2029

Why this may be worth a closer look

• Large budget suggests more room for personnel or project growth.

Project Abstract

Leveraging our experience as a KL2 program, we submit this Northwestern University Clinical and Translational Sciences Institute (NUCATS) K12 application in conjunction with the NUCATS UM1, T32, and R25 applications. Through a needs assessment, brainstorming sessions, and interviews, we identified k...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Erika S Trapl

CASE WESTERN RESERVE UNIVERSITY, CLEVELAND, OH

Exploratory lead · 38/100

Training-friendly

Solid budget

Active award

$456,728

FY 2025

Project Title

Clinical and Translational Science Collaborative of Northern Ohio, CTSA Predoctoral T32 at Case Western Reserve University

Grant Number:

1T32TR004521-01A1

Activity Code:

T32

Mechanism:

Training, Institutional

Agency:

NIH

Start Date:

7/8/2025

End Date:

6/30/2030

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

Enter the text here that is the new abstract information for your application. This section must be no longer than 30 lines of text. Clinical and translational (C/T) scientists are increasingly important in biomedical research as they address critically unmet health needs. Consequently, translationa...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Scott Matthew Williams

CASE WESTERN RESERVE UNIVERSITY, CLEVELAND, OH

Exploratory lead · 38/100

Training-friendly

Solid budget

Active award

$456,728

FY 2025

Project Title

Clinical and Translational Science Collaborative of Northern Ohio, CTSA Predoctoral T32 at Case Western Reserve University

Grant Number:

1T32TR004521-01A1

Activity Code:

T32

Mechanism:

Training, Institutional

Agency:

NIH

Start Date:

7/8/2025

End Date:

6/30/2030

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

Enter the text here that is the new abstract information for your application. This section must be no longer than 30 lines of text. Clinical and translational (C/T) scientists are increasingly important in biomedical research as they address critically unmet health needs. Consequently, translationa...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

VICKI L ELLINGROD

UNIVERSITY OF MICHIGAN AT ANN ARBOR, ANN ARBOR, MI

Exploratory lead · 38/100

Training-friendly

Solid budget

Active award

$446,734

FY 2024

Project Title

CTSA Postdoctoral T32 at the University of Michigan

Grant Number:

1T32TR004764-01

Activity Code:

T32

Mechanism:

Training, Institutional

Agency:

NIH

Start Date:

12/1/2023

End Date:

11/30/2028

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

Project Summary The Michigan Institute for Clinical and Health Research (MICHR) at the University of Michigan seeks to develop a new postdoctoral T32 training program to prepare early-stage postdoctoral fellows for careers in translational science and research. This two-year program emphasizes train...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Steven Edward Harte

UNIVERSITY OF MICHIGAN AT ANN ARBOR, ANN ARBOR, MI

Exploratory lead · 38/100

Training-friendly

Solid budget

Active award

$446,734

FY 2024

Project Title

CTSA Postdoctoral T32 at the University of Michigan

Grant Number:

1T32TR004764-01

Activity Code:

T32

Mechanism:

Training, Institutional

Agency:

NIH

Start Date:

12/1/2023

End Date:

11/30/2028

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

Project Summary The Michigan Institute for Clinical and Health Research (MICHR) at the University of Michigan seeks to develop a new postdoctoral T32 training program to prepare early-stage postdoctoral fellows for careers in translational science and research. This two-year program emphasizes train...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Charles C Miller

UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, HOUSTON, TX

Exploratory lead · 36/100

Above-average budget

Active award

Career award

$972,000

FY 2025

Project Title

CTSA K12 Program at The University of Texas Health Science Center at Houston

Grant Number:

5K12TR004908-02

Activity Code:

K12

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

7/25/2024

End Date:

6/30/2029

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.

Project Abstract

The recent pandemic dramatically highlighted the need for a well-trained, highly adaptable clinical and translational science workforce; especially one that is capable of rapid design and deployment of clinical trials and key capabilities that accelerate research translation. The University of Texas...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

JON E. TYSON

UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, HOUSTON, TX

Exploratory lead · 36/100

Above-average budget

Active award

Career award

$972,000

FY 2025

Project Title

CTSA K12 Program at The University of Texas Health Science Center at Houston

Grant Number:

5K12TR004908-02

Activity Code:

K12

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

7/25/2024

End Date:

6/30/2029

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.

Project Abstract

The recent pandemic dramatically highlighted the need for a well-trained, highly adaptable clinical and translational science workforce; especially one that is capable of rapid design and deployment of clinical trials and key capabilities that accelerate research translation. The University of Texas...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

DEBORAH A HOGAN

DARTMOUTH-HITCHCOCK CLINIC, LEBANON, NH

Exploratory lead · 36/100

Above-average budget

Active award

Career award

$757,992

FY 2025

Project Title

Green Scholars in Translational Science Program at Dartmouth

Grant Number:

1K12TR004768-01A1

Activity Code:

K12

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

8/15/2025

End Date:

7/31/2030

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.

Project Abstract

The overall goal of the Green Scholars in Clinical and Translational Science K12 Program is to identify, recruit, train, and support high-potential early-career faculty, promoting the development and successful future of these scholars as independent investigators leading high-impact clinical and tr...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jon D Lurie

DARTMOUTH-HITCHCOCK CLINIC, LEBANON, NH

Exploratory lead · 36/100

Above-average budget

Active award

Career award

$757,992

FY 2025

Project Title

Green Scholars in Translational Science Program at Dartmouth

Grant Number:

1K12TR004768-01A1

Activity Code:

K12

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

8/15/2025

End Date:

7/31/2030

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.

Project Abstract

The overall goal of the Green Scholars in Clinical and Translational Science K12 Program is to identify, recruit, train, and support high-potential early-career faculty, promoting the development and successful future of these scholars as independent investigators leading high-impact clinical and tr...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Deepa Rastogi

ALBERT EINSTEIN COLLEGE OF MEDICINE, BRONX, NY

Exploratory lead · 36/100

Above-average budget

Active award

Career award

$756,000

FY 2025

Project Title

CTSA K12 Program at Einstein-Montefiore

Grant Number:

5K12TR004411-03

Activity Code:

K12

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

7/1/2023

End Date:

6/30/2028

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.

Project Abstract

This application seeks to continue a longstanding CTSA-supported career development program to identify, nurture, and support dedicated and talented health professionals and scientists so that they obtain the knowledge and skills they need to build successful, impactful careers as clinical/translati...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Shane A Phillips

UNIVERSITY OF ILLINOIS AT CHICAGO, Chicago, IL

Exploratory lead · 36/100

Above-average budget

Active award

Career award

$756,000

FY 2025

Project Title

UIC Center for Clinical And Translational Science: Advancing Health Training for All (K12)

Grant Number:

1K12TR005434-01

Activity Code:

K12

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

8/15/2025

End Date:

5/31/2030

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.

Project Abstract

The K12 program at the University of Illinois Chicago (UIC) program will focus on the development of scholars in clinical and translational sciences, with the overarching goal of bridging the divide between clinical scholar development and the needs of our research and external community. Our curren...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

PAUL R MARANTZ

ALBERT EINSTEIN COLLEGE OF MEDICINE, BRONX, NY

Exploratory lead · 36/100

Above-average budget

Active award

Career award

$756,000

FY 2023

Project Title

CTSA K12 Program at Einstein-Montefiore

Grant Number:

1K12TR004411-01

Activity Code:

K12

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

7/1/2023

End Date:

6/30/2028

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT This application seeks to continue a longstanding CTSA-supported career development program to identify, nurture, and support dedicated and talented health professionals and scientists so that they obtain the knowledge and skills they need to build successful, impactful careers as clinical/...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

SERGE PATRICK NANASINKAM

VIRGINIA COMMONWEALTH UNIVERSITY, RICHMOND, VA

Exploratory lead · 36/100

Above-average budget

Active award

Career award

$749,462

FY 2025

Project Title

CTSA K12 Program at Virginia Commonwealth University

Grant Number:

5K12TR004364-03

Activity Code:

K12

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

5/5/2023

End Date:

4/30/2028

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.

Project Abstract

Increasing burdens on the health system and reductions in overall community health highlight the critical importance of translational research to eradicate human disease, tackle emerging public health threats and promote health, for all Americans. To take on these challenges, we need a well-resource...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Gretchen N Neigh

VIRGINIA COMMONWEALTH UNIVERSITY, RICHMOND, VA

Exploratory lead · 36/100

Above-average budget

Active award

Career award

$749,462

FY 2025

Project Title

CTSA K12 Program at Virginia Commonwealth University

Grant Number:

5K12TR004364-03

Activity Code:

K12

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

5/5/2023

End Date:

4/30/2028

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.

Project Abstract

Increasing burdens on the health system and reductions in overall community health highlight the critical importance of translational research to eradicate human disease, tackle emerging public health threats and promote health, for all Americans. To take on these challenges, we need a well-resource...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

ARUN J SANYAL

VIRGINIA COMMONWEALTH UNIVERSITY, RICHMOND, VA

Exploratory lead · 36/100

Above-average budget

Active award

Career award

$749,462

FY 2023

Project Title

CTSA K12 Program at Virginia Commonwealth University

Grant Number:

1K12TR004364-01

Activity Code:

K12

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

5/5/2023

End Date:

4/30/2028

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.

Project Abstract

The COVID-19 pandemic highlighted the critical importance of translational research to eradicate human disease, tackle emerging public health threats and promote health, especially in hard-to-reach communities that face health disparities. To take on these challenges, we need a diverse, well-resourc...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Laura Starbird

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Exploratory lead · 36/100

Training-friendly

Active award

Career award

$182,596

FY 2024

Project Title

Implementation of PrEP for Women Who Inject Drugs through Practice Facilitation in Primary and Reproductive Health Care

Grant Number:

5K01DA051348-05

Activity Code:

K01

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

6/15/2020

End Date:

5/31/2026

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

PROJECT SUMMARY/ABSTRACT: The goal of this research is to prevent HIV among women who inject drugs (WWID) through organization-level change in the way pre-exposure prophylaxis (PrEP) is delivered to this population. Dr. Starbird is proposing a research and career development plan which will prepare ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Megan Rist Haymart

UNIVERSITY OF MICHIGAN AT ANN ARBOR, ANN ARBOR, MI

Exploratory lead · 34/100

Large award

Active award

$3,097,384

FY 2025

Project Title

mHealth Outcomes in Behavioral Interventions & Longitudinal Evaluation (MOBILE) Platform

Grant Number:

1RC2TR004899-01A1

Activity Code:

RC2

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

8/15/2025

End Date:

7/31/2029

Why this may be worth a closer look

• Large budget suggests more room for personnel or project growth.

Project Abstract

Clinical researchers increasingly recognize the potential for mobile health (mHealth) technologies to transform health and medicine by facilitating real-time data collection, self-management, and information sharing between patients, researchers, and clinicians. Yet despite their great promise, use ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Predrag Klasnja

UNIVERSITY OF MICHIGAN AT ANN ARBOR, ANN ARBOR, MI

Exploratory lead · 34/100

Large award

Active award

$3,097,384

FY 2025

Project Title

mHealth Outcomes in Behavioral Interventions & Longitudinal Evaluation (MOBILE) Platform

Grant Number:

1RC2TR004899-01A1

Activity Code:

RC2

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

8/15/2025

End Date:

7/31/2029

Why this may be worth a closer look

• Large budget suggests more room for personnel or project growth.

Project Abstract

Clinical researchers increasingly recognize the potential for mobile health (mHealth) technologies to transform health and medicine by facilitating real-time data collection, self-management, and information sharing between patients, researchers, and clinicians. Yet despite their great promise, use ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

BRAHMAJEE K NALLAMOTHU

UNIVERSITY OF MICHIGAN AT ANN ARBOR, ANN ARBOR, MI

Exploratory lead · 34/100

Large award

Active award

$3,097,384

FY 2025

Project Title

mHealth Outcomes in Behavioral Interventions & Longitudinal Evaluation (MOBILE) Platform

Grant Number:

1RC2TR004899-01A1

Activity Code:

RC2

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

8/15/2025

End Date:

7/31/2029

Why this may be worth a closer look

• Large budget suggests more room for personnel or project growth.

Project Abstract

Clinical researchers increasingly recognize the potential for mobile health (mHealth) technologies to transform health and medicine by facilitating real-time data collection, self-management, and information sharing between patients, researchers, and clinicians. Yet despite their great promise, use ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

RODNEY J.Y. HO

UNIVERSITY OF WASHINGTON, SEATTLE, WA

Exploratory lead · 34/100

Large award

Active award

$1,373,809

FY 2025

Project Title

NextGen Long-acting and targeted combination ART for Children with HIV

Grant Number:

5R33AI149665-05

Activity Code:

R33

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/6/2020

End Date:

3/31/2027

Why this may be worth a closer look

• Large budget suggests more room for personnel or project growth.

Project Abstract

ABSTRACT The Targeted, Long-acting and Combination Anti-Retroviral Therapeutic (TLC-ART) Program has developed a scalable, drug-combination nano-platform technology called DcNPs (drug combination nanoparticles) that enables the stabilizing of insoluble and soluble short-acting antiretroviral drugs t...

Research Terms

<0-11 years old><21+ years old><AIDS Virus><Abbreviations><Acceleration><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Adherence><Adolescent><Adolescent Youth><Adult><Adult Human><Anti-Retroviral Agents><Blood><Blood Plasma><Blood Reticuloendothelial System><Body Tissues><Cell Body><Cells><Child><Child Youth><Childhood><Children (0-21)><Clinical><Clinical Paths><Clinical Pathways><Combination Drug Therapy><Combined Modality Therapy><Communication><Data><Data Set><Deglutition><Development><Development Plans><Development and Research><Disease><Disorder><Dosage Forms><Dose><Drug Combinations><Drug Kinetics><Drug Targeting><Drugs><EC 2.7.7.49><Ensure><Evaluation><Exhibits><FDA approved><Fatigue><Food and Drug Administration><Formulation><Funding><Generic Drugs><HIV><HIV Integrase><HIV Integration Protein><HIV Protease><HIV Proteinase><HTLV-III Protease><Human Figure><Human Immunodeficiency Viruses><Human body><Hydrogen Oxide><Injectable><Integrase><Integrase Inhibitors><Investigational Drugs><Investigational New Drugs><Kaletra><LAV-HTLV-III><Lack of Energy><Lead><Lopinavir><Lopinavir/Ritonavir><Lymphadenopathy-Associated Virus><Marketing><Medication><Modeling><Multimodal Therapy><Multimodal Treatment><NHP models><NIAID><NIH><Nanoplatform><Nanotechnological platform><National Institute of Allergy and Infectious Disease><National Institutes of Health><Non-proprietary Drugs><Nonproprietary Drugs><Oral><PBPK><Pb element><Pharmaceutical Preparations><Pharmacokinetics><Phase><Plasma><Plasma Serum><Polychemotherapy><Primates><Primates Mammals><Process><Proteins><R & D><R&D><RNA Transcriptase><RNA-Dependent DNA Polymerase><RNA-Directed DNA Polymerase><Recommendation><Research><Research Resources><Resources><Reticuloendothelial System, Serum, Plasma><Reverse Transcriptase><Revertase><Ritonavir><Route><SHIV><Safety><Schedule><Source><Specific qualifier value><Specified><Suspension substance><Suspensions><Swallowing><Technology><Tenofovir><Testing><Therapeutic><Time><Tissues><USFDA><United States Food and Drug Administration><United States National Institutes of Health><Update><Validation><Viral><Viread><Virus-HIV><Water><Work><adulthood><anti-retroviral><anti-viral efficacy><antiretroviral therapy><antiretroviral treatment><clinical development><combat><combination chemotherapy><combination pharmacotherapy><combination therapy><combined modality treatment><combined treatment><developmental><drug action><drug/agent><first in man><first-in-human><full scale manufacturing><heavy metal Pb><heavy metal lead><industrial partnership><industry partner><industry partnership><innovate><innovation><innovative><interest><juvenile><juvenile human><kids><large scale manufacturing><large scale production><mass production><meeting><meetings><multi-modal therapy><multi-modal treatment><nano><nano particle><nano-sized particle><nanoparticle><nanosized particle><nanotechnology platform><new drug combination><new pharmacotherapy combination><non-human primate><nonhuman primate><nonhuman primate models><norvir><novel drug combination><novel pharmacotherapy combination><oral HIV><pediatric><pediatric HIV><pediatric human immunodeficiency virus><pharmacokinetic model><physiologically based pharmacokinetics><pill><pre-clinical development><preclinical development><preference><programs><public-private partnership><research and development><safety study><simian HIV><simian human immunodeficiency virus><success><technology platform><technology system><timeline><validations><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Robert Wilson Frenck

CINCINNATI CHILDRENS HOSP MED CTR, CINCINNATI, OH

Exploratory lead · 34/100

Likely hiring

Team-scale grant

$245,431

FY 2022

Project Title

Cincinnati Children's Hospital Medical Center Vaccine and Treatment Evaluation Units (UM1 Clinical Trial Required)

Grant Number:

3UM1AI148372-03S4

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

8/6/2021

End Date:

11/30/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY Throughout history, infectious diseases have been, and continue to be, a leading cause of morbidity and mortality throughout the world. While all ages are affected by infectious diseases, the ends of the spectrum of life (young children and elderly) are particularly vulnerable. Thus,...

Research Terms

<0-11 years old><21+ years old><Address><Adolescent><Adolescent Youth><Adult><Adult Human><Affect><Age><Airway infections><Applied Research><Applied Science><Area><Assay><Award><Bioassay><Biologic Assays><Biologic Products><Biological Agent><Biological Assay><Biological Products><Budgets><Child><Child Youth><Children (0-21)><Children's Hospital><Clinical><Clinical Research><Clinical Study><Clinical Trials><Collaborations><Communicable Diseases><Consent Documents><Consent Forms><Cooperative Agreements><Data Analyses><Data Analysis><Development><Devices><Diagnostic><Diagnostic Device><Diagnostic Equipment><Disease><Disease Outbreaks><Disorder><Elderly><Emerging Communicable Diseases><Emerging Infectious Diseases><Enrollment><Ensure><Enteral><Enteric><Epidemiology><Evaluation><Faculty><Future><Goals><Grippe><Group Structure><H1N1><H1N1 Virus><H5N1><H5N1 virus><History><Human><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunosuppressed Host><Infant><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Influenza><Influenza A Virus, H1N1 Subtype><Influenza A Virus, H5N1 Subtype><Influenza Vaccines><Informed Consent Documents><Informed Consent Forms><Intervention Trial><Interventional trial><Investigators><Laboratories><Leadership><Letters><Life><Manuals><Medical center><Mentors><Methods><Microbiology><Mission><Modeling><Modern Man><Modification><Morbidity><Morbidity - disease rate><Multi-center studies><Multicenter Studies><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><Norovirus><Norwalk-like Viruses><Ohio><Organization Charts><Out-patients><Outbreaks><Outpatients><Participant><Pediatric Hospitals><Performance><Persons><Phase><Population><Pregnant Women><Preparation><Prevention><Preventive><Prognostic Marker><Protocol><Protocols documentation><Public Health><Publications><Quality Control><Recording of previous events><Research Design><Research Personnel><Researchers><Respiratory Infections><Respiratory Tract Infections><S sonnei><S. sonnei><Scientific Publication><Sexually Transmitted Diseases><Sexually Transmitted Disorder><Sexually Transmitted Infection><Shigella sonnei><Site><Specialty><Study Type><Systems Biology><Technology><Testing><Therapeutic><Training><U-Series Cooperative Agreements><United States National Institutes of Health><Vaccines><Venereal Diseases><Venereal Disorders><Venereal Infections><adulthood><advanced age><ages><avian influenza H5N1><avian influenza H5N1 virus><biodefense><biologics><biopharmaceutical><biotherapeutic agent><clinical research site><clinical site><clinical trial implementation><data dissemination><data interpretation><data tools><design><designing><develop a vaccine><develop vaccines><development of a vaccine><developmental><elders><emerging pathogen><enroll><enteral pathogen><enteric pathogen><enteropathogen><epidemiologic><epidemiological><evaluate vaccines><expectant mother><expecting mother><flu vaccine><flu virus vaccine><geriatric><immunosuppressed patient><implementation of clinical trials><infectious disease treatment><influenza virus vaccine><innovate><innovation><innovative><intestinal pathogen><intestine pathogen><investigator-initiated trial><juvenile><juvenile human><late life><later life><medical specialties><mortality><neglected tropical diseases><new pathogen><novel><novel pathogen><older adult><older person><operation><organizational structure><predictive biomarkers><predictive marker><predictive molecular biomarker><pregnant mothers><prevent><preventing><prognostic biomarker><recruit><respiratory pathogen><response><senior citizen><study design><trial design><vaccination study><vaccination trial><vaccine against flu><vaccine against influenza><vaccine candidate><vaccine development><vaccine effectiveness><vaccine evaluation><vaccine screening><vaccine study><vaccine testing><vaccine trial><vaccine-induced immunity><vaccine-induced protection><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Donald YM Leung

NATIONAL JEWISH HEALTH, DENVER, CO

Exploratory lead · 34/100

Likely hiring

Team-scale grant

$234,998

FY 2023

Project Title

National Jewish Health CoFAR Clinical Research Unit

Grant Number:

5UM1AI130780-07

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/2/2017

End Date:

2/29/2024

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary/Abstract This application is being submitted in response to RFA-AI-15-051, Consortium for Food Allergy Research (CoFAR): Clinical Research Units (UM1). The goal of this proposal is to establish an infrastructure and clinical strategies to prevent and manage food allergy (FA). Our cen...

Research Terms

<2 year old><2 years of age><Academy><Allergens><Allergic Reaction><Allergic to food><Allergy><Allergy to food><American><Anaphylactic Reaction><Anaphylactic Shock><Anaphylaxis><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Antiinflammatories><Antiinflammatory Agents><Area><Asthma><Atopic Allergy><Atopic Dermatitis><Atopic Eczema><Atopic Neurodermatitis><Biological Specimen Banks><Biological Substance Banks><Birth><Bronchial Asthma><Cell Body><Cells><Childhood><Clinical><Clinical Protocols><Clinical Research><Clinical Study><Clinical Trials><Cohort Studies><Concurrent Studies><DNA><Data><Deoxyribonucleic Acid><Disseminated Neurodermatitis><Dysfunction><Elements><Environment><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Food><Food Allergy><Food Analyses><Food Analysis><Food Hypersensitivity><Functional Metagenomics><Functional disorder><Future><Goals><Health><House Dust><Housedust><Hydrogen Oxide><Hypersensitivity><IgE><Immune Plasma><Immunoglobulin E><Individual><Infant><Infrastructure><Investigators><Jewish><Judaism><Linoleic Acids><Measures><Metagenomics><Microbe><Microbiomics><Milk><Non-Polyadenylated RNA><Nuts><PBMC><Parturition><Pathogenicity><Pediatrics><Peripheral Blood Mononuclear Cell><Physiopathology><Prevention><Property><RNA><RNA Gene Products><Randomized><Recommendation><Research><Research Personnel><Researchers><Ribonucleic Acid><Risk><Role><S aureus><S. aureus><S. aureus infection><Sampling><Skin><Skin Care><Staph aureus><Staph aureus infection><Staphylococcus aureus><Staphylococcus aureus infection><Sunflower Oil><Swab><Technology><Trees><Water><Wheat><Work><age 2 years><aged 2 years><aged two years><allergic dermatitis><allergic eczema><anti-microbial><antiinflammatory><antimicrobial><atopic triad><atopy><biological specimen repository><biosample repository><biospecimen bank><biospecimen repository><clinical trial implementation><cohort><cutaneous barrier><dermal barrier><egg><environmental allergy><epidermal barrier><epigenetically><follower of religion Jewish><food allergen><high risk><home dust><household dust><implementation of clinical trials><infected with S. aureus><infected with Staph aureus><infected with Staphylococcus aureus><metatranscriptomics><microbiome research><microbiome science><microbiome studies><operation><operations><pathophysiology><pediatric><preservation><prevent><preventing><prospective><randomisation><randomization><randomly assigned><residential dust><respiratory><response><skills><skin barrier><social role><soy><specimen bank><specimen repository><standard of care><sunflower seed oil><transcriptomics><two year old><two years of age>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

FREDERICK Gerard MOELLER

VIRGINIA COMMONWEALTH UNIVERSITY, RICHMOND, VA

Exploratory lead · 34/100

Likely hiring

Team-scale grant

$215,488

FY 2024

Project Title

Wright Regional Center for Clinical and Translational Science

Grant Number:

3UM1TR004360-02S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/1/2023

End Date:

4/30/2025

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY/ABSTRACT Abstract of NCATS-Funded UM1 Project The C. Kenneth and Dianne Wright Center for Clinical and Translational Research (CCTR) at Virginia Commonwealth University (VCU) elevates clinical and translational science by strengthening community engagement efforts, promoting the deve...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Eric P. Winer

YALE UNIVERSITY, NEW HAVEN, CT

Exploratory lead · 34/100

Likely hiring

Team-scale grant

$209,375

FY 2023

Project Title

Cancer Center Support Grant

Grant Number:

3P30CA016359-43S6

Activity Code:

P30

Mechanism:

Research Centers

Agency:

NIH

Start Date:

7/1/1997

End Date:

7/31/2024

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

OVERALL PROJECT SUMMARY/ABSTRACT! Now in its 43rd year as an NCI-Designated Comprehensive Cancer Center, Yale Cancer Center (YCC) has established a strong tradition of high-impact cancer research and a deep culture of communication and collaboration that unites 286 basic, translational, population, ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Eric P. Winer

YALE UNIVERSITY, NEW HAVEN, CT

Exploratory lead · 34/100

Likely hiring

Team-scale grant

$209,375

FY 2022

Project Title

Cancer Center Support Grant

Grant Number:

3P30CA016359-43S2

Activity Code:

P30

Mechanism:

Research Centers

Agency:

NIH

Start Date:

7/1/1997

End Date:

7/31/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

OVERALL PROJECT SUMMARY/ABSTRACT! Now in its 43rd year as an NCI-Designated Comprehensive Cancer Center, Yale Cancer Center (YCC) has established a strong tradition of high-impact cancer research and a deep culture of communication and collaboration that unites 286 basic, translational, population, ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Clarence Buddy Creech

VANDERBILT UNIVERSITY MEDICAL CENTER, NASHVILLE, TN

Exploratory lead · 34/100

Likely hiring

Team-scale grant

$192,338

FY 2021

Project Title

Vanderbilt Vaccine and Treatment Evaluation Unit

Grant Number:

3UM1AI148452-02S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/25/2020

End Date:

11/30/2021

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

ABSTRACT The goal of this UM1 proposal is to use the remarkable research infrastructure at Vanderbilt University Medical Center and collaborating sites (Washington University, University of Pittsburgh, and University of Pennsylvania) to conceptualize, design, implement, and analyze clinical research...

Research Terms

<0-11 years old><21+ years old><Academic Medical Centers><Adult><Adult Human><Age><Area><Assay><Award><Bacterial Infections><Bioassay><Biologic Assays><Biological><Biological Assay><Body Tissues><Child><Child Youth><Childhood><Children (0-21)><Clinical><Clinical Investigator><Clinical Research><Clinical Study><Clinical Trials><Communicable Diseases><Conduct Clinical Trials><Data><Development><Disease><Disorder><Drugs><Education><Educational aspects><Elderly><Emerging Communicable Diseases><Emerging Infectious Diseases><Enrollment><Environment><Evaluation><Faculty><Feasibility Studies><Fellowship><Fostering><Funding><Fungus Diseases><Geography><Goals><Grippe><Home><Human><Immune response><Immunity><Immunization><Immunologic Sensitization><Immunologic Stimulation><Immunological Sensitization><Immunological Stimulation><Immunological response><Immunologist><Immunostimulation><Individual><Infant><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Influenza><Influenza Vaccines><Institution><International><Intervention><Intervention Strategies><Investigators><Laboratories><Laboratory Scientists><Lead><Leadership><Length of Life><Licensure><Longevity><Malaria><Malaria Vaccines><Malarial Vaccines><Medical><Medical center><Medication><Mentors><Mentorship><Methods><Modeling><Modern Man><Mycoses><NIH><National Institutes of Health><Nurses><Paludism><Parasitic infection><Pathogenesis><Pb element><Pennsylvania><Pertussis Vaccine><Peru><Pharmaceutic Preparations><Pharmaceutical Preparations><Phase><Physicians><Plasmodium Infections><Pneumococcal vaccine><Population><Population Heterogeneity><Position><Positioning Attribute><Pregnant Women><Prevention><Principal Investigator><Procedures><Process><Protocol><Protocols documentation><Research><Research Infrastructure><Research Personnel><Researchers><Safety><Scientist><Sexually Transmitted Diseases><Sexually Transmitted Disorder><Sexually Transmitted Infection><Site><Smallpox Vaccine><Special Population><Standardization><Streptococcus pneumoniae vaccine><Systems Biology><Tissues><Training><United States National Institutes of Health><Universities><University Medical Centers><Vaccination><Vaccine Research><Vaccines><Venereal Diseases><Venereal Disorders><Venereal Infections><Viral><Viral Diseases><Virus Diseases><Visit><Washington><Work><adulthood><advanced age><ages><antibiotic resistant infections><bacteria infection><bacterial disease><base><career><career development><clinical research site><clinical site><co-morbid><co-morbidity><comorbidity><design><designing><developmental><diverse populations><drug/agent><early clinical trial><early phase clinical trial><elders><emerging pathogen><enroll><ethnic diversity><ethnically diverse><expectant mother><expecting mother><experience><flu vaccine><flu virus pandemic><flu virus vaccine><fungal infection><fungus infection><geriatric><heavy metal Pb><heavy metal lead><heterogeneous population><host response><immune system response><immunogenicity><immunoresponse><influenza virus pandemic><influenza virus vaccine><innovate><innovation><innovative><interventional strategy><late life><later life><life span><lifespan><new approaches><new drug treatments><new drugs><new pathogen><new therapeutics><new therapy><new vaccines><next generation><next generation therapeutics><next generation vaccines><novel><novel approaches><novel drug treatments><novel drugs><novel pathogen><novel strategies><novel strategy><novel therapeutics><novel therapy><novel vaccines><nurse><older adult><older person><pandemic flu><pandemic influenza><pandemic strain of influenza><parasite infection><pathogen><pediatric><population diversity><pregnant mothers><recruit><research study><respiratory><response><senior citizen><tool><vaccination study><vaccination trial><vaccine against flu><vaccine against influenza><vaccine study><vaccine trial><vaccines against malaria><vaccinology><viral infection><virus infection><virus-induced disease><volunteer><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ignacio E. Sanz

EMORY UNIVERSITY, ATLANTA, GA

Exploratory lead · 34/100

Likely hiring

Team-scale grant

$171,686

FY 2021

Project Title

Molecular Regulation of B cells and T cells in Human SLE

Grant Number:

3U19AI110483-08S3

Activity Code:

U19

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/21/2021

End Date:

4/30/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

The overarching objective of the Emory Autoimmunity Center of Excellence (ACE) U19 is to decipher the molecular programs responsible for the aberrant effector immune responses that lead to autoimmune disease. Specifically, based on the work performed by the Emory ACE during the current funding cycle...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Steven D Leach

DARTMOUTH COLLEGE, HANOVER, NH

Exploratory lead · 34/100

Likely hiring

Team-scale grant

$100,000

FY 2023

Project Title

Implementation of electronic patient reported outcomes and impact on communication with patients

Grant Number:

3P30CA023108-44S1

Activity Code:

P30

Mechanism:

Research Centers

Agency:

NIH

Start Date:

8/4/1997

End Date:

11/30/2024

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Abstract This application is submitted in response to the Notice of Special Interest (NOSI) identified as NOT-CA-23-041. “Implementation of Electronic Patient Reported Outcomes and Impact on Communication with Patients” leverages a unique opportunity (1) to evaluate sustainability of the use...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Patricia M. LoRusso

YALE UNIVERSITY, NEW HAVEN, CT

Exploratory lead · 34/100

Likely hiring

Team-scale grant

$100,000

FY 2021

Project Title

Administrative Supplement for VICKtOrY Early Clinical Trials Consortium

Grant Number:

3UM1CA186689-06S3

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2021

End Date:

2/28/2022

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

ABSTRACT: This application is being submitted to request additional funds for three Affiliated Organizations (AOs) to an NCI Experimental Therapeutics-Clinical Trials Network (ETCTN) UM1 Lead Academic Organization. The purpose of the ETCTN is to develop new therapeutic options while also defining be...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

SUSANNE M ARNOLD

OHIO STATE UNIVERSITY, Columbus, OH

Exploratory lead · 34/100

Likely hiring

Team-scale grant

$100,000

FY 2021

Project Title

The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network

Grant Number:

3UM1CA186712-06S2

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/12/2021

End Date:

2/28/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY The LAO OH-007 UM1 research group consists of an experienced and innovative multi-disciplinary team of basic scientists and clinical investigators dedicated to finding effective new therapies for patients with cancer utilizing the resources available through CTEP NCI. The Ohio State ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

WILLIAM E. CARSON

OHIO STATE UNIVERSITY, Columbus, OH

Exploratory lead · 34/100

Likely hiring

Team-scale grant

$100,000

FY 2021

Project Title

The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network

Grant Number:

3UM1CA186712-06S2

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/12/2021

End Date:

2/28/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY The LAO OH-007 UM1 research group consists of an experienced and innovative multi-disciplinary team of basic scientists and clinical investigators dedicated to finding effective new therapies for patients with cancer utilizing the resources available through CTEP NCI. The Ohio State ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ignacio Garrido-Laguna

OHIO STATE UNIVERSITY, Columbus, OH

Exploratory lead · 34/100

Likely hiring

Team-scale grant

$100,000

FY 2021

Project Title

The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network

Grant Number:

3UM1CA186712-06S2

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/12/2021

End Date:

2/28/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY The LAO OH-007 UM1 research group consists of an experienced and innovative multi-disciplinary team of basic scientists and clinical investigators dedicated to finding effective new therapies for patients with cancer utilizing the resources available through CTEP NCI. The Ohio State ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Robert Wilson Frenck

CINCINNATI CHILDRENS HOSP MED CTR, CINCINNATI, OH

Exploratory lead · 34/100

Likely hiring

Team-scale grant

$92,389

FY 2022

Project Title

Cincinnati Children's Hospital Medical Center Vaccine and Treatment Evaluation Units (UM1 Clinical Trial Required)

Grant Number:

3UM1AI148372-03S1

Activity Code:

UM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/11/2019

End Date:

11/30/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY Throughout history, infectious diseases have been, and continue to be, a leading cause of morbidity and mortality throughout the world. While all ages are affected by infectious diseases, the ends of the spectrum of life (young children and elderly) are particularly vulnerable. Thus,...

Research Terms

<0-11 years old><21+ years old><Address><Adolescent><Adolescent Youth><Adult><Adult Human><Affect><Age><Airway infections><Applied Research><Applied Science><Area><Assay><Award><Bioassay><Biologic Assays><Biologic Products><Biological Agent><Biological Assay><Biological Products><Budgets><Child><Child Youth><Children (0-21)><Children's Hospital><Clinical><Clinical Research><Clinical Study><Clinical Trials><Collaborations><Communicable Diseases><Consent Documents><Consent Forms><Cooperative Agreements><Data Analyses><Data Analysis><Development><Devices><Diagnostic><Diagnostic Device><Diagnostic Equipment><Disease><Disease Outbreaks><Disorder><Elderly><Emerging Communicable Diseases><Emerging Infectious Diseases><Enrollment><Ensure><Enteral><Enteric><Epidemiology><Evaluation><Faculty><Future><Goals><Grippe><Group Structure><H1N1><H1N1 Virus><H5N1><H5N1 virus><History><Human><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunosuppressed Host><Infant><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Influenza><Influenza A Virus, H1N1 Subtype><Influenza A Virus, H5N1 Subtype><Influenza Vaccines><Informed Consent Documents><Informed Consent Forms><Intervention Trial><Interventional trial><Investigators><Laboratories><Leadership><Letters><Life><Manuals><Medical center><Mentors><Methods><Microbiology><Mission><Modeling><Modern Man><Modification><Morbidity><Morbidity - disease rate><Multi-center studies><Multicenter Studies><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><Norovirus><Norwalk-like Viruses><Ohio><Organization Charts><Out-patients><Outbreaks><Outpatients><Participant><Pediatric Hospitals><Performance><Persons><Phase><Population><Pregnant Women><Preparation><Prevention><Preventive><Prognostic Marker><Protocol><Protocols documentation><Public Health><Publications><Quality Control><Recording of previous events><Research Design><Research Personnel><Researchers><Respiratory Infections><Respiratory Tract Infections><S sonnei><S. sonnei><Scientific Publication><Sexually Transmitted Diseases><Sexually Transmitted Disorder><Sexually Transmitted Infection><Shigella sonnei><Site><Specialty><Study Type><Systems Biology><Technology><Testing><Therapeutic><Training><U-Series Cooperative Agreements><United States National Institutes of Health><Vaccines><Venereal Diseases><Venereal Disorders><Venereal Infections><adulthood><advanced age><ages><avian influenza H5N1><avian influenza H5N1 virus><biodefense><biologics><biopharmaceutical><biotherapeutic agent><clinical research site><clinical site><clinical trial implementation><data dissemination><data interpretation><data tools><design><designing><develop a vaccine><develop vaccines><development of a vaccine><developmental><elders><emerging pathogen><enroll><enteral pathogen><enteric pathogen><enteropathogen><epidemiologic><epidemiological><evaluate vaccines><expectant mother><expecting mother><flu vaccine><flu virus vaccine><geriatric><immunosuppressed patient><implementation of clinical trials><infectious disease treatment><influenza virus vaccine><innovate><innovation><innovative><intestinal pathogen><intestine pathogen><investigator-initiated trial><juvenile><juvenile human><late life><later life><medical specialties><mortality><neglected tropical diseases><new pathogen><novel><novel pathogen><older adult><older person><operation><organizational structure><predictive biomarkers><predictive marker><predictive molecular biomarker><pregnant mothers><prevent><preventing><prognostic biomarker><recruit><respiratory pathogen><response><senior citizen><study design><trial design><vaccination study><vaccination trial><vaccine against flu><vaccine against influenza><vaccine candidate><vaccine development><vaccine effectiveness><vaccine evaluation><vaccine screening><vaccine study><vaccine testing><vaccine trial><vaccine-induced immunity><vaccine-induced protection><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Steven D Leach

DARTMOUTH COLLEGE, HANOVER, NH

Exploratory lead · 34/100

Likely hiring

Team-scale grant

$75,000

FY 2022

Project Title

Administrative supplement for Early Drug Development Opportunity Program (EDDOP)

Grant Number:

3P30CA023108-43S2

Activity Code:

P30

Mechanism:

Research Centers

Agency:

NIH

Start Date:

9/1/2022

End Date:

11/30/2024

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

ABSTRACT This proposal addresses Dartmouth Cancer Center’s (DCC) ability to conduct and participate in cancer early phase clinical trials through the Experimental Therapeutics Clinical Trials Network (ETCTN) of the National Cancer Institute (NCI). It serves as a comprehensive response to the NCI’s P...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

KUNLE ODUNSI

UNIVERSITY OF CHICAGO, CHICAGO, IL

Exploratory lead · 34/100

Likely hiring

Team-scale grant

$74,665

FY 2023

Project Title

CCSG - Administrative Supplement - ETCTN EDDOP {Accruals} 2022

Grant Number:

3P30CA014599-47S4

Activity Code:

P30

Mechanism:

Research Centers

Agency:

NIH

Start Date:

9/1/1997

End Date:

3/31/2024

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY This application is being submitted in response to the PA-20-272. This application supports participation of the University of Chicago Medicine Comprehensive Cancer Center (UCCCC) in the Early Therapeutics-Clinical Trials Network (ETCTN) to provide access by NCI Cancer Centers to age...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Eric P. Winer

YALE UNIVERSITY, NEW HAVEN, CT

Exploratory lead · 34/100

Likely hiring

Team-scale grant

$60,000

FY 2022

Project Title

Cancer Center Support Grant

Grant Number:

3P30CA016359-43S1

Activity Code:

P30

Mechanism:

Research Centers

Agency:

NIH

Start Date:

7/1/1997

End Date:

7/31/2023

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

OVERALL PROJECT SUMMARY/ABSTRACT! Now in its 43rd year as an NCI-Designated Comprehensive Cancer Center, Yale Cancer Center (YCC) has established a strong tradition of high-impact cancer research and a deep culture of communication and collaboration that unites 286 basic, translational, population, ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ignacio E. Sanz

EMORY UNIVERSITY, ATLANTA, GA

Exploratory lead · 34/100

Likely hiring

Team-scale grant

$46,256

FY 2022

Project Title

Molecular Regulation of B cells and T cells in Human SLE

Grant Number:

3U19AI110483-09S1

Activity Code:

U19

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/1/2014

End Date:

4/30/2024

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

The overarching objective of the Emory Autoimmunity Center of Excellence (ACE) U19 is to decipher the molecular programs responsible for the aberrant effector immune responses that lead to autoimmune disease. Specifically, based on the work performed by the Emory ACE during the current funding cycle...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Cheryl A London

TUFTS UNIVERSITY BOSTON, BOSTON, MA

Exploratory lead · 28/100

Above-average budget

Active award

$815,091

FY 2025

Project Title

Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention

Grant Number:

5RC2TR004377-03

Activity Code:

RC2

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/20/2023

End Date:

6/30/2028

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Experimentally induced animal models of disease play a critical role in the development, evaluation and optimization of therapeutics for human disease. With the advent of genetic engineering, such model systems have substantially improved; however, translational failure rates remain ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

ANTHONY BLIKSLAGER

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Exploratory lead · 28/100

Above-average budget

Active award

$768,064

FY 2025

Project Title

Porcine Related apprOach to Multidisciplinary cOllaborative Translational ModEl Research (PROMOTER)

Grant Number:

1RC2TR005123-01A1

Activity Code:

RC2

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/15/2025

End Date:

5/31/2030

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.

Project Abstract

Porcine Related Approach to Multidisciplinary Collaborative Translational Model Research (PROMOTER) ABSTRACT Large animal models of human disease are essential to the development, testing, and translation of therapeutics, but fully characterized large animal models of digestive diseases are relative...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Evan Samuel Dellon

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Exploratory lead · 28/100

Above-average budget

Active award

$768,064

FY 2025

Project Title

Porcine Related apprOach to Multidisciplinary cOllaborative Translational ModEl Research (PROMOTER)

Grant Number:

1RC2TR005123-01A1

Activity Code:

RC2

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/15/2025

End Date:

5/31/2030

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.

Project Abstract

Porcine Related Approach to Multidisciplinary Collaborative Translational Model Research (PROMOTER) ABSTRACT Large animal models of human disease are essential to the development, testing, and translation of therapeutics, but fully characterized large animal models of digestive diseases are relative...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

LISA A CAREY

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Exploratory lead · 28/100

Solid budget

Active award

Team-scale grant

$454,681

FY 2024

Project Title

UNC Lead Academic Participating Site

Grant Number:

5UG1CA233373-06

Activity Code:

UG1

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

5/1/2019

End Date:

2/28/2027

Project Abstract

UNC Lineberger Comprehensive Cancer Center (UNC LCCC) seeks to continue to serve as a Lead Academic Participating Site for the National Clinical Trials Network (NCTN). UNC LCCC is the only public NCI-designated comprehensive cancer center in North Carolina, dedicated to improving outcomes of cancer ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Matthew I Milowsky

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Exploratory lead · 28/100

Solid budget

Active award

Team-scale grant

$454,681

FY 2024

Project Title

UNC Lead Academic Participating Site

Grant Number:

5UG1CA233373-06

Activity Code:

UG1

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

5/1/2019

End Date:

2/28/2027

Project Abstract

UNC Lineberger Comprehensive Cancer Center (UNC LCCC) seeks to continue to serve as a Lead Academic Participating Site for the National Clinical Trials Network (NCTN). UNC LCCC is the only public NCI-designated comprehensive cancer center in North Carolina, dedicated to improving outcomes of cancer ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

LISA A CAREY

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Exploratory lead · 28/100

Solid budget

Active award

Team-scale grant

$454,679

FY 2025

Project Title

UNC Lead Academic Participating Site

Grant Number:

3UG1CA233373-06S1

Activity Code:

UG1

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

5/1/2019

End Date:

2/28/2027

Project Abstract

UNC Lineberger Comprehensive Cancer Center (UNC LCCC) seeks to continue to serve as a Lead Academic Participating Site for the National Clinical Trials Network (NCTN). UNC LCCC is the only public NCI-designated comprehensive cancer center in North Carolina, dedicated to improving outcomes of cancer ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

ELIZABETH CLAIRE DEES

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Exploratory lead · 28/100

Solid budget

Active award

Team-scale grant

$454,679

FY 2025

Project Title

UNC Lead Academic Participating Site

Grant Number:

3UG1CA233373-06S1

Activity Code:

UG1

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

5/1/2019

End Date:

2/28/2027

Project Abstract

UNC Lineberger Comprehensive Cancer Center (UNC LCCC) seeks to continue to serve as a Lead Academic Participating Site for the National Clinical Trials Network (NCTN). UNC LCCC is the only public NCI-designated comprehensive cancer center in North Carolina, dedicated to improving outcomes of cancer ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ellen L Jones

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Exploratory lead · 28/100

Solid budget

Active award

Team-scale grant

$454,679

FY 2025

Project Title

UNC Lead Academic Participating Site

Grant Number:

3UG1CA233373-06S1

Activity Code:

UG1

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

5/1/2019

End Date:

2/28/2027

Project Abstract

UNC Lineberger Comprehensive Cancer Center (UNC LCCC) seeks to continue to serve as a Lead Academic Participating Site for the National Clinical Trials Network (NCTN). UNC LCCC is the only public NCI-designated comprehensive cancer center in North Carolina, dedicated to improving outcomes of cancer ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Matthew I Milowsky

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Exploratory lead · 28/100

Solid budget

Active award

Team-scale grant

$454,679

FY 2025

Project Title

UNC Lead Academic Participating Site

Grant Number:

3UG1CA233373-06S1

Activity Code:

UG1

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

5/1/2019

End Date:

2/28/2027

Project Abstract

UNC Lineberger Comprehensive Cancer Center (UNC LCCC) seeks to continue to serve as a Lead Academic Participating Site for the National Clinical Trials Network (NCTN). UNC LCCC is the only public NCI-designated comprehensive cancer center in North Carolina, dedicated to improving outcomes of cancer ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Linda Van Le

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Exploratory lead · 28/100

Solid budget

Active award

Team-scale grant

$454,679

FY 2025

Project Title

UNC Lead Academic Participating Site

Grant Number:

3UG1CA233373-06S1

Activity Code:

UG1

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

5/1/2019

End Date:

2/28/2027

Project Abstract

UNC Lineberger Comprehensive Cancer Center (UNC LCCC) seeks to continue to serve as a Lead Academic Participating Site for the National Clinical Trials Network (NCTN). UNC LCCC is the only public NCI-designated comprehensive cancer center in North Carolina, dedicated to improving outcomes of cancer ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

PAUL R MARANTZ

ALBERT EINSTEIN COLLEGE OF MEDICINE, BRONX, NY

Exploratory lead · 28/100

Training-friendly

Active award

$227,398

FY 2023

Project Title

CTSA Predoctoral T32 at Albert Einstein College of Medicine

Grant Number:

1T32TR004537-01

Activity Code:

T32

Mechanism:

Training, Institutional

Agency:

NIH

Start Date:

7/6/2023

End Date:

6/30/2028

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

ABSTRACT This application seeks to continue a longstanding CTSA-supported predoctoral program, the PhD in Clinical Investigation (PCI) at the Albert Einstein College of Medicine (Einstein). PCI combines specialized training to prepare biomedical scientists to understand and appreciate the methodolog...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Juilee Thakar

UNIVERSITY OF ROCHESTER, ROCHESTER, NY

Exploratory lead · 28/100

Training-friendly

Active award

$223,364

FY 2025

Project Title

CTSA Predoctoral T32 Program at University of Rochester

Grant Number:

1T32TR005439-01

Activity Code:

T32

Mechanism:

Training, Institutional

Agency:

NIH

Start Date:

9/12/2025

End Date:

8/31/2030

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

The University of Rochester (UR) Clinical and Translational Science Institute (CTSI) T32 Pre-Doctoral Training Program aims to cultivate the next generation of leaders in translational science research (TSR). It encompasses a comprehensive mentored research experience, transdisciplinary educational ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Edwin van Wijngaarden

UNIVERSITY OF ROCHESTER, ROCHESTER, NY

Exploratory lead · 28/100

Training-friendly

Active award

$223,364

FY 2025

Project Title

CTSA Predoctoral T32 Program at University of Rochester

Grant Number:

1T32TR005439-01

Activity Code:

T32

Mechanism:

Training, Institutional

Agency:

NIH

Start Date:

9/12/2025

End Date:

8/31/2030

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

The University of Rochester (UR) Clinical and Translational Science Institute (CTSI) T32 Pre-Doctoral Training Program aims to cultivate the next generation of leaders in translational science research (TSR). It encompasses a comprehensive mentored research experience, transdisciplinary educational ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

H Dean Hosgood

ALBERT EINSTEIN COLLEGE OF MEDICINE, BRONX, NY

Exploratory lead · 28/100

Training-friendly

Active award

$218,364

FY 2025

Project Title

CTSA Predoctoral T32 at Albert Einstein College of Medicine

Grant Number:

5T32TR004537-03

Activity Code:

T32

Mechanism:

Training, Institutional

Agency:

NIH

Start Date:

7/6/2023

End Date:

6/30/2028

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

This application seeks to continue a longstanding CTSA-supported predoctoral program, the PhD in Clinical Investigation (PCI) at the Albert Einstein College of Medicine (Einstein). PCI combines specialized training to prepare biomedical scientists to understand and appreciate the methodologies of cl...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

VINCENT James CAIOZZO

UNIVERSITY OF CALIFORNIA-IRVINE, IRVINE, CA

Exploratory lead · 28/100

Training-friendly

Active award

$168,352

FY 2025

Project Title

Institute for Clinical and Translational Science NRSA Postdoctoral Research Training Core

Grant Number:

1T32TR005459-01

Activity Code:

T32

Mechanism:

Training, Institutional

Agency:

NIH

Start Date:

7/1/2025

End Date:

6/30/2030

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

The goal of the proposed T32 Postdoctoral Program is to provide a robust mentored career development and training environment that pursues the following specific aims. Specific Aim 1: Champion mentored career development and training by nurturing an integrated T32 Postdoctoral Program that consists ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Michael Demetriou

UNIVERSITY OF CALIFORNIA-IRVINE, IRVINE, CA

Exploratory lead · 28/100

Training-friendly

Active award

$168,352

FY 2025

Project Title

Institute for Clinical and Translational Science NRSA Postdoctoral Research Training Core

Grant Number:

1T32TR005459-01

Activity Code:

T32

Mechanism:

Training, Institutional

Agency:

NIH

Start Date:

7/1/2025

End Date:

6/30/2030

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

The goal of the proposed T32 Postdoctoral Program is to provide a robust mentored career development and training environment that pursues the following specific aims. Specific Aim 1: Champion mentored career development and training by nurturing an integrated T32 Postdoctoral Program that consists ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Elizabeth Head

UNIVERSITY OF CALIFORNIA-IRVINE, IRVINE, CA

Exploratory lead · 28/100

Training-friendly

Active award

$168,352

FY 2025

Project Title

Institute for Clinical and Translational Science NRSA Postdoctoral Research Training Core

Grant Number:

1T32TR005459-01

Activity Code:

T32

Mechanism:

Training, Institutional

Agency:

NIH

Start Date:

7/1/2025

End Date:

6/30/2030

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

The goal of the proposed T32 Postdoctoral Program is to provide a robust mentored career development and training environment that pursues the following specific aims. Specific Aim 1: Champion mentored career development and training by nurturing an integrated T32 Postdoctoral Program that consists ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Lauren M Aleksunes

RUTGERS BIOMEDICAL AND HEALTH SCIENCES, Newark, NJ

Exploratory lead · 28/100

Training-friendly

Active award

$106,372

FY 2025

Project Title

5/6 NJ ACTS: A Platform for Translational Science in New Jersey: CTSA R25 at Rutgers, Biomedical Health Sciences

Grant Number:

5R25TR004777-02

Activity Code:

R25

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

9/1/2024

End Date:

8/31/2029

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

PROJECT SUMMARY Creating a pathway for trainees to enter the clinical and translational science (CTS) workforce, including students from backgrounds often underrepresented in STEM and CTS, requires early engagement while in training. Addressing the needs of trainees at the forefront of their CTS edu...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Celine Gelinas

RUTGERS BIOMEDICAL AND HEALTH SCIENCES, Newark, NJ

Exploratory lead · 28/100

Training-friendly

Active award

$106,372

FY 2025

Project Title

5/6 NJ ACTS: A Platform for Translational Science in New Jersey: CTSA R25 at Rutgers, Biomedical Health Sciences

Grant Number:

5R25TR004777-02

Activity Code:

R25

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

9/1/2024

End Date:

8/31/2029

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

PROJECT SUMMARY Creating a pathway for trainees to enter the clinical and translational science (CTS) workforce, including students from backgrounds often underrepresented in STEM and CTS, requires early engagement while in training. Addressing the needs of trainees at the forefront of their CTS edu...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Christine Tagliaferri Rael

UNIVERSITY OF COLORADO DENVER, Aurora, CO

Exploratory lead · 26/100

Training-friendly

Career award

$51,681

FY 2022

Project Title

Supplement: Developing Tailored Delivery and Adherence Interventions for use of Long-Acting Biomedical HIV Prevention Strategies by Transgender Women

Grant Number:

3K01MH115785-04S1

Activity Code:

K01

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

9/1/2021

End Date:

8/31/2023

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

The proposed K01 Award provides the candidate with the skills needed to achieve her long-term goal of becoming an independent investigator in the field of biomedical HIV prevention focused on transgender women (TW). To do this, the candidate will submit an R01 to develop TW-focused strategies to imp...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Laura Starbird

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Exploratory lead · 26/100

Training-friendly

Career award

$49,769

FY 2022

Project Title

Implementation of PrEP for Women Who Inject Drugs through Practice Facilitation in Primary and Reproductive Health Care

Grant Number:

3K01DA051348-02S1

Activity Code:

K01

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

6/15/2020

End Date:

5/31/2025

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

PROJECT SUMMARY/ABSTRACT: The goal of this research is to prevent HIV among women who inject drugs (WWID) through organization-level change in the way pre-exposure prophylaxis (PrEP) is delivered to this population. Dr. Starbird is proposing a research and career development plan which will prepare ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ann Jorns Melvin

UNIVERSITY OF WASHINGTON, SEATTLE, WA

Exploratory lead · 24/100

Large award

$1,424,502

FY 2023

Project Title

NextGen Long-acting and targeted combination ART for Children with HIV

Grant Number:

5R33AI149665-04

Activity Code:

R33

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/6/2020

End Date:

3/31/2026

Why this may be worth a closer look

• Large budget suggests more room for personnel or project growth.

Project Abstract

ABSTRACT The Targeted, Long-acting and Combination Anti-Retroviral Therapeutic (TLC-ART) Program has developed a scalable, drug-combination nano-platform technology called DcNPs (drug combination nanoparticles) that enables the stabilizing of insoluble and soluble short-acting antiretroviral drugs t...

Research Terms

<0-11 years old><21+ years old><AIDS Virus><Abbreviations><Acceleration><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Adherence><Adolescent><Adolescent Youth><Adult><Adult Human><Anti-Retroviral Agents><Antiretroviral Agents><Blood><Blood Plasma><Blood Reticuloendothelial System><Body Tissues><Cell Body><Cells><Child><Child Youth><Childhood><Children (0-21)><Clinical><Clinical Paths><Combination Drug Therapy><Combined Modality Therapy><Communication><Data><Data Set><Deglutition><Development><Development Plans><Development and Research><Disease><Disorder><Dosage Forms><Dose><Drug Combinations><Drug Kinetics><Drug Targeting><Drugs><EC 2.7.7.49><Ensure><Evaluation><Exhibits><FDA approved><Fatigue><Food and Drug Administration><Formulation><Funding><Generic Drugs><HIV><HIV Integrase><HIV Integration Protein><HIV Protease><HIV Proteinase><HTLV-III Protease><Human Figure><Human Immunodeficiency Viruses><Human body><Hydrogen Oxide><Injectable><Integrase><Integrase Inhibitors><Investigational Drugs><Investigational New Drugs><Kaletra><LAV-HTLV-III><Lack of Energy><Lead><Lopinavir><Lopinavir/Ritonavir><Lymphadenopathy-Associated Virus><Marketing><Medication><Modeling><Multimodal Therapy><Multimodal Treatment><NIAID><NIH><Nanoplatform><Nanotechnological platform><National Institute of Allergy and Infectious Disease><National Institutes of Health><Non-proprietary Drugs><Nonproprietary Drugs><Oral><PBPK><Pb element><Pharmaceutic Preparations><Pharmaceutical Preparations><Pharmacokinetics><Phase><Plasma><Plasma Serum><Polychemotherapy><Primates><Primates Mammals><Process><Proteins><R & D><R&D><RNA Transcriptase><RNA-Dependent DNA Polymerase><RNA-Directed DNA Polymerase><Recommendation><Research><Research Resources><Resources><Reticuloendothelial System, Serum, Plasma><Reverse Transcriptase><Revertase><Ritonavir><Route><SHIV><Safety><Schedule><Source><Specific qualifier value><Specified><Suspension substance><Suspensions><Swallowing><Technology><Tenofovir><Testing><Therapeutic><Time><Tissues><USFDA><United States Food and Drug Administration><United States National Institutes of Health><Update><Validation><Viral><Viread><Virus-HIV><Water><Work><adulthood><anti-retroviral><anti-retroviral therapy><anti-retroviral treatment><anti-viral efficacy><antiretroviral><antiretroviral therapy><antiretroviral treatment><antiviral efficacy><clinical development><combat><combination chemotherapy><combination pharmacotherapy><combination therapy><combined drug therapy><combined modality treatment><combined treatment><developmental><drug action><drug/agent><first in man><first-in-human><full scale manufacturing><heavy metal Pb><heavy metal lead><industrial partnership><industry partner><industry partnership><innovate><innovation><innovative><interest><juvenile><juvenile human><kids><large scale manufacturing><large scale production><mass production><meeting><meetings><multi-modal therapy><multi-modal treatment><nano><nano particle><nano-sized particle><nanoparticle><nanosized particle><nanotechnology platform><new drug combination><new pharmacotherapy combination><non-human primate><nonhuman primate><norvir><novel drug combination><novel pharmacotherapy combination><oral HIV><pediatric><pediatric HIV><pediatric human immunodeficiency virus><pharmacokinetic model><physiologically based pharmacokinetics><pill><pre-clinical development><preclinical development><preference><programs><public-private partnership><research and development><safety study><simian HIV><simian human immunodeficiency virus><success><technology platform><technology system><timeline><validations><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

DEBORAH STEPHENS

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Exploratory lead · 22/100

Recent

Active award

$151,525

FY 2026

Project Title

Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas

Grant Number:

5R50CA275929-05

Activity Code:

R50

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/6/2023

End Date:

2/29/2028

Project Abstract

Deborah Stephens, DO is an Associate Professor at the Lineberger Comprehensive Cancer Center (LCCC) at the University of North Carolina (UNC) who focuses on evaluation of novel targeted agents and combination therapies in patients with chronic lymphocytic leukemia (CLL) and B-cell lymphomas with the...

Research Terms

<21+ years old><Adult><Adult Human><Advisory Committees><Award><B-Cell CLL><B-Cell Chronic Lymphocytic Leukemia><B-Cell Chronic Lymphogenous Leukemia><B-Cell Chronic Lymphoid Leukemia><B-Cell Lymphocytic Leukemia><B-Cell Lymphomas><B-Lymphocytic Leukemia><CLL Lymphoplasmacytoid Lymphoma><Cancer Center><Cancers><Caring><Chronic B-Lymphocytic Leukemia><Chronic Lymphatic Leukemia><Chronic Lymphoblastic Leukemia><Chronic Lymphocytic Leukemia><Chronic Lymphogenous Leukemia><Clinical><Clinical Investigator><Clinical Trials><Clinical Trials Network><Collaborations><Combined Modality Therapy><Comprehensive Cancer Center><Data><Dedications><Development><ECOG><Eastern Cooperative Oncology Group><Evaluation><Experimental Therapies><Faculty><Funding><Germinoblastic Sarcoma><Germinoblastoma><Goals><Grant><Hematology><Hematopoietic Cell Tumor><Hematopoietic Malignancies><Hematopoietic Neoplasms><Hematopoietic Neoplasms including Lymphomas><Hematopoietic Tumor><Hematopoietic and Lymphoid Cell Neoplasm><Hematopoietic and Lymphoid Neoplasms><Industry><International><Investigational Therapies><Investigational Treatments><Investigators><Lead><Leadership><Lymphocytic Lymphoma><Lymphoma><Lymphoma, Lymphocytic, Plasmacytoid><Lymphoma, Lymphocytic, Well-Differentiated><Malignant Hematopoietic Neoplasm><Malignant Lymphoma><Malignant Neoplasms><Malignant Tumor><Medical Oncology><Mentors><Mentorship><Multimodal Therapy><Multimodal Treatment><NCI Organization><National Cancer Institute><North Carolina><Ohio><Outcome><Outcomes Research><Patient Care><Patient Care Delivery><Patients><Pb element><Principal Investigator><Recurrent disease><Refractory><Relapse><Relapsed Disease><Research><Research Personnel><Researchers><Reticulolymphosarcoma><Role><SWOG><Scientist><Small-Cell Lymphoma><Southwest Oncology Group><Specialist><Task Forces><Therapeutic><Time><Universities><Work><adulthood><advisory team><associate faculty><associate professor><blood cancer><cancer of blood><cancer of the blood><care for patients><care of patients><caring for patients><chronic lymphoid leukemia><clinical care><combination therapy><combined modality treatment><combined treatment><developmental><experimental therapeutic agents><experimental therapeutics><fighting><heavy metal Pb><heavy metal lead><improved><leukemia><leukemia/lymphoma><lymphoma/leukemia><malignancy><meeting><meetings><member><mid-career faculty><midcareer faculty><multi-modal therapy><multi-modal treatment><neoplasm/cancer><novel><programs><social role><standard of care><targeted agent><work group><working group>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Brian A. Jonas

UNIVERSITY OF CALIFORNIA AT DAVIS, DAVIS, CA

Exploratory lead · 22/100

Recent

Active award

$87,347

FY 2026

Project Title

NCI R50 Clinician Scientist Award

Grant Number:

5R50CA276013-04

Activity Code:

R50

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2023

End Date:

3/31/2028

Project Abstract

ABSTRACT/SUMMARY NCI clinical trials networks are essential to strengthen the cancer care of the nation by expediting the discovery of novel cancer treatments and therapeutic strategies. Central to this effort are the clinician scientists who development, implement, manage, and provide oversight to ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Vinay Duddalwar

UNIVERSITY OF SOUTHERN CALIFORNIA, Los Angeles, CA

Exploratory lead · 18/100

Solid budget

Team-scale grant

$390,494

FY 2024

Project Title

NCTN - Network Lead Academic Participating Site: USC

Grant Number:

5UG1CA180830-11

Activity Code:

UG1

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

4/17/2014

End Date:

2/28/2026

Project Abstract

ABSTRACT The USC Norris Comprehensive Cancer Center first participated in the research activities of SWOG in 1987 and was initially funded in 1992. This five-year grant cycle has had increased administrative and academic participation, with maintenance of high clinical and correlative trial entry, c...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Anthony Boutros El-Khoueiry

UNIVERSITY OF SOUTHERN CALIFORNIA, Los Angeles, CA

Exploratory lead · 18/100

Solid budget

Team-scale grant

$390,494

FY 2024

Project Title

NCTN - Network Lead Academic Participating Site: USC

Grant Number:

5UG1CA180830-11

Activity Code:

UG1

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

4/17/2014

End Date:

2/28/2026

Project Abstract

ABSTRACT The USC Norris Comprehensive Cancer Center first participated in the research activities of SWOG in 1987 and was initially funded in 1992. This five-year grant cycle has had increased administrative and academic participation, with maintenance of high clinical and correlative trial entry, c...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

HEINZ JOSEF LENZ

UNIVERSITY OF SOUTHERN CALIFORNIA, Los Angeles, CA

Exploratory lead · 18/100

Solid budget

Team-scale grant

$390,494

FY 2024

Project Title

NCTN - Network Lead Academic Participating Site: USC

Grant Number:

5UG1CA180830-11

Activity Code:

UG1

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

4/17/2014

End Date:

2/28/2026

Project Abstract

ABSTRACT The USC Norris Comprehensive Cancer Center first participated in the research activities of SWOG in 1987 and was initially funded in 1992. This five-year grant cycle has had increased administrative and academic participation, with maintenance of high clinical and correlative trial entry, c...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jyoti Mayadev

UNIVERSITY OF CALIFORNIA, SAN DIEGO, LA JOLLA, CA

Exploratory lead · 10/100

Active award

$173,920

FY 2024

Project Title

NCI Clinical Trial Research Strategy, Harnessing of Equity, and Implementation

Grant Number:

5R50CA282102-02

Activity Code:

R50

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/4/2023

End Date:

8/31/2028

Project Abstract

PROJECT SUMMARY/ABSTRACT I am a female board-certified radiation oncologist and Professor at the University of California (UC), San Diego, in the Department of Radiation Medicine. My research and clinical efforts involve every phase of gynecologic (GYN) clinical trials with a focus on translational ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Joaquina C Baranda

UNIVERSITY OF KANSAS MEDICAL CENTER, KANSAS CITY, KS

Exploratory lead · 10/100

Active award

$159,574

FY 2025

Project Title

Increasing Access and Participation to Early Phase Clinical Trials

Grant Number:

5R50CA290098-02

Activity Code:

R50

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

8/7/2024

End Date:

7/31/2029

Project Abstract

Access to health care including clinical trials leading to paradigm-changing cancer treatments is critical for high quality cancer care. Compared to later phase clinical trials, early phase trials are more complicated but are pivotal in the development of novel and more effective therapies. Particip...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Cathy Eng

VANDERBILT UNIVERSITY MEDICAL CENTER, NASHVILLE, TN

Exploratory lead · 10/100

Active award

$130,426

FY 2025

Project Title

Cultivating programmatic efforts to optimize the conduct and implementation of NCI-funded clinical trials

Grant Number:

5R50CA285499-02

Activity Code:

R50

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/18/2024

End Date:

8/31/2029

Project Abstract

Dr. Cathy Eng is an exemplary Clinician Scientist who, throughout her career, has held numerous roles within the National Clinical Trials Network (NCTN) and is viewed, by her peers, to be one of the leading senior female NCTN members in the field of gastrointestinal (GI) oncology. Dr. Eng has partic...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

NIH Grant Search by PI — Funded Principal Investigator Finder

Search NIH grants by research area to find funded PIs

Search Results

Opportunity Digest

Michael A Hogarth

Project Title

Project Abstract

Research Terms

David Mitchell Smith

Project Title

Project Abstract

Research Terms

PATRICE DELAFONTAINE

Project Title

Project Abstract

Research Terms

Orlando M Gutierrez

Project Title

Project Abstract

Research Terms

RACHEL HESS

Project Title

Project Abstract

Research Terms

Jennifer Juhl Majersik

Project Title

Project Abstract

Research Terms

Michael Z. Lin

Project Title

Project Abstract

Research Terms

Kaspar Podgorski

Project Title

Project Abstract

Research Terms

Karel Svoboda

Project Title

Project Abstract

Research Terms

Lin Tian

Project Title

Project Abstract

Research Terms

Sanjay Sethi

Project Title

Project Abstract

Research Terms

Robert Wilson Frenck

Project Title

Project Abstract

Research Terms

Ting Wang

Project Title

Project Abstract

Research Terms

MARIA MARGARITA BEHRENS

Project Title

Project Abstract

Research Terms

Joseph R Ecker

Project Title

Project Abstract

Research Terms

Daofeng Li

Project Title

Project Abstract

Research Terms

Bing Ren

Project Title

Project Abstract

Research Terms

XIANGMIN XU

Project Title

Project Abstract

Research Terms

KIMBERLY S. JOHNSON

Project Title

Project Abstract

Research Terms